Copy of EULAR 2021 Programme Export 2021-5-18
EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing no session group Posters View
Rapid response to Baricitinib in patients with rheumatoid arthritis and an inadequate response to methotrexate and at least one biologic (blank) (blank) DMARD: a clinical and power Doppler ultrasound study. Clinical features and the course of COVID-19 in patients with Familial Mediterranean Fever
KZR-616, A Selective Immunoproteasome Inhibitor for the Treatment of Systemic Lupus Erythematosus: Results from the Completed Dose Escalation Phase 1b Portion of the MISSION Study Are smoking and alcohol associated with peripheral musculoskeletal involvement in patients with Spondyloarthritis? Results from the ASAS-PerSpA study.
Histopathological analysis of lupus nephritis incorporating BANFF criteria emphasizes the importance of tubulointerstitial changes for creatinine and proteinuria at 12 months after renal biopsy
EFFICACY AND SAFETY OF OLOKIZUMAB: RESULTS FROM THE PHASE III RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS INADEQUATELY CONTROLLED BY TNF INHIBITOR THERAPY
Effect of tofacitinib on spinal vertebral body and posterolateral element inflammation and structural lesions using the Canada-Denmark MRI scoring system in patients with ankylosing spondylitis: results from a Phase 2 study Long term safety and tolerability with etanercept biosimilar (YLB113), results from a 2‑year Open Label Extension study (Study No. YLB113-003) Post Covid arthritis; Reactive arthritis or Rheumatic disease Flare or Both 18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-Vessel Vasculitis Knee joint distraction results in MRI cartilage thickness increase up to ten years after treatment Next-generation online telemedicine system utilizing mixed reality for rheumatoid arthritis Impact of the COVID-19 pandemic on morbidity and mortality among Swedish patients with inflammatory joint diseases versus the general population
Long-term treatment with ixekizumab in patients with axial spondyloarthritis: Two-year results from COAST-Y
HOW DOES GENDER AFFECT SECUKINUMAB TREATMENT OUTCOMES AND RETENTION RATES IN PATIENTS WITH ANKYLOSING SPONDYLITIS? - REAL WORLD DATA FROM THE GERMAN AQUILA STUDY
Senescence did not alter the chondroprotective effect of extracellular vesicles from mesenchymal stromal cells
Lifestyle habits in patients with rheumatoid arthritis – a cross sectional study on two Scandinavian cohorts Ixekizumab efficacy on spinal pain, disease activity and quality of life in patients with psoriatic arthritis presenting with symptoms suggestive of axial involvement PROMIS Assessment of Response to Treatment with Golimumab IV or Infliximab in Rheumatoid Arthritis Patients: Results from the Phase-4 AWARE Study Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis? – A Pilot Clinical Trial Novel Long non-coding RNA expression profile of peripheral blood monouclear cell revealed potential biomarkers and regulatory mechanism in Systemic Lupus Erythematosus
Pro-inflammatory effects of human apatite crystals extracted from patients suffering from calcific tendinopathy
Are antimalarials safe for the heart of patients with systemic lupus erythematosus? Analysis of factors associated with the development of heart failure in patients in the Spanish Society of Rheumatology Lupus Registry (RELESSER) The Musculoskeletal System Manifestations in Children with Familial Mediterranean Fever Liraglutide has potent anti-inflammatory and anti-catabolic in vitro activities in osteoarthritis. Identifying Meaningful Change in the RA Flare Questionnaire Scores in Rheumatoid Arthritis Development of a risk prediction model for venous thromboembolism in patients with systemic lupus erythematosus: The SLE-VTE score
Role of intraarticular biologics and methotrexate in the management of active inflammatory monoarthritis. Determining in which preclinical stage HLA-shared epitope alleles and smoking exert their effect in the development of rheumatoid arthritis
Metabolic Changes Induced by Anti-Malondialdehyde/Malindialdehyde-Acetaldehyde Antibodies Promote Osteoclast Development
Predictors of Change in Disease Activity in Rheumatoid Arthritis after Start of Treatment with Abatacept
Willingness To Get The COVID-19 Vaccine Among Patients With Rheumatic Diseases, Health Workers and General Population BARRIERS AND FACILITATORS OF A NEW MODEL OF STRATIFIED EXERCISE THERAPY IN KNEE OSTEOARTHRITIS: A QUALITATIVE STUDY EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Risk factors of low bone mineral density in women with systemic sclerosis Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study PERFUSE: A French Prospective/Retrospective Noninterventional Cohort Study of Infliximab-Naïve and Transitioned Patients Receiving Infliximab Biosimilar SB2; 12-month Analysis
Tocilizumab decreases angiogenesis in Rheumatoid Arthritis through its regulatory effect on EMMPRIN/CD147 Nurse led remote management of osteoporosis – do patients approve? NCOA3 amplifies profibrotic transcriptional programs in Systemic Sclerosis Sequence complementarity between SARS-CoV-2 genome and human noncoding RNAs associated with immunological disorders: an in silico pivotal study.
Knee and hip osteoarthritis are associated with subclinical and manifest atherosclerosis: a systematic review and meta-analysis
Patients' safety skills assessment with biologics and JAK inhibitors: update of the BioSecure questionnaire Effect of socio-economic status and educational level on COVID-19 outcomes in patients with rheumatic diseases from Argentina: Data from the SAR-COVID Registry Trajectories of Glucocorticoid-Therapy in Early Rheumatoid Arthritis: First Results of a Scoping Systematic Review and Meta-Analysis of Observational Cohort Studies Pulmonary artery pseudoaneurysms in Behcet’s Disease Treatment compliance of patients with rheumatoid arthritis during the first wave of the SARS-CoV-2/COVID-19 pandemic in Portugal: results from the COVID in RA (COVIDRA) survey.
Ultrasound assessment of gout lesions in an Algerian population with asymptomatic hyperuricemia Diagnostic accuracy of Conventional Radiography of the knee for Calcium Pyrophosphate Deposition Disease: an ancillary study of the OMERACT Ultrasound – CPPD group Improvements in patient-reported impact of psoriatic arthritis with IL-12/23 (ustekinumab) or tumour necrosis factor inhibitors: 1-year data from the large, real-world PsABio study Differences in range of motion and mechanical muscle characteristics among inflammatory and mechanical spinal pain: a case-control study. A negative interferon biomarker CD169 / SIGLEC-1 rules out systemic lupus erythematosus
Clinical and immunological characteristics of patients with juvenile-, adult- and late-onset systemic lupus erythematosus Are biologic and targeted synthetic DMARDs safe to use in patients with renal impairment?
Efficacy of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Knee or Hip: A Post-hoc Subgroup Analysis of Patients from a Randomized, NSAID-Controlled Study with a History of Depression, Anxiety, or Insomnia The impact of cardiovascular comorbidities on knee osteoarthritis progression
Post-traumatic stress disorder and quality of life in systemic lupus erythematosus. A cross sectional web survey-based study. Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study Subchondral bone normalization after knee joint distraction treatment as measured with CT
The OMERACT Knee Inflammation MRI Scoring System: Validation of Quantitative Methodologies and Tri-compartmental Overlays by Comparison with the MRI Osteoarthritis Knee Score
A Longitudinal Study of Sarcopenia, Locomotive Syndrome, and Frailty in Patients with Rheumatoid Arthritis: from the CHIKARA study
The utility of ultrasound to predict patient outcomes in shoulder pain: a prospective observational study of 500 patients
The application of MTX-loading DNA tetrahedron in treating Collagen-induced arthritis mice via regulating macrophage Effects of tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: a metabolomic approach Similar Clinical Responses Achieved with Lower Versus Standard Doses of Infliximab Biosimilar CT-P13 in Patients with Ankylosing Spondylitis: Real-world Results from the RAAS Study
Safety and Efficacy of Biologics in Elderly Patients with Rheumatoid Arthritis in a Real World Study: Use of Intravenous Golimumab and Infliximab in Adults with Rheumatoid Arthritis ≥65 Years of Age
Bimekizumab Safety and Efficacy in Patients with Psoriatic Arthritis: 3-Year Results from a Phase 2b Open-Label Extension Study Incidence Rates of Difficult-to-treat Rheumatoid Arthritis in Real-world Clinical Practice
CHEMOPROPHYLAXIS IN LATENT TUBERCULOSIS ASSOCIATED WITH RHEUMATIC IMMUNE-MEDIATED DISEASES. STUDY OF 240 PATIENTS FROM A SINGLE UNIVERSITY HOSPITAL
Prevalence of Hypophosphatasia in Adult Rheumatology Patients Screened by Low Levels of Alkaline Phosphatase
BELIMUMAB ADD-ON THERAPY MOBILISES MEMORY B CELLS INTO THE CIRCULATION OF PATIENTS WITH SLE EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Chaperone-mediated Autophagy is a Hallmark of Joint Disease in Osteoarthritic Patients
THE EFFECT OF RITUXIMAB BIOSIMILAR THERAPY ON THE EXPRESSION OF INTERFERON-STIMULATED GENES ("INTERFERON SIGNATURE") IN PATIENTS WITH RHEUMATOID ARTHRITIS Safety and Efficacy of Combining Methotrexate and Leflunomide among patients with Inflammatory Arthropathies: Findings from the PRIME registry Effect of Anti-Ro/SSA antibodies for treatment response to methotrexate in rheumatoid arthritis: a retrospective multicenter observational study Telemedicine consultations in rheumatology: identified problems of new technology. Disease Activity and Patients-Reported Outcomes After Switching Between IL-6 Receptor Inhibitors and JAK Inhibitors: An Analysis from the Corrona Registry Adverse Outcomes and Rehospitalization after Delivery Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis and Their Infants COVID-19 in patients with rheumatic diseases: Comparison of data from the Argentine registry (SAR-COVID), with the Latin American and Global registry (Global Rheumatology Alliance). Novel Stringent Outcome Measures Applied to the Phase 2 and 3 Anifrolumab Trials Pregnancy course in a cohort of women with myositis - Results from RevNatus Juvenile systemic sclerosis (jSSc) patients with overlap characteristics do not have mild disease. Results from the jSSc inception cohort. www.juvenile-scleroderma.com IMPLEMENTATION OF TELEMEDICINE IN RHEUMATOLOGY: VIRTUAL CONSULTATION AS A TOOL FOR DIRECT COMMUNICATION WITH PRIMARY CARE. Bone mineral density, lean and fat mass in postmenopausal women with rheumatoid arthritis
Sustainability of ixekizumab response at the individual patient level over time in radiographic axial spondyloarthritis Effect of Secukinumab versus Adalimumab on ACR Core Components and Health-Related Quality of Life in Patients with Psoriatic Arthritis: Results From the EXCEED Study Factors associated with subclinical atherosclerosis in patients with rheumatoid arthritis.
Behavior and feelings of patients with systemic lupus erythematosus during lockdown measures for the COVID-19 outbreak REVAMPING BIOLOGIC THERAPY DURING COVID-19
Pharmacokinetics and Serum Urate Lowering Effects of AR882, a Novel, Potent and Selective Uricosuric Agent, in Patients with Gout AUTOIMMUNE SYSTEMIC DISEASES AND COVID-19 INFECTION CD21-/low B-cells are increased in patients with ankylosing spondylitis A deep learning method uncovers novel pathway associations in systemic lupus erythematosus
Validation of the Disease Activity Index for Psoriatic Arthritis (DAPSA) with a quick quantitative C-reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis (PsA): A prospective, national, multicenter study.
Anthropometric measurements in upper extremity rehabilitation of patients with rheumatic diseases Is enthesitis a sonographic biomarker of disease severity in psoriatic arthritis? The link between ultrasound entheseal abnormalities and peripheral joint erosive damage.
Large joint disease in rheumatoid arthritis and the role of rheumatoid factor. Results from the Early Rheumatoid Arthritis Study.
Effectiveness of screening in patients with rheumatic disease on biological therapy and risk of active tuberculosis.
Patients with immune mediated inflammatory diseases are overrepresented in low- frequency viral symptom clusters CCN1: An angiogenic actor implicated in the structural damages of rheumatoid arthritis Baseline vitamin D levels and disease activity and response in Portuguese patients with psoriatic arthritis under bMDARD: does it make a difference? Depression, Anxiety and Stress among outpatients with Rheumatoid Arthritis followed up at a Tertiary Care Hospital in Sri Lanka; a Cross-Sectional Study NETAKIMAB REDUCES PSORIATIC ARTHRITIS ACTIVITY IN PATIENTS WITH OR WITHOUT AXIAL DISEASE: SUBANALYSIS OF THE PATERA STUDY Effects of Anifrolumab on Renal Disease in Patients With SLE
HOW DOES GENDER AFFECT SECUKINUMAB TREATMENT OUTCOMES AND RETENTION RATES IN PATIENTS WITH PSORIATIC ARTHRITIS? – REAL WORLD DATA FROM THE GERMAN AQUILA STUDY
New faces of polyarteritis nodosa: 18F-fluorodeoxyglucose Positron Emission Tomography findings in a series of 10 patients.
Genetic susceptibility variants for Rheumatoid Arthritis are not associated with early remission; a multi-cohort study
Serum fetuin-A and visfatin levels in women with rheumatoid arthritis depending on disease activity
Outcomes of COVID-19 Infection among Children and Young People with Pre-existing Rheumatic and Musculoskeletal Diseases. Unveiling axial involvement in psoriatic arthritis: an ancillary analysis of the ASAS-perSpA study. EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Insulin resistance and leptin levels in systemic lupus erythematosus patients without diabetes mellitus or fasting hyperglycemia
Expansion of CD4+/CD8+ double-positive T cells is associated with a severe disease course in rheumatoid arthritis Vasculitis in patients with sarcoidosis: a single-institution case series of 17 patients Abnormal electrochemical skin conductance values in patients with AA amyloidosis
Are there clues for the screening of spondyloarthritis in patients with inflammatory bowel diseases? Real world effectiveness of baricitinib in the Swiss rheumatoid arthritis register (SCQM-RA)
Sexual experience in male patients with ankylosing spondylitis: results from a cross-sectional study of 113 patients Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study BIIB059 Demonstrated a Consistent Therapeutic Effect on SRI-4 Response Across Subgroups of Participants With Systemic Lupus Erythematosus in the LILAC Phase 2 Study
Synovitis is factor of osteoarthritis knee progression in patients with less than 5 years of disease duration GENDER DIFFERENCES IN THROMBOTIC PRIMARY ANTIPHOSPHOLIPID SYNDROME IN A LARGE COHORT OF PATIENTS FROM FOUR EUROPEAN CENTERS Prevalence of bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis
MULTICENTER STUDY OF 71 PATIENTS WITH REFRACTORY UVEITIS RELATED TO IMMUNE-MEDIATED INFLAMMATORY DISEASES ON CERTOLIZUMAB PEGOL TREATMENT
Diagnostic value of muscle strength tests for the diagnosis of sarcopenia in rheumatoid arthritis patients A randomised dose ranging, placebo-controlled, Phase II study assessing the efficacy and safety of BI 655064, an antagonistic anti- CD40 antibody, in patients with lupus nephritis Aberrant spliceosome and altered expression of IFN-response related genes are hallmarks of monocytes from lupus patients with renal disease Predictors of toxicity with Hydroxychloroquine and Chloroquine use: a Systematic Review Characteristics and 6-Month Outcomes Among Real-world Patients with Rheumatoid Arthritis Initiating Upadacitinib: Analysis from the Corrona Registry
CARDIAC ADVERSE EFFECTS OF LONG-TERM USE OF HYDROXYCHLOROQUINE IN SYSTEMIC LUPUS ERYTHEMATOSUS. SINGLE UNIVERSITY CENTER STUDY OF 109 PATIENTS Reliability of Conventional Radiography of the knee for the assessment of chondrocalcinosis: an ancillary study of the OMERACT Ultrasound – CPPD group
HORMONES OF ADIPOSE TISSUE IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAVE REDUCED BODY WEIGHT
Epione Application: An integrated genotype analysis web server for clinical genomics in Systemic lupus erythematosus (SLE) Segmented Short-Format Online Education Significantly Increases Prediction, Prognosis, and Management of Fibrosing Interstitial Lung Disease Associated with Connective Tissue Disease Clinical Associations of Cognitive Dysfunction in Systemic Lupus Erythematosus (SLE)
Validation of the SIMPLE index for disease activity of systemic lupus erythematosus in Chinese patients Outcomes of surgically resected thoracic aortitis: results from a prospective multi-centre registry Molecular profiling of the remission state in Psoriatic Arthritis: is the fire extinguished? CIRCULATING ENDOTHELIAL CELLS AS A MARKER OF CARDIOVASCULAR DISEASES IN PATIENTS WITH PSORIATIC ARTHRITIS
Anti-TNF Glucocorticoid Receptor Modulator Antibody Drug Conjugate for the Treatment of Autoimmune Diseases Digital rheumatology in the era of COVID-19: Results of a national patient and physician survey TOCILIZUMAB FOR THE TREATMENT OF IMMUNE-RELATED ADVERSE EVENTS TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES
Identifying high-cost drugs for rare rheumatic diseases in routinely collected NHS data. Results from a pilot study of rituximab use in vasculitis using data from the National Disease Registration Service and the Registration of Complex Rare Diseases-exemplars in Rheumatology (RECORDER) project Clinical manifestations, treatment, and outcomes of “non-criteria” antiphospholipid syndrome in comparison with definite antiphospholipid syndrome: A systematic review and meta-analysis
Can a specialist nurse lead a comprehensive osteoporosis service with remote supervision – an innovative concept Description of sacroiliac CT findings in patients with ankylosing spondylitis aged over 50 years: preliminary results of the CASIAGE study FIBROMYALGIA IN MEXICAN PATIENTS WITH RHEUMATOID ARTHRITIS Determination of the Reliability and Validity of the BETY-Biopsychosocial Questionnaire in Patients with a Diagnosis of Psoriatic Arthritis Patients at risk for RA show the same amount of acute soluble cartilage degradation markers after physical activity compared to patients with established RA EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) The Incidence and Prevalence of Cardiovascular Diseases in Gout: A Systematic Review and Meta-analysis
Cardiac biomarkers are associated with the development of cardiovascular events in patients with psoriatic arthritis and psoriasis Safety of biologic treatments in solid organ transplant recipients: a systematic review
Air pollution is a predictor of poor response to biological therapies in chronic inflammatory arthritides
Measuring subclinical inflammation in hand and forefoot in patients with arthralgia using 1.5T or 3.0T MRI: does field strength matter?
COVID-19 stress: does it augment pain in people with fibromyalgia and might psychological flexibility protect against this influence?
External Validation of a Multi-biomarker-Based Cardiovascular Disease Risk Prediction Score for Rheumatoid Arthritis Patients ASSESSMENT OF THE ASSOCIATION BETWEEN ESTIMATED CARDIOVASCULAR RISK AND MASEI INDEX IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS Influence of various factors on the immunogenicity of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus
Prevalent comorbidities associated with clinically diagnosed osteoarthritis: a case-control analysis including 1,936,792 people. Is there an association between autoantibodies induction and loss of therapeutic efficacy in patients with axial spondyloarthritis and psoriatic arthritis treated with anti-TNF-α agents?
Randomized, Controlled, Phase 2 Trial of Type 1 IFN Inhibitor Anifrolumab in Patients with Active Proliferative Lupus Nephritis Risk of ACPA positivity by motif-based classification of HLA-DRB1 shared epitope alleles in RA
The Negative Impact of Undiagnosed Depression in Axial Spondyloarthroparthy: Results of a Screening Study IDENTIFICATION OF PATIENTS AFFECTED WITH ANKYLOSING SPONDYLITIS AND INFLAMMATORY BOWEL DISEASE OVERLAP USING COLLAGEN BIOMARKERS
Food sources of dietary fibre and risk of total knee replacement related to severe osteoarthritis, the Singapore Chinese Health Study RELATIONSHIP BETWEEN FIBRINOGEN TO ALBUMIN RATIO AND DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Exploring Equivalence Between Biosimilar SB4 and Reference Etanercept by Assessing Effectiveness in Rheumatoid Arthritis Patients Treated in Ordinary Clinical Practice Citrullination induces epigenetic memory of the innate immune system
A new risk model is able to identify Systemic Sclerosis patients with a low risk of disease progression Associations between the neovascularization of carotid atherosclerotic plaques, lipid parameters and immunological disorders in patients with rheumatoid arthritis
Optimization of Dual Energy Computed Tomography post-processing to reduce lower limb artifacts in gout. Ianalumab (VAY736) Safety and Efficacy in Patients with Sjogren’s Syndrome: 52 Week Results from a Randomised, Placebo- controlled, Phase 2b Dose-ranging Trial Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: A national, multicenter study. Treatment of giant cell arteritis with tocilizumab: A retrospective cohort study of 119 patients
The impact of telemedicine and COVID-19 on a tertiary rheumatology service: a retrospective audit Comparison of MBDA Score, Patient Global Assessment and Evaluator Global Assessment for Predicting Risk of Radiographic Progression Expectations and potential concerns of patients with autoimmune and rheumatic diseases regarding vaccination against SARS-CoV-2 (COVID-19): the worldwide online VAXICOV study
Redefining the Clinical and Laboratory Features of Rheumatic Pleural Effusion: A 30-case Series.
Long-term Effectiveness of the Rituximab Half Dose Regimen Following a Response to the Licensed Dose in Rheumatoid Arthritis
QRISK3 Relation to Carotid Plaque is Higher than that of SCORE In Patients with Systemic Lupus Erythematosus Gastrointestinal symptoms and Rheumatic Diseases: two sides of the same coin
Evaluation of a virtual reality-based application to educate healthcare professionals and medical students about inflammatory arthritis Assessing senescent human lymph node stromal cells during rheumatoid arthritis development EFFECTIVENESS AND SAFETY OF COMBINED BIOLOGICAL THERAPY IN PATIENTS WITH REFRACTORY SPONDYLOARTHRITIS Immunogenicity of Rituximab biosimilar GP2013: a rare event, but not without consequences ...
Herpes Zoster In A Multi-ethnic Systemic Lupus Erythematosus (SLE) Cohort : Clinical Features and Risk Factors EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
In Phase-3 trials DISCOVER 1 & 2, Guselkumab Reduced Fatigue over 52 weeks in Patients with Psoriatic Arthritis and Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Demonstrated Independent Treatment Effects on Fatigue after Adjustment for Clinical Response (ACR20) Development of a new and simplified formula to predict mortality in patients with ANCA-associated vasculitis admitted to the intensive care unit
Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Results of the Multicenter, Randomised, Double-blind, Phase IV ASTRUM-trial ASSOCIATION OF NAIL PSORIASIS WITH WORSE DISEASE OUTCOMES IN PSORIATIC ARTHRITIS PATIENTS. DATA FROM CLINICAL PRACTICE Patients’ perceptions of person-centred care in early RA: A qualitative study
Combination Treatment of AR882, a New URAT1 Inhibitor, and Xanthine Oxidase Inhibitors Allopurinol or Febuxostat: Effect on Uric Acid, Hypoxanthine and Xanthine in Plasma or Serum and Urine The effect of SARS-CoV-2 on the course and the treatment of rheumatic inflammatory diseases. Experience form the northwestern Greece. A tocilizumab dosing strategy in rheumatoid arthritis patients with stable disease aiming to prevent overtreatment and unnecessary costs Clinical course of COVID-19 in children with rheumatic disease under biologic therapy
Sleep disturbance and bone mineral density, risk of falls and fracture: results from a 10.7-year prospective cohort study UVEAL CATARACT IN PATIENTS WITH SPONDYLOARTHRITIS AND OTHER IMMUNO-INFLAMMATORY DISEASES AND ITS SURGICAL TREATMENT The reduction of retinal microvascular alterations and the decrease of a potentially related T-cell subset in patients with active rheumatoid arthritis treated with abatacept. Antibodies to Porphyromonas gingivalis associate with the presence of rheumatoid arthritis-related autoantibodies in patients with periodontitis
Impact of Upadacitinib on Reducing Pain in Patients With Active Psoriatic Arthritis: Results From Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs
ANALYSIS OF FACTORS ASSOCIATED WITH THE EFFECTIVENESS OF ABATACEPT IN THE ORIGAMI STUDY
Can the SLE-DAS substitute BILAG to measure Lupus disease activity in clinical trials? Post-hoc analysis of the BLISS-76 trial. Risk of malnutrition in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): further analyses of the SENSCIS trial Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy As Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis Identification of molecular phenotypes and immune cell infiltration in psoriatic arthritis patients’ skin tissues by integrated bioinformatics analysis
Efficacy and Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 Study Anxiety in psoriatic arthritis patients: results from the HUR-BIO biologic registry Echocardiographic findings in Psoriatic Arthritis, Rheumatoid Arthritis and controls Switching of treatment from reference etanercept to Sandoz etanercept biosimilar in patients with rheumatic diseases: an interim analysis of real-world data from the COMPACT study MANAGEMENT OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS DURING THE COVID-19 PANDEMIC: EVIDENCE FROM THE ITALIAN EPICENTER Comparative efficacy of combination therapy with biologic or target synthetic drugs for Rheumatoid Arthritis: a Bayesian network meta- analysis.
Evaluating the multivisceral involvement on adult-onset Still's disease to retrieve imaging-based differences in patients with and without macrophage activation syndrome; results from a single-centre observational study
Treatment effectiveness of upadacitinib at 3 months in US patients with rheumatoid arthritis from the United Rheumatology Normalized Integrated Community Evidence (NICE[TM]) real-world data
THE ROLE OF VIRTUAL TELEPHONE VISITS IN THE TIGHT CONTROL OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TARGETED THERAPIES DURING THE COVID-19 PANDEMIC
miRNAs deregulated in response to IL17A inhibitors in psoriatic arthritis regulate gene products in Rho-GTPase pathways
Trends in the Incidence of Giant Cell Arteritis across Seven Decades and Changes in Diagnostic Modalities: a Population-based Study The efficacy, safety and outcome after 5-8 years of parenteral anti-osteoporotic therapy evaluated at a district general hospital in the UK.
Mortality patterns and their prognostic value in patients with systemic lupus erythematosus in Cuba EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Secukinumab 150 mg Provides Sustained Improvement in Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: 2-year Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Results From the PREVENT Study
Biologics initiation in moderate vs severe rheumatoid arthritis patients: prospective observational study from a Canadian registry A Multicenter Randomized Study in Rheumatoid Arthritis to Compare Iguratimod, Methotrexate, or Combination: 52 Week Efficacy and Safety Results of the SMILE Trial TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN REAL-WORLD SETTINGS: A NATIONAL MULTICENTER STUDY OF 167 PATIENTS FROM ARGENTINA Characteristics and burden of disease in patients with radiographic versus non-radiographic axial spondyloarthritis in the Ankylosing Spondylitis Registry of Ireland cohort Characterization of PK/PD of Anifrolumab in Patients With Moderate to Severe SLE Evaluation of spinal radiographic progression in patients with radiographic axial spondyloarthritis receiving ixekizumab therapy over 2 years Skin limited IgA vasculitis in adults
Clinical characteristics associated with glandular involvement evaluated by salivary gland ultrasonography in Sjögren's syndrome Genetic variants within psoriatic arthritis (PsA)-weighted genes FBXL19 and HLA-B*39 may serve as a potential link between PsA and obesity
Effect of tofacitinib on patient-reported outcomes in patients with active ankylosing spondylitis: results from a Phase 3 trial
Cluster Analysis and Comparison of Cumulative Damage by DIAPS in a Single Center Cohort of APS Patients
Experience with adalimumab biosimilar use in clinical practice: data from the German BIKER-Registry Impact of lockdown during COVID-19 pandemic on the onset of post-traumatic stress disorder (PTSD) in systemic sclerosis patients: a case-control study A 6-MONTH OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS Baricitinib decreases anti-dsDNA and IgG antibodies in adults with systemic lupus erythematosus from a phase 2 double-blind, randomized, placebo-controlled trial How do clinical and socioeconomic factors impact on work disability in early axial spondyloarthritis? Five-year data from the DESIR cohort.
Splenic Extramedullary Hematopoiesis is Omnipresent and Correlates with Disease Severity in the Lupus NZB/W F1 Murine Model Lung ultrasound to assess the severity of interstitial lung disease in systemic sclerosis.
Proteomics Analysis Comparing the Mode of Action of Upadacitinib Between Non-Biologic-DMARD-IR and Biologic-DMARD-IR PsA Patients Identifies Distinct Pathogenic Pathways in the SELECT-PsA 1 and SELECT-PsA 2 Phase 3 Studies Prevalence of Joint Effusion, Hyperperfusion and Enthesitis in Young Healthy Individuals
Decreased risk of osteonecrosis over time in patients with systemic lupus erythematosus using Japanese health insurance database Epidemiologic profile and channeling to treatment in Rheumatoid Arthritis patients treated with Abatacept over the last 5 years: Data from the Spanish register BIOBADASER 3.0
Synovial myeloid-stromal pathotype predicts one-year radiographic progression in active rheumatoid arthritis Bimekizumab Shows Sustained Long-Term Improvements in Patient-Reported Outcomes and Quality of Life in Ankylosing Spondylitis: 3-Year Results from a Phase 2b Study Effect of the COVID19 pandemic on rheumatologist prescription behaviour of new advanced therapy: data of the TARDIS-RA registry, a nationwide Belgian Biologic registry Hepatotropic viruses with higher rheumatoid factor, but not rheumatic diseases link to prevalent Cryoglobulinemia. Correlation of clinical and serological markers with etiological causes. ELIGIBILITY FOR ANTI-FIBROTIC TREATMENT WITH NINTEDANIB OF PATIENTS WITH SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE
Alcohol and inflammatory arthritis disease activity: perspectives from a 979-patient cohort with systematic review and meta-analysis
Identification of Common Functional Pathways in Patients with Lupus and COVID-19 by Time-series Analysis
Damage progression of finger joint cartilage evaluated by ultrasound and X-ray in patients with rheumatoid arthritis (RA)
Mortality and its related factors in patients with IgG4-related disease: A Japanese single-center study
The association of clinical and structural knee osteoarthritis with physical activity in the middle-aged population: The NEO study
Medical costs for patients starting treatment for rheumatoid arthritis who have comorbid diabetes mellitus in Japan
EFFECTIVENESS AND SAFETY OF SECUKINUMAB IN NAïVE OR TNF-INHIBITORS FAILURE AXIAL SPONDYLOARTHRITIS PATIENTS IN REAL LIFE: A 24-MONTHS PROSPECTIVE MULTICENTRIC STUDY
Increased Keratin 9 expression in Systemic sclerosis skin is driven by the lncRNA HOTAIR from fibroblast derived exosomes EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Cardiovascular and disease related features in axial spondylitis with and without concomitant psoriasis. A multicenter study with 882 Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) patients.
Deep phenotyping of dermatomyositis based on lipid ferroptosis-related genes by Machine Learning Clinical characterization and predictive factors for progression in a cohort of ILD patients with features of autoimmunity: Are IPAF criteria sufficient?
Meteorological variables have different influence on core measures of disease activity in patients with rheumatoid arthritis SARS-CoV2 serology screening in spondyloarthritis patients in North-Eastern Italy: a pilot study Fall risk assessment in rheumatoid arthritis patients Specificity of pANCA autoantibodies in autoimmune diseases
LOW PRECONCEPTIONAL COMPLEMENT LEVEL IS RELATED WITH ADVERSE OBSTETRIC OUTCOME IN A MULTICENTRIC COHORT OF PREGNANCY IN PATIENTS WITH APS AND aPL POSITIVITY Unusually high prevalence of atrial fibrillation in patients with rheumatoid arthritis. Regulation of IFN signature by HDAC class IIa-CD52 axis in systemic sclerosis Adoption of digital manikins to self-report pain: a systematic review
Speckle tracking better detects subclinical myocardial dysfunction in patients with rheumatoid arthritis
Factors associated with use of telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak
Risk of cardiovascular disease in newly diagnosed rheumatoid arthritis: a current risk assessment
Survival analysis of time to first adverse drug reaction and drug survival in rheumatoid arthritis patients treated with methotrexate and hydroxychloroquine monotherapies or combination therapy
National Burden of Rheumatoid Arthritis in Canada 1990-2017: Findings from the Global Burden of Disease Study 2017
How does multimorbidity impact on the direct and indirect costs in patients with rheumatoid arthritis? Co-morbidities may not Change Treatment Characteristics of the Rheumatoid Arthritis Patients SAFETY AND EFFICACY OF BELIMUMAB IN OLDER ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF AN INTEGRATED ANALYSIS
ULTRASOUND-DETECTED TENOSYNOVITIS IN ANKLES WITH CLINICALLY ACTIVE DISEASE OF CHILDREN WITH NEW- ONSET JUVENILE IDIOPATHIC ARTHRITIS DOES NOT AFFECT THE CHANCE TO ACHIEVE DISEASE REMISSION Short-term risk of osteoporosis in adults treated with corticosteroids: an observational study Sexual Function Is Impaired in Women with Systemic Sclerosis Compared to Healthy Controls
Assessment of microvascular involvement in lupus nephritis patients by retinal OCT-angiography and kidney biopsies Comparison of baseline characteristics between patients continuing or discontinuing apremilast at twelve months in the REWARD study (The Netherlands) Factors influencing patient-reported outcomes in ANCA-associated vasculitis Predictors of 1-year treatment response among upadacitinib-treated patients with ankylosing spondylitis: A post hoc analysis of SELECT-AXIS 1 Improvements in Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated With Golimumab: Sub-Analysis of Asian Patients Enrolled in Phase-3 Clinical Trials Association between immune-serological profile and pulmonary manifestations in Colombian patients with systemic lupus erythematosus (LES) SUBSPECIALTY LUPUS CLINIC CARE IS ASSOCIATED WITH HIGHER QUALITY FOR PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Filgotinib Demonstrates Clinical Efficacy in Rheumatoid Arthritis Independent of Smoking Status: A Post-Hoc Subgroup Analysis of Three Phase 3 Clinical Trials Real-World Economic Implications of Achieving Low Disease Activity in Lupus Nephritis Comorbidity and long-term outcome in patients with congenital heart block: preliminary data of the Italian Registry on the Immune- Mediated Congenital Heart Block.
Extrapolation of long-term outcomes in systemic lupus erythematosus: replicating a Hopkins Lupus Cohort analysis with the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort Spondyloarthritis and sleep disorders Consistent Efficacy With Apremilast in Men and Women to Treat Oral Ulcers Associated With Behçet’s Syndrome: Phase 3 Relief Study Results Interleukin 40 (IL-40) is up-regulated in rheumatoid arthritis (RA) and associated with disease activity, levels of autoantibodies and chemokines Socio-economic impact of Sjögren's syndrome in Western Switzerland: a cross-sectional study The dynamics of inflammatory markers in COVID-19 patients treated with levilimab
PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS- ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING
Easy-BILAG: a new tool for faster and more accurate recording of BILAG-2004 disease activity in SLE
Sexual Function Is Impaired in Women with Idiopathic Inflammatory Myopathies Compared to Healthy Controls
Short-term effect of anti-IL-6 therapy on adiponectin serum levels in patients with rheumatoid arthritis IMPACT OF CANAKINUMAB AND ANAKINRA ON PATIENT-REPORTED OUTCOMES IN ADULT-ONSET STILL’S DISEASE PATIENTS EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) modifications
Prevalence of COVID-19 among patients with rheumatic diseases: an observational survey during the two waves in Italy
Therapeutic management of rheumatologists versus otorhinolaryngologists of cervicogenic dizziness Findings consistent with subclinical vasculitis in patients with new onset polymyalgia: a systematic literature review and a meta-analysis of cohort data
Rheumatoid arthritis and interstitial lung disease: prevalence and drug prescriptions in German claims data
Factors Associated with Baseline Hypertension in Early Rheumatoid Arthritis : Data from a Real-World Large Incident Cohort
Unsupervised Clustering Identifies Unique Subsets of Patients in a Racially and Ethnically Diverse Rheumatoid Arthritis Cohort. Impact of rheumatoid arthritis on stress: a systematic scoping review Risk Factors for Hospitalization in Patients with Systemic Lupus Erythematosus: a Latin Cohort
Ixekizumab shows a distinct pattern of pain improvement beyond inflammation in radiographic axial spondyloarthritis
ANALYSIS OF BIOLOGIC THERAPY RETENTION RATE IN PSORIATIC ARTHRITIS PATIENTS WITH AND WITHOUTV AXIAL INVOLVEMENT. DATA FROM CLINICAL PRACTICE
Presence of four serum autoantibodies associates with the ACPA status in early rheumatoid arthritis Diagnosis of osteoporosis using Radiofrequency Echographic Multi Spectrometry (REMS) at the lumbar spine in patients with different Body Mass Index
MiRNAs correlate with improvement in disease activity in patients with rheumatoid arthritis on tumour necrosis factor inhibitors Pregnancy in SLE patients treated with belimumab: experience from 3 Italian Centers
Hypoglycaemia following JAK inhibitor treatment in diabetes mellitus patients with rheumatoid arthritis Patient perspectives of biologic treatments for axial spondyloarthritis: satisfaction, wear-off between doses, and use of supplemental medications Guselkumab Provides Sustained Improvements in Work Productivity and Non-work Activity in Patients With Psoriatic Arthritis: Results Through 1 Year of a Phase 3 Trial Identification of autophagy-related phenotypes in primary Sjogren's syndrome Gene expression microarray in lupus nephritis by bioinformatic analysis
Impact of COVID-19 pandemic on adherence behavior of Latin-American patients with rheumatic diseases Disease control in psoriatic arthritis patients with or without axial manifestations in real clinical practice in Spain: Results from the midas study Hydroxychloroquine Induced Retinal Toxicity In Patients with Rheumatic Diseases Targeting JAK-STAT signalling alters the phenotypic characteristics of PsA synovial fibroblasts in response to the JAK/STAT activator oncostatin M The development of a novel ePRO delivery system to measure patient quality of life in routine clinical care: An analysis of 5 years of experience The Collaboration of Rheumatology-Dermatology in the Evaluation of Rheumatic Diseases Patients: Experience in a University Hospital
EPIDEMIOLOGY OF LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH RHEUMATIC IMMUNE-MEDIATED DISEASES. SINGLE UNIVERSITY STUDY OF 1117 PATIENTS Safety and efficacy of Anakinra in severe SARS-CoV2 infection (COVID19) at a tertiary hospital Evaluation of the intima-media thickness index by carotid Doppler in patients with Rheumatoid Arthritis at Hospital Docente Padre Billini, Dominican Republic
SAFETY OF BELIMUMAB IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE INTEGRATED SAFETY ANALYSIS OF CONTROLLED CLINICAL TRIAL DATA
Non-Radiographic Axial Spondyloarthritis In The Afro-Caribbean Population, Clinical Aspects And Particularities Prevalence and correlates of underweight, overweight and obesity among patients with juvenile idiopathic arthritis (JIA): Evidence from the National paediatric rheumatologic database (NPRD)
DISCORDANCE BETWEEN PATIENT’S AND PHYSICIAN’S DISEASE ACTIVITY ASSESSMENT IN RHEUMATOID ARTHRITIS: WHICH DOMAINS CAN INFLUENCE THIS DISCREPANCY WHEN REMISSION IS ACHIEVED? Clinical manifestations of SARS-CoV2 infections in children and adolescents with rheumatic and musculuskeletal diseases – survey data from Germany The influence of escalated PGA score on disease activity, daily activity, and quality of life, and solution for optimal PGA level that deserves clinical remission in patient with rheumatoid arthritis
Interstitial lung involvement in Systemic Lupus Erythematosus: Relevant clinical characteristics. Our experience in a third level hospital.
PREGNANT AND POSTPARTUM WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASES AND COVID-19: A CASE SERIES
Effect of Biologic DMARDs Treatment on Gene Expression and Activity of Natural Killer Cells in Rheumatoid Arthritis
Effects of serial locally applied water-filtered infrared A radiation in patients with systemic sclerosis with severe raynaud's syndrome receiving prostaglandine treatment – a randomized controlled trial EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Anti-acetylated protein antibodies in rheumatoid arthritis (RA): clues for the starting point of autoantibody responses in RA
Treatment pathways of rheumatoid arthritis patients leading to biologic therapy visualized in a Sankey diagram ANTI INFLIXIMAB ANTIBODIES DETECTED BY A DRUG TOLERANT ASSAY ARE FREQUENT BUT, IN MANY CASES, WITHOUT RELEVANT CLINICAL SIGNIFICANCE The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile
The subgroup of ACPA-negative rheumatoid arthritis patients achieving sustained DMARD-free remission is characterized by a different response in serological markers within the first year of DMARD-initiation Tofacitinib treatment in patients with psoriatic arthritis and probable depression and/or anxiety: a post hoc analysis of two Phase 3 clinical trials A change in a rehabilitation model increases work capacity at 36 months in low back pain MAPPING THE NATIONWIDE CLINICAL PROFILE AND PATTERNS OF CARE OF SLE IN BRAZIL – FINDINGS FROM THE MACUNAÍMA STUDY ANTIINFLAMMATORY, ANTIOXIDANT AND ANTI-ATHEROSCLEROTIC EFFECTS OF A COMBINATION OF NATURAL SUPPLEMENTS ON PATIENTS WITH FMF RELATED AA AMYLOIDOSIS: A NON-RANDOMIZED 24 WEEKS OPEN LABEL INTERVENTIONAL STUDY
STATE OF ADIPOCYTOKINES IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH SUBCLINICAL ATHEROSCLEROSIS Drug Survival for IL-6 Inhibitor Tocilizumab: data from a single-center observation
The Prevalence of Hypertension and Its Potential Associated Factors in Chinese Patients with Rheumatoid Arthritis Is imaging detected joint inflammation helpful in explaining fatigue in rheumatoid arthritis at diagnosis and during the disease course? – a large MRI study Cardiovascular disease risk in inflammatory arthritis patients still substantially elevated in 2020
High dose intravenous pulse Methotrexate in refractory Eosinophilic Fasciitis: What are the Adverse Events? Effect of carotid ultrasound on the achievement of LDL-cholesterol targets in the routine clinical care of patients with Rheumatoid Arthritis
CAN LOW-DOSE ASPIRIN DURING PREGNANCY PREVENT THE DEVELOPMENT OF ADVERSE PREGNANCY OUTCOMES IN WOMEN WITH ARTHRITIS? DATA FROM THE P-RHEUM.it STUDY
Study of methotrexate metabolites concentrations in red blood cells and mononuclear cells in rheumatoid arthritis
How has our management of SLE changed over the last three decades? Real life data from a monocentric cohort Efficacy and Safety of Belimumab in patients with Lupus Nephritis in Real-Life setting: results from a large, nationwide, multicentric, prospective cohort Functional impact of forefoot involvement in rheumatoid arthritis Accuracy and performance of a handheld ultrasound device to assess articular and periarticular pathologies in patients with inflammatory arthritis Psychiatric disorders in juvenile idiopathic arthritis - a population-based cohort study
Pain Is an Independent Associated Factor on Functional Limitation in Chinese Patients with Early Rheumatoid Arthritis Glucocorticoid discontinuation in early rheumatoid and undifferentiated arthritis patients. A sub-analysis of the BeSt and IMPROVED studies.
Reduced Bone Mineral Density in Patients with Idiopathic Inflammatory Myopathies: A Case control Study THE REMITTING SERONEGATIVE SYMMETRICAL SYNOVITIS WITH PITTING EDEMA SYNDROME (RS3PE): REVIEW OF TEN YEARS AT A REFERENCE HOSPITAL
Blunted cerebral oxygenation during exercise in non-neuropsychiatric systemic lupus erythematosus
CHARACTERISTICS OF GIANT CELL ARTERITIS FLARES AFTER SUCCESSFUL TREATMENT WITH TOCILIZUMAB: RESULTS FROM THE LONG-TERM EXTENSION OF A RANDOMIZED CONTROLLED PHASE 3 TRIAL Usefulness of FDG-PET/CT for predicting spontaneous regression in MTX associated lymphoproliferative disorder with rheumatoid arthritis. A novel Grey Scale and Power Doppler ultrasonographic score for idiopathic inflammatory myopathies: Siena Myositis Ultrasound Grading Scale. Associations between HLA-DRB1 shared epitopes alleles and anti-RA33 antibodies in different subsets of rheumatoid arthritis in Malaysian population SARS-COV-2 VACCINE HESITANCY AMONG PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES: A MESSAGE FOR RHEUMATOLOGISTS. Identifying adult hypophosphatasia in the rheumatology unit A Biomarker Profile Aiding An Early Diagnosis of Giant Cell Arteritis Influence of Colchicine prescription in COVID19-related hospital admissions: A survival analysis Quantitative autofluorescence findings in patients undergoing hydroxychloroquine treatment Temporal trends and factors associated with vitamin D prescription and intake
Detection of ABCG2 variants in encoding of urate transporters associated with the hyperuricemia in haemodialysis patients
In depth identification of risk factors for severe COVID-19, requiring hospitalization, in patients with inflammatory rheumatic diseases: results of a Dutch nested case control study (preliminary results)
Association between body shapes and body shape trajectories, and the risk of Rheumatoid Arthritis in the French E3N cohort. EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) ACPA status correlates with differential immune profile of Rheumatoid Arthritis Patients
Non-steroidal anti-inflammatory drug use is associated with disease activity and reduced significantly in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors; data from a real life experience Efficacy and safety of two courses of Rituximab Biosimilar Acellbia in patients with interstitial lung disease associated with systemic sclerosis: a prospective observational study Optimal assessment of the rheumatoid arthritis ankle and hindfoot: A comparative study between clinical examination and ultrasonography
Histopathologic patterns of lupus nephritis predict the risks of mortality- a single-center retrospective study
Patient Characteristics and Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: The OM1 RA Registry During development of rheumatoid arthritis, intermetatarsal bursitis may occur before clinical joint swelling: a large MRI study in patients with clinically suspect arthralgia
Low prevalence of SSA (anti-Ro) and SSB (anti-La) autoantibodies in female rheumatoid arthritis patients with a wish to conceive
High Correlations Between Question 1 & 2 of the BASFI: an Opportunity to Streamline the BASFI The effects and safety of apremilast and cytokine expression in Behcet's disease patients Experience with COVID-19 in German paediatric rheumatology centres
Normalization of high sensitivity CRP versus clinical response to ixekizumab at week 16 in patients with radiographic & non- radiographic axial spondyloarthritis: Results from the COAST studies
Comparison of two approaches in fractures risk assessment in women with rheumatoid arthritis and glucocorticoid use
Scores of cardiovascular risk calculators as predictors of early atherosclerosis in patients with rheumatoid arthritis
Rheumatoid arthritis per se is not risk factor for clinical fractures: Nine-year findings of the TOMORROW study Baricitinib Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo and Adalimumab in Rheumatoid Arthritis
Prevalence and Associated Factors of Sleep Disorders in Patients with Axial Spondyloarthritis. Results from the Spanish Atlas
Factors Associated with Pain Intensity in Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS) CLINICAL ASSOCIATIONS OF ANTI-RO52 ANTIBODIES IN PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES Comparative efficacy of TNF inhibitors versus other cytokine inhibitor bDMARDs on psoriatic arthritis impact of disease (PsAID) score and domains.
Decrease in anti-topoisomerase-1 antibody titer in patients with systemic sclerosis during long-term rituximab therapy
Tenosynovitis has a high sensitivity for early ACPA-positive and ACPA-negative RA: a large cross-sectional MRI study
Best cardiovascular risk calculator to predict abnormalities in left ventricular geometry in Rheumatoid Arthritis
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody in Systemic Lupus Erythematosus- A Meta Analysis Prevalence of axial spondyloarthritis among young people consulting because of chronic low back pain in a University Hospital in Argentina. Identification of molecular phenotypes in systemic sclerosis by integrative systems analysis
Serum proteomics reveals insulin-like growth factor binding proteins-1 as biomarkers for idiopathic multicentric Castleman's disease Allelic variants in the ABCG2 gene can lead to hyperuricemia and gout EPIDEMIOLOGY OF LUPUS NEPHRITIS IN BRAZIL: FINDINGS FROM THE MACUNAÍMA STUDY - A NATIONWIDE MULTICENTRIC STUDY Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co- treatment of Methotrexate Average prednisolone dose of only 1 mg per day was risk factor for clinical fractures in patients with rheumatoid arthritis - Nine-year findings of the TOMORROW study- Autoimmunity Against Collagen in Rheumatoid Arthritis (RA): Serum Levels of IgG Against Denatured Type II Collagen Significantly Elevated in RA
The relationship of genetics and clinically suspect arthralgia in RA development assessed using HC, CSA and RA patients
Association between higher intake of carbohydrates and free sugar with higher disease activity in patients with axial spondyloarthritis Acute Kidney Injury (AKI) in patients with rheumatoid arthritis (RA)
Biological reproducibility of targeted lipidome analyses in plasma and erythrocytes over a 6-week period
Investigating the anti-inflammatory potential of a novel MK2 inhibitor in a vitro model of enthesitis
Comparative metabolomic analysis of serum samples from patients with coincidental rheumatological and malignant diseases
Clinicians' perspectives on psychological distress and meeting patients' support needs in rheumatology care settings
INFLUENCE OF CONFINEMENT CARRIED OUT BY PATIENTS WITH AUTOIMMUNE AND IMMUNE- MEDIATED INFLAMMATORY DISEASE WITH BIOLOGICAL TREATMENT ON COVID-19 INFECTION EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Two-dimensional HRCT-based radiomic features in SSc-ILD distinguish drug responders from non-responders Factors associated with the development of anti-drug antibodies to tumour necrosis factor inhibitors in patients with axial spondyloarthritis; a two year follow-up study Factors Associated with Inability to Work and Disability in Patients with Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS) Fibrin Deposition is an Active Trigger of Cartilage Degeneration in Rheumatoid Arthritis Tocilizumab is safe and effective in elderly patients with rheumatoid arthritis Pain catastrophizing is associated with residual pain after reaching improved conditions of swollen/tender joints and serum C-reactive protein level OCULAR SCLERAL PATHOLOGY. UNDERLYING DISEASES AND SYSTEMIC TREATMENT. STUDY OF 175 PATIENTS FROM A SINGLE UNIVERSITY CENTER. Disease control perception by physicians and patients with ankylosing spondylitis and psoriatic arthritis in real clinical practice in Spain: MIDAS study results
Arthritic pain as a surrogate marker for asymptomatic cardiovascular risk factors: offering practitioners a ‘teachable moment’
Association of anti-citrullinated protein antibodies of IgA subclasses with sustained remission and flare in rheumatoid arthritis.
Prevalence and relevance of antibodies against citrullinated alpha enolase (anti-CEP1) in connective tissue diseases
NAILFOLD CAPILLAROSCOPY IN UNDIFFERENTIATED AND MIXED CONNECTIVE TISSUE DISEASES Effect of Filgotinib on PASDAS: Drivers of Low and Very Low Activity up to Week 100 Identification of molecular phenotypes and immune cell infiltration in systemic lupus erythematosus patients according to longitudinal gene expression
Screening and Bioinformatics Analysis of hub genes and pathways for primary Sjögren's Syndrome Based on GEO database Associations of remission and persistence of biologics at 1 and 12 years
Clinical characteristics of patients with systemic sclerosis and gastric antral vascular ectasia (GAVE) NEUTROPHIL AND MONOCYTE EXTRACELLULAR TRAPS IN RHEUMATOID ARTHRITIS: POTENTIAL SOURCE OF DIAGNOSTIC BIOMARKERS
TOLEROGENIC DENDRITIC CELLS IN RHEUMATOID ARTHRITIS PATIENTS: NEWS AND PROMISES
Wood smoke exposure is associated with higher Anti-CCP antibody titers in Hispanic Patients with Rheumatoid Arthritis.
Money matters: Assessing the value of the adalimumab biosimilar switch for Rheumatology patients Disease Activity in Pregnant Women with Rheumatoid Arthritis: Impact on the Soluble Fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio Secukinumab in patients with psoriatic arthritis and axial manifestations: Predictors of response from the double-blind, randomised, phase 3b MAXIMISE trial
Rheumatic manifestations in COVID-19 patients - single-center experience amidst the pandemic
Integrative clinical, molecular and computational analyses allow the identification of distinctive phenotypes of Rheumatoid Arthritis patients related to the clinical involvement and the response to TNF inhibitors. Oral dysbiosis reflects the immunological alteration of RA regarding to HLA DRB1*SE, ACPA and cigarette smoking : Nagasaki Island Study
Association of neutrophil lymphocyte and platelet lymphocyte ratios with joint inflammation in rheumatoid arthritis
Determining Circulating Endothelial Cells using CellSearch System in Systemic Sclerosis patients Reliability of vertebral fracture assessment on dual-energy X-ray absorptiometry THE BLOOD T-CELL SUBSETS IN RHEUMATOID ARTHRITIS PATIENTS ON LONG-TERM IL-6 RECEPTOR BLOCKER THERAPY
Clinicogenetic study of five novel susceptibility loci for Takayasu arteritis: susceptibility loci in the IL12B and PTK2B region, but not the LILRA3, DUSP22, KLHL33 regions, are associated with vascular damage in Takayasu Arteritis Multivariate Analysis of Risk Factors for Reduced Bone Mineral Density assessed with Radiofrequency Echographic Multi Spectrometry (REMS)
Using lipidomics to predict prednisolone treatment response in patients with inflammatory hand osteoarthritis: The HOPE study The association of stigma with disease variables in patients with fibromyalgia (FM) Impact of Rheumatoid Arthritis on Left Ventricular Remodeling EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Cytokine production by blood lymphocytes defines a profile associated with non-remission in patients with rheumatoid arthritis treated Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) with TNF inhibitors EPIDEMIOLOGY AND CLINICAL FEATURES OF OCULAR SARCOIDOSIS. STUDY OF 65 PATIENTS OF A SERIES OF 384 PATIENTS FROM A SINGLE UNIVERSITY HOSPITAL. Successful treatment of severe COVID-19 pneumonia and cytokine release with simultaneous tocilizumab and anakinra with one- month follow-up
First-in-Human Study of GS-5718, an Oral IRAK-4 Inhibitor, in Healthy Subjects: Pharmacokinetics, Safety, Tolerability, and Assessment of Effect of Food and Acid Reducing Agents on Exposure
The characteristics of systemic lupus erythematosus who have constitutional symptoms and lymphadenopathy
Retinal vessel calibers as a non-invasive biomarker of inflammatory burden in Primary Systemic Vasculitis The arthritis component of the SLEDAI should only be scored if there is joint swelling
Identification of hub genes and molecular pathways in patients with rheumatoid arthritis by bioinformatics analysis. Serum uric acid-to-creatinine ratio: a potential marker for gout Diastolic dysfunction associated with increased activity in Rheumatoid Arthritis. Which Prognostic Factors might predict the need for treatment adaptation in early Rheumatoid Arthritis? A comparison of machine learning, survival analysis and regression methods.
Validation of ANCA-Associated Vasculitis as the Cause of End-Stage Renal Disease in the United States Renal Data System Real World Population-based Assessment of COVID-19 Outcomes Among Rheumatoid Arthritis Patients Using Biologic or Synthetic DMARDs Trends and predictors of inpatient mortality in patients with Clostridiodes difficile infection among those with and without rheumatoid arthritis: A Nationwide analysis Cluster analysis of ankylosing spondylitis patients reveals differential drug survival of anti-TNF agents according to distinct clinical phenotype Systemic Lupus Erythematosus (SLE) Diagnosed During Hospitalization: Clinical Phenotype and Performance of the SLE Risk Probability Index (SLERPI) Effectiveness and Safety of Tocilizumab in patients with systemic sclerosis: a propensity score control matched observational study of the EUSTAR cohort
Influence of Eating Habits on Frailty among Patients with Rheumatoid Arthritis: KURAMA Cohort Relationship between hindfoot deformities and ultrasound tenosynovitis in rheumatoid arthritis Performance of ASDAS versus BASDAI during pregnancy Familial Mediterranean Fever During Pregnancy: A 26 Case Series With 38 Pregnancies The natural course of rheumatoid arthritis-associated interstitial lung disease focusing on lung physiology: a prospective observational cohort study (Part 1) High disease activity at baseline and seropositivity are associated with treatment response at one year post synovial biopsy in rheumatoid arthritis patients
Geographic Variation of Ankylosing Spondylitis (AS) Diagnosis and Treatment in the United States: A Real-World Evidence Study
LOW POSITIVITY RATE IN ANTIBODY SARS-COV2 TESTS IN PATIENTS WITH RHEUMATIC DISEASES TREATED WITH RITUXIMAB. A CASE CONTROL STUDY OF A HIGH IMPACT SARS-COV2 INFECTION AREA. IL-6 higher level after Tocilizumab treatment as a predictor of not-survival in COVID19 severe pneumonia: the experience of the COVIBAS-study
“Where does it hurt?”: Identifying pain content and its context within paediatric and adolescent rheumatology training NAD+ Boosters reestablish the altered NAD+ metabolism of Leukocytes from Rheumatoid Arthritis patients improving their Oxidative, Apoptotic and Inflammatory Status
The Importance of Physical Activity in relation to being Overweight/Obese with Axial Spondyloarthritis. Results from the Spanish Atlas The Impact of Axial Spondyloarthritis on Patients’ Sexual Life: Results from the Spanish Atlas Incidence and outcome of COVID-19 in ANCA-associated vasculitis: impact of COVID-19 in patients undergoing rituximab for maintenance Causes of Hospitalization in Behçet Syndrome
Patients’ perspective on continuation versus temporary interruption of immunomodulatory agents during infections in patients with immune-mediated inflammatory diseases: An interview study Does older really mean wiser?
A novel mechanism linking mucosal bacteria with autoantibody responses in RA: acetylated bacterial lysate as a model antigen EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Age at onset in axial spondyloarthritis around the world: data from the international ASAS-perSpA study Diagnostic value of SPECT/CT in axial spondyloarthritis and other low back pain. Efficacy of Secukinumab in TNFi-naïve Patients across the axial Spondyloarthritis Spectrum over 52 weeks: A Post hoc Analysis of the MEASURE and PREVENT Clinical Trials The impact of COVID-19 on patient management and prescribing strategy across the EU and US: A real-world survey of rheumatologists, dermatologists, and gastroenterologists
Clinical responses to upadacitinib or abatacept in patients with rheumatoid arthritis by type of prior biologic disease-modifying antirheumatic drug: Data from the phase 3 SELECT-CHOICE study
Impact of the EULAR HCP core competencies on Rheumatology Physiotherapists in the UK: survey results.
Changes of RF isotype profile in patients with rheumatoid arthritis: data from 10 years follow-up study
Query algorithms and machine learning methods as tools to identify comorbidities in large-scale free-text based fields: a case-report.
The pattern of COVID 19 pandemic among patients with autoimmune inflammatory rheumatic diseases (AIIRD)
Routine Assessment of Patient Index Data 3 (RAPID3) in patients with rheumatoid arthritis treated with long-term upadacitinib therapy
Circulating microRNA profiling in patients with Anti-synthetase syndrome and interstitial lung disease The impact of flares on patient reported outcomes in rheumatoid and undifferentiated arthritis patients – a sub-analysis of the IMPROVED study Computed tomography-based assessment of radiographic progression in spine and sacroiliac joints after pregnancy in women with ankylosing spondylitis
Treatment response to tumor necrosis factor inhibitors in adults with juvenile idiopathic arthritis: Data from the NOR-DMARD study Substantial impact of autoantibody enrichment on outcomes in early rheumatoid arthritis treated with abatacept: data from a large pooled analysis of 4 RCTs Persistence of Tfh cells after rituximab is associated with IgG4-related disease relapse Symptom rates, attitudes and medication adherence of rheumatic and musculoskeletal disease patients during the SARS-CoV2 pandemic Identification of Potential Crucial Genes and Key Pathways in pulmonary arterial hypertension with systemic sclerosis by Bioinformatic Analysis
Deep phenotyping of Psoriasis based on lipid metabolism related genes by integrative systems analysis
Analysis of primary care consultation patterns to aid diagnosis of Axial Spondyloarthritis – an exploratory case series Is it possible to identify individuals at imminent-risk of sub-clinical joint involvement?
Effect of sex in co-existent fibromyalgia and enthesitis in spondyloarthritis: ancillary analysis of the ASAS-PerSpA study MyRA Touch For Disease Activity Evaluation In Rheumatoid Arthritis: A Comparison Of Patient-Reported Outcomes With Physician’s Assessment Response to Biologic Therapy in Rheumatoid Arthritis: Rethinking Our Classification Failure to sustain treatment target after tapering tocilizumab in patients with rheumatoid arthritis: 4-year longitudinal data from a nationwide cohort Juvenile idiopathic arthritis in the context of the coronavirus disease 19 pandemic: impact on the decrease in treatment and the return to school
The accuracy of osteoporotic fracture risk prediction in patients with rheumatoid arthritis using the predictive model developed at V.A. Nasonova Reasearch Institute of Rheumatology (Russia) and Fracture Risk Assessment Tool (FRAX)
Medical cost and resource use in patients starting treatment for rheumatoid arthritis treated with and without corticosteroids in Japan
The Relation between Involvement of Individual Joints of the Upper Extremity and Grip Force in Early Rheumatoid Arthritis Canakinumab is a rescue treatment for macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis: single center experience.
NETAKIMAB EFFICACY IN ANTI-TNF-NAIVE AND ANTI-TNF-EXPERIENCED PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS OF SUBANALYSIS OF PHASE 3 ASTERA TRIAL
SECUKINUMAB LEADS TO IMPROVEMENT ACROSS PSORIATIC ARTHRITIS MANIFESTATIONS OVER 2 YEARS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR: A POST HOC ANALYSIS OF FUTURE 5 Peritenon thickening is associated with the intensity of manual sports activity. Pulmonary findings on high-resolution computed tomography in Takayasu arteritis
Interval between symptom onset and diagnosis among patients with autoimmune rheumatic diseases in a multi-ethnic Asian population Different clinical relevance of anti-citrullinated proteins antibodies in RA patients EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Identification of hub genes and pathways in dermatomyositis by bioinformatics analysis Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early vs Late Disease Through Week 52 of GO- ALIVE Study
Efficacy and safety of Acemetacin in the treatment of 1215 active ankylosing spondylitis patients: Data from a prospective cohort managed by Smart-phone SpondyloArthritis Management System
Inflammation of the hip joints in early axial spondyloatritis: data analysis of visualization methods.
Contextual factors should complete the assessment of functioning in patients with axial Spondyloarthritis (axSpA)
Differentiating the dominance of pulmonary vascular disease or interstitial lung disease on hemodynamic abnormalities in systemic sclerosis and clarifying each characteristic by using quantitative evaluation of chest CT
Non-Rheumatologists find it difficult to Identify Axial Spondyloarthritis in Women and Young people. Results from the Spanish Atlas
Greater Reduction in CLASI-A Scores Achieved With BIIB059 Versus Placebo Independently of Disease Severity at Baseline Retention Rate and Treatment Response of Biological Agents in Advanced Spinal Ankylosis and Bamboo Spine: The Real Life Data from the HUR-BIO Registry
Exogenous CXCL5 restores endogenous blood-tissue chemokine gradient to improve survival in murine lupus SCLERODERMIC HAND SENSOR: SMART TECHNOLOGY APPLIED TO RHEUMATOLOGY
Influence of baseline demographics on improvements in disease activity measures in patients with ankylosing spondylitis receiving upadacitinib: A post hoc subgroup analysis of SELECT-AXIS 1 Modelling of disease activity in patients with inflammatory arthropathies treated with etanercept originator or biosimilar as first-line biologic in an Australian real-world dataset. Assessing antibody status for SARS-CoV-2 in people with coronavirus infection: a time course study in people with autoimmune conditions
DEVELOPMENT OF A CONCEPTUAL MODEL TO UNDERSTAND DISEASE BURDEN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND LONG-TERM ORGAN DAMAGE
Sexual function in male and female patients with rheumatoid arthritis: a post-hoc analysis of the FINCH studies
Morning stiffness in clinically suspect arthralgia is explained by local subclinical synovitis and systemic inflammation. Efficacy and safety of levilimab in combination with methotrexate in subjects with active rheumatoid arthritis: phase III, double-blind, placebo-controlled, randomized trial Secukinumab Improves Physical Function and Inhibits Structural Damage in PsA Patients with Sustained Remission or Low Disease Activity: Results from a Phase 3 Study
High satisfaction with ustekinumab treatment in patients with active psoriatic arthritis – Final results of the non-interventional study SUSTAIN demonstrate early and long-term treatment response and high tolerability Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Psoriatic Arthritis – Analyses of the Phase 3 SELECT-PsA Studies Long-term effectiveness after multiple cycles with rituximab following an on-flare retreatment strategy in patients with Rheumatoid Arthritis Sarilumab attenuates disease activity in seronegative RA patients – preliminary data from a non-interventional study in regular care in Germany Immunosuppressants (Cyclophosphamide and Mycophenolate Mofetil) versus Rituximab a single-agent therapy in Scleroderma- related Interstitial Lung Disease: real clinical practice. Evaluation of the Effectiveness of Mobile App-based Exercises Programme in Patients with Neck Pain: The Randomized Controlled Trial NAILFOLD CAPILLARY DILATIONS IN RAYNAUD’S PHENOMENON: QUANTIFYING A PREDICTIVE THRESHOLD FOR THE ‘SCLERODERMA PATTERN’
Realizing early recognition of arthritis in times of increased telemedicine: The value of patient-reported swollen joints Impact of the COVID-19 Pandemic and Lockdown on Wellbeing on Patients with Rheumatic Diseases. Results from the REUMAVID Study (Phase 1) Simultaneous assessment of joint and vascular inflammation by PET-CT in tofacitinib-treated patients with rheumatoid arthritis: a prospective study PREDICTIVE FACTORS ASSOCIATED WITH DEVELOPMENT OF PSORIATIC ARTHRITIS IN PATIENTS WITH UNDERLYING PSORIASIS Improvement in the diagnostic delay of axial spondyloarthritis, results from real world data Sexual dysfunction in male patients with rheumatic diseases
Psoriatic arthritis and obesity impact drug persistence in ustekinumab-treated patients with psoriasis in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR): A 10-year follow-up study EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start PREDICTORS OF DISEASE PROGRESSION IN A MONOCENTRIC COHORT OF 100 PATIENTS WITH CHILDHOOD-ONSET Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) SYSTEMIC LUPUS ERYTHEMATOSUS
Axial psoriatic arthritis and ankylosing spondylitis. Same or different? A real-world study with emphasis on comorbidities RAS Guanyl Releasing Protein 1 (RASGRP1) in peripheral B Cells links RA to COVID-19 Prediction of Rheumatoid Arthritis Disease Activity by an Adaptive Deep Neural Network: Better Results in Seropositive Patients with Longer Disease Duration Post-trial survey of participants of a Phase 3 clinical trial in SSc-ILD RENAL DYSFUNCTION AND METABOLIC CHANGES IN PATIENTS WITH RHEUMATOID ARTHRITIS ARE ASSOCIATED WITH ANGIOPOIETIN-LIKE PROTEIN TYPE 4 A quantitative assessment of the likelihood that patients with rheumatoid arthritis will communicate information about rheumatoid arthritis risk to relatives.
Potential Efficacy Predictors Of Anti-B-Cell Therapy In the Patients with Systemic Sclerosis Associated With Interstitial Lung Disease
Ultrasound-guided Core Needle Biopsy for salivary gland enlargement in Sjögren’s syndrome: procedure safety and patient tolerance Low-intensity pulsed electromagnetic fields improve physical performance in a dose-dependent manner: an observational study in older adults with rheumatic diseases. Factors Associated with Engaging in Physical Activity in Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS)
Apical fibrosis and interstitial lung disease in patients with psoriatic arthritis: Do we underestimate? Characteristics of surgically treated tuberculous and brucellar spondylodiscitis Clinical characteristics of nonradiographic axial spondyloarthritis in Asian countries compared to other regions: results of the international cross-sectional ASAS-COMOSPA study Subclinical atherosclerosis in the first five years of Rheumatoid Arthritis diagnosis
The level of peripheral regulatory T cells is associated with the changes of intestinal microbiota in patients with rheumatoid arthritis Disease-specific adverse drug reaction profiles of adalimumab and etanercept as reported by immune-mediated inflammatory disease patients Real-life physical activity in SLE patients: associations with fatigue and quality of sleep Angiographic characteristics of vasculopathy in patients with connective tissue diseases.
Gender Differences in Clinical Features and Burden in Patients with Familial Mediterranean Fever : Preliminary Report
Scleroderma pattern in nailfold capillaries of (childhood-onset) systemic lupus erythematosus: lessons from longitudinal follow-up
Seroprevalence of SARS-CoV-2 Antibodies in Autoimmune Inflammatory Rheumatologic Patients Epidemiology and Outcomes of Patients with Rheumatic Diseases and SARS-CoV-2 Infection: Data from the Argentinean SAR- COVID Registry The role of SOCS3 in colchicine anti-inflammatory effect on COVID-19 infection Persistence of remission after tapering of Golimumab in inflammatory joint disease (IJD) Ultrasound synovitis, unlike enthesitis or clinical joint assessment, is associated with joint damage progression in patients with psoriatic arthritis
Clinical utility of breath-holding test for measuring cardiopulmonary function in patients with systemic sclerosis The Effect of One Dry Needling Session on Pain and Central Pain Processing in Patients With Knee Osteoarthritis: a Randomized Controlled Trial Monosodium urate crystals reduce Schwann cells viability
Treatment of Interstitial Lung Disease in Patients with Primary Sjogren syndrome: A Single-Center Retrospective Analysis Real-world effectiveness of etanercept and adalimumab in children and young people with juvenile idiopathic arthritis (JIA) without uveitis.
Regional Differences in Disease Characteristics of Familial Mediterranean Fever in Turkey: Preliminary Report Association of HLA-DRB1 haplotypes with cardiovascular mortality in Inflammatory Polyarthritis: Results from the Norfolk Arthritis Register Anti-TNF and methotrexate protect against Rheumatoid Arthritis atherosclerosis Gender differences in disease control and health status in patients with ankylosing spondylitis in clinical practice in Spain: Results of the MiDAS study
Targeted Serum Proteomic Analysis following Upadacitinib treatment in Ankylosing Spondylitis shows robust suppression of innate and adaptive immune pathways with tissue repair modulation
Predictive factors for pulmonary progression in patients with connective tissue disease and interstitial lung disease Cardiovascular Risk Factors in a Mexican Mestizo patients with Psoriatic Arthritis
Biomarkers reflecting disturbed gut barrier differ in patients with spondyloarthritis, Crohn’s disease and acute anterior uveitis EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
TREATMENT STRATEGIES IN CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS (CMRO) OR CHRONIC NON- Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) BACTERIAL OSTEOMYELITIS (CNO): SYSTEMATIC REVIEW AND META-ANALYSIS Work Participation in Patients with Axial Spondyloarthritis in Germany: Results from a Multicenter, Observational Survey (ATTENTUS- axSpA)
SEX DIFFERENCES IN SYSTEMIC SCLEROSIS PATIENTS IN A SINGLE CENTER IN EASTERN EUROPE SARS-CoV-2 infection among patients with Behçet’s syndrome Comparative Analysis of the Clinical and Laboratory Properties of Gout, Osteoarthritis, and Calcium Pyrophosphate Deposition Disease COVID-19 vaccine willingness in RA? Results from the RA Louvain Brussels cohort Six-year results from the Esperanza Cohort: evaluation of clinical features, disease activity measures and treatment aspects in axial and peripheral early Spondyloarthritis. Rheumatological patients performing blood self-sampling for DMARD therapy safety: A proof of concept study comparing with venous blood samples. OSTEOPOROSIS AND INSUFFICIENCY RISK FACTORS IN PSORIATIC ARTHRITIS Ultrasound-guided core needle biopsy: an effective and safe tool to diagnose Sjögren`s syndrome and lymphoma of the major salivary glands
Verification of manifestations of sarcopenia in obese patients with three methods for body composition assessment Improvement in modified Rodnan Skin Score (mRSS) in Systemic Sclerosis patients treated with Rituximab: a systematic review and Meta-analysis of the Scientific literature Overlapping features of relapsing polychondritis and Sweet’s syndrome: could this be VEXAS (vacuoles, ubiquitin A1E mutation, X- linked, autoinflammatory, somatic) syndrome? Ultrasound assessment of dermal thickness and skin stiffness in undifferentiated connective tissue disease at risk for systemic sclerosis Exploring novel tenosynovitis and combined inflammation imaging outcomes: results from a randomised controlled trial in early rheumatoid arthritis PERIODONTAL DISEASE IN RHEUMATOID ARTHRITIS: RESULTS FROM A COHORT AT TREATMENT WITH BIOLOGICAL, CLASSICAL AND TARGETED SYNTHETIC DMARDs Factors associated with chronotropic response in people with rheumatoid arthritis.
DNA methylation signatures characterize psoriasis and psoriatic arthritis in monozygotic twins discordant for the disease
Investigating the Ankylosing Spondylitis-Associated Regulatory SNPs at the RUNX3 Locus with a Functional Genomics approach Incidence of gastro-intestinal complications in rheumatoid arthritis patients receiving biological DMARDs in observational cohort studies: a systematic literature review and meta-analysis Sarcopenia in myositis patients: a marker of muscle damage associated with handicap Do peripheral and extra musculoskeletal manifestations have an impact on biologic DMARD prescribing patterns in axial spondyloarthritis: the results of TREASURE experience
Quantitative CT indexes: Promising Tools for Objective Assessment of Pulmonary Fibrosis in Systemic Sclerosis Quantification of Bone Marrow Edema by MRI of the Sacroiliac Joints in Patients Diagnosed with Axial Spondyloarthritis: Results from the ESPeranza Cohort The spectrum of non-tuberculous osteoarticular infections in a rheumatology department during the years 2010-2020: a retrospective study of 102 consecutive cases in a single center.
UNMET TREATMENT NEEDS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A CROSS-SECTIONAL ASSESSMENT OF DISEASE ACTIVITY IN SLE PATIENTS DURING THEIR LAST VISIT Evaluation of E148Q and concomitant AA Amyloidosis secondary to familial Mediterranean fever after adjusted clinical-demographic characteristics
Alteration of duodenal histology in systemic sclerosis patients after fecal microbiota transplantation The Impact of COVID-19 on rheumatology health care workers and their scientific output: heavy lies the crown on female rheumatologists ADULT-ONSET STILL’S DISEASE: A Single-Center Experience
Is bioelectrical phase angle associated with functional status and disease impact in patients with Rheumatoid Arthritis? The natural course of rheumatoid arthritis-associated interstitial lung disease focusing on lung physiology and disease activity: a prospective cohort study (Part 2) A new approach for ultrasound guided sacroiliac joint injections in spondyloarthritis Factors associated with mortality in patients with rheumatic diseases and COVID-19 in Mexico Positive impact of the first lockdown in patients with chronic inflammatory rheumatism Radiosynovectomy in a clinical setting: An underexploited tool at our disposal.
Do JIA patients response to re-treatment after a flare during tapering of bDMARDs? A descriptive study
Clinical and surrogate cardiovascular risk assessment and its relationship with Psoriatic Arthritis pathogenesis
Safety profile of Pfizer-BioNTech COVID-19 vaccine in patients with rheumatic diseases: preliminary assessment
UVEITIS IN 1449 PATIENTS WITH INFLAMMATORY BOWEL DISEASE. STUDY FROM A SINGLE UNIVERSITY CENTER
Hyperkyphosis in axial spondyloarthritis: factors that produce its appearance and effect on mobility and function. Emergence of De Novo Manifestations During Infliximab Treatment in Behçet Syndrome Comparison of demographic and clinical features of Familial Mediterranean Fever patients and patients with Axial Spondyloarthritis accompanying Familial Mediterranean Fever EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
COMORBIDITY BURDEN IS HIGH IN RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS PATIENTS STARTING Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) BIOLOGICS AND PREDICTS THE INCIDENCE OF SERIOUS ADVERSE EVENTS DURING THERAPY
Treatment of Polymyalgia rheumatica with TOCILIZUMAB: Results of an Observational Retrospective Multicenter Study
Familial Periodic Fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA)syndrome; is it a separate disease? Higher prevalence of subclinical atherosclerosis in Psoriatic Arthritis patients How important would be the impact of spondyloarthritis on military population's working life?
Anti-IL-6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single Center Experience. Disease activity and pain levels are not influenced by the current COVID19 pandemic in patients with rheumatic diseases in Germany – Data from the German COVID-19 patient survey
A novel model to assess disease activity in Takayasu arteritis based on 18F-FDG-PET/CT: a Chinese cohort study A Data Science Evaluation Of The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) Questionnaire For Improving Management Of JIA Patients
Type I interferon pathway assays in patients with rheumatic and musculoskeletal diseases - Systematic literature review (SLR) and development of consensus terminology from a EULAR taskforce.
Clinical features and outcomes of COVID-19 in patients with IgG4-related disease. A collaborative European multi-centre study. Clinical and functional response to tofacitinib in patients with rheumatoid arthritis: probability plot analysis of results from a 48-week Phase 3b/4 methotrexate withdrawal study The impact of antinuclear antibodies induced by anti-tumour necrosis factor alpha agents on the long-term treatment outcomes in rheumatoid arthritis patients Complex landscape of BIRC5/survivin genome binding in human CD4+ T cells
BIOLOGICAL THERAPY IN UVEITIS ASOCIATED TO AXIAL SPONDYLOARTHRITIS. SINGLE CENTER UNIVERSITY STUDY Effectiveness and safety of original and biosimilar etanercept (Enbrel® vs Benepali®) in bDMARD-naïve patients in a real-world cohort of Portugal
Influenza infection as a trigger for systemic lupus erythematosus flares resulting in hospitalization Tuberculous spondylodiscitis in elderly: epidemiology, clinical, features, treatment and outcomes Multisystem Inflammatory Syndrome in Children During the COVID-19 Pandemic in Turkey: First Report from The Eastern Mediterranean
Rituximab for induction of remission in type 1 autoimmune pancreatitis: a systematic review and meta-analysis. HYDROXYCLOROQUINE-INDUCED ATRIOVENTRICULAR BLOCK IN IMMUNE-MEDIATED DISEASES. SINGLE UNIVERSITY CENTER STUDY OF 293 PATIENTS
ANTIRESORPTIVE THERAPY AFTER TERIPARATIDE DISCONTINUATION – WHEN IS THE BEST TIME TO STARTING IT?
Clinical and radiological manifestations of coxitis in patients with ankylosing spondylitis (AS) treated with TNF-alpha inhibitor golimumab: results of a 24-months observation (GO-COX study) Detection of Autoantibodies against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort Performance of the new ACR/EULAR 2019 classification criteria for systemic lupus erythematosus (SLE) in a cohort of argentinian patients.
Audiologic Evaluation In Systemic Lupus Erythematosus Patients and Impact Of Hydroxychloroquine Therapy
HAVE THE CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AN EXCESS OF ADIPOSITY? What is the role of vitamin D status in disease activity in rheumatoid arthritis patients treated with bDMARDs? – data from a Rheumatology Center Sex differences in the efficacy and safety of tofacitinib in rheumatoid arthritis patients: a post hoc analysis of Phase 3 and long-term extension trials Dysregulated CD38 expression on peripheral blood immune cell subsets in SLE Non-contiguous multifocal spondylodiscitis: a case series and review of literature
RETINOL BINDING PROTEIN 4 AS AN ACUTE PHASE REACTANT AND BIOMARKER IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND AMYLOIDOSIS COMPARED TO INFECTIONS
The role of chest CT in understanding interstitial lung disease (ILD): Systemic Sclerosis (SSc). versus COVID-19 RELATIONSHIP BETWEEN IMPAIRED MELATONIN SECRETION AND DURATION, RADIOLOGICAL STAGE AND PHYSICAL ACTIVITY OF RHEUMATOID ARTHRITIS Development of rheumatoid arthritis among anti-citrullinated protein antibodies positive asymptomatic individuals: A prospective observational study
Use of Baricitinib and Tocilizumab for the treatment of moderate to severe COVID-19 in hospitalized patients
PREDICTING CARDIOVASCULAR EVENTS IN PATIENTS WITH SPONDYLOARTHRITIS : 3 RISK ALGORITHMS Sacroiliac Joint MRI Abnormalities in Juvenile Spondyloarthritis: an Update of Definitions and Scoring of the OMERACT Juvenile Idiopathic Arthritis MRI Score COVID-19 INFECTION IN RHEUMATIC IMMUNE-MEDIATED INFLAMMATORY DISEASES. EPIDEMIOLOGICAL STUDY IN A SINGLE UNIVERSITY HOSPITAL EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Predictive value of anti-interferon-inducible protein 16 antibodies for digital ulcers of systemic sclerosis The experience of a Rheumatology Unit during the COVID19 lockdown: Telemedicine allows a safe follow up of patients with rheumatic diseases Aminaphtone long-term treatment in Systemic Sclerosis Clinical course of new SARS-CoV-2 infection in children with rheumatic diseases: retrospective study of single pediatric rheumatology center
Assessment of interreader reliability in scoring patients with hand osteoarthritis and psoriatic arthritis by fluorescence optical imaging Long-term outcome in children with juvenile dermatomyositis from southern India Incidence and phenotype of antiphospholipid syndrome (APS) after preeclampsia Association of Rheumatoid Arthritis with Mortality in a cohort of Chronic Kidney Disease patients
MORTALITY RATE RELATED TO COVID - 19 IN RHEUMATIC AND MUSCULOSKELETAL DISEASES (RMDs) Berberine modulate lupus syndrome via the regulation of gut microbiota in MRL/Lpr mice Long-Term Outcomes of Children Born to Women with Rheumatoid Arthritis Anxiety, depression, fibromyalgia syndrome and pain intensity in patients with low back pain Comparing the ultrasonographic evaluation in patients with Japanese rheumatoid arthritis between Baricitinib and TNF antagonist therapy
Chondrocalcinosis as predictor of development of primary hyperparathyroidism: results of the follow-up observation.
Incidence and outcome of COVID-19 in routine rheumatology care: Data from a single outpatient center in Germany
Mortality of COVID-19 in patients with rheumatic diseases: comparison to the general population in México Noncoding RNA contribute to pathogenesis in primary gouty arthritis Visual function and quality of life: preliminary results from a pivotal cross-sectional study on one hundred patients with juvenile idiopathic arthritis-associated and idiopathic uveitis Mental Health Screening in Patients with Juvenile Idiopathic Arthritis Clinical features, prognostic factors, and outcome of Anti-MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease: a multicenter study of 238 patients Infliximab For Vascular Involvement In Behçet Syndrome
Interleukin-4 activates eosinophils and CCR3-positive T helper cells migration to fascia and promotes fibrosis in eosinophilic fasciitis
Two-minute walk test as a simple and objective outcome measure in Idiopathic Inflammatory Myositis Relationship between involved joint for region and modified Health Assessment Questionnaire score in Japanese patient with rheumatoid arthritis Automated detection of sclerodermiform patterns using Capillary.io Spondilodiscitis without documented germ: what therapeutic management? Clinical features and outcome of 1054 patients with Systemic Sclerosis: an analysis of the Portuguese Reuma.pt registry for Scleroderma (Reuma.pt/SSc) Oral Status in patients with Rheumatoid Arthritis
Incidence and determinants associated with retransitioning from biosimilar SB4 to originator etanercept Clinical utility of screening tools in referral of patients with hand arthralgia to rheumatologists
Obesity rates and BMI are similar in age and sex matched rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients Osteoporosis in Psoriatic Arthritis: A 5 Year Prospective Study of an Outpatient Clinic Cohort A multi-predictor model to predict risk of scleroderma renal crisis in systemic sclerosis Combined Analysis of Metabolic and Transcriptomic Kidney Profiles of NZW/B-F1 Murine Lupus Uncovers Biological Mechanisms Preceding the Onset of nephritis
Short-term and mid-term efficacy of caudal epidural steroid injections in the management of degenerative sciatica
Trajectory clusters of radiographic progression in rheumatoid arthritis patients: associations with clinical variables
Myocardial infarctions, subtypes, locations and coronary atherosclerosis in SLE - a comparative study with matched controls
Outcome following COVID-19 infection in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Comparison of three different algorithms for the treatment of children with polyarticular JIA: the first year after diagnosis Comprehensive immune profiling of peripheral blood in psoriatic arthritis (PsA) patients: Expansion of intermediate monocytes and decreased T reg and CD8 T cells Relationship between paraoxonase-1 genotype, activity and major adverse cardiovascular events in patients with rheumatoid arthritis receiving tofacitinib NLRC4 AND FC-γ-R CROSSTALK ON CD1C+ DENDRITIC CELLS DIFFERENTIALLY CONTRIBUTES TO RHEUMATOID ARTHRITIS IMMUNOPATHOLOGY. ANNALYSIS OF PRO-INFLAMMATORY BIOMARKERS IN A POLYMYALGIA RHEUMATICA COHORT DURING THE ACUTE ONSET OF THE DISEASE
Evaluation of patients with (suspected) Behçet syndrome; diagnostic value of pathergy testing and ophthalmologic examination Non-Invasive Cutaneous Assessment Of Systemic Sclerosis- The New Outlooks Long-term efficacy and safety of canakinumab in patients with TRAPS (tumor necrosis factor receptor-associated periodic syndrome) - Interim analysis of the RELIANCE Registry Let’s take a look at the symphysis pubic area in spondylarthritis EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start serum Matrix Metaloprotinase 3 as a marker to discriminate subclinical disease activity from ultrasound defined remission in patients Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) with rheumatoid arthritis
Drug Retention Rate, Reasons for Discontinuation and Outcome of Infliximab Use in Behçet Syndrome Disconnect between treatment switches and disease activity state in early Psoriatic Arthritis
Differential clinical presentation between SLE ruphus patients and SLE non-rhupus patients: a case-control study
Echocardiographic findings in systemic lupus erythematosus patients and its relation to antibodies titers Impact of COVID-19 on initiation and renewal of biotherapies and targeted synthetic treatments Launching a New Relapsing Polychondritis ("RP") Program Raynaud’s Phenomenon in a Single Center Cohort of Turkish Children Foot Disorders and Falls risk in Older Persons Impact of the change in administration route of Tocilizumab and Abatacept, due to the COVID-19 lockdown on disease activity in patients with rheumatoid arthritis. Non-obese Rheumatoid arthritis patients with low Low-density lipoprotein have greater coronary atherosclerosis burden, plaque progression and cardiovascular event risk ASSOCIATION BETWEEN SERUM URATE AND INFLAMMATORY MARKERS IN YOUNG ADULTS: CROSS-SECTIONAL FINDINGS FROM A BIRTH COHORT
Effect of rheumatoid arthritis treatments on the intima-media thickness of supra-aortic trunks and on cardiovascular risk: Prognostic factors for aggravated vascular damage in Takayasu arteritis
The role of serum calprotectin in the diagnosis of inflammatory bowel disease in patients with Ankylosing spondylitis Myositis-specific antibodies in a retrospective single-center observational study
Characteristics of interstitial lung disease in patients with systemic sclerosis during long term follow-up, single center experience. The prevalence and clinical significance of ultrasonographic findings of distal medial hamstring tendons in patients with posteromedial knee pain The longitudinal associations of methotrexate and biologic use on hospital admission for rheumatoid arthritis patients in Western Australia population (1995- 2014) Biologic Treatment of Adult-Onset Still’s Disease: A Single Center Experience Catastrophizing in patients with psoriatic arthritis Catastrophizing in patients with spondyloarthritis Gout and Joint Replacements in the US
BIOLOGICAL THERAPY IN REFRACTORY NEUROBEHÇET’S DISEASE. MULTICENTER STUDY OF 42 PATIENTS Comparison of the frequency of detection of early signs of atherosclerosis in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis.
Elevated expression of Tim-3 on neutrophils correlates with disease activity and severity of Ankylosing spondylitis Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Treatment of ankylosing spondylitis with tumor necrosis factor-alpha inhibitors lowers the risk of renal function decline
Disease Severity and Outcomes Among Patients With Rheumatoid Arthritis Who Receive a Newly Approved Biologic: Real-World US Experience with Sarilumab from the ACR RISE Registry Symptoms characteristics of seropositive individuals at-risk for developing rheumatoid arthritis are versatile and comparable to those in people with early rheumatoid arthritis
Prevalence and risk factors for herpes zoster reactivation in 1542 patients with rheumatic diseases
Expression and clinical significance of autophagy-related genes in peripheral blood mononuclear cells of systemic sclerosis Infections and other adverse effects with biological therapies over the past 10 years
Descriptive study of the perceptions and preventive practices of postmenopausal tunisian women regarding osteoporosis Comorbidities associated to spondyloarthritis Follicular dendritic cell networks in minor salivary gland biopsies: a marker of disease activity at baseline and during the follow-up in Sjögren’s syndrome Ultra High‑resolution Ultrasound (UHFUS) of labial glands is a strong predictor of salivary gland histopathology in Sjögren's syndrome (pSS) Relationships between saliva immunoglobulins free light chains concentration and clinical, immunological, histological parameters in patient with primary Sjogren’s syndrome Vitamin D deficiency is mainly associated with severe lung involvement, longer disease duration and risk of death in elderly COVID-19 patients. TREATMENT ACCESS AND ADHERENCE DURING SOCIAL PREVENTIVE AND MANDATORY ISOLATION IN ARGENTINIAN PATIENTS WITH SPONDYLARTHRITIS AGGREGATED SURVIVIN BINDING AROUND HISTONE H3 EPIGENETIC MODIFICATIONS IN RISK LOCI ASSOCIATED WITH RHEUMATOID ARTHRITIS High Prevalence of Abdominal Obesity in Females with Axial Spondyloarthropathy Survival of giant cell arteritis patients in Slovenia NEUROSARCOIDOSIS. STUDY OF 30 PATIENTS FROM A SERIES OF 384 SYSTEMIC SARCOIDOSIS FROM A TERTIARY UNIVERSITY HOSPITAL A molecular signature response classifier predicts the likelihood of EULAR non-response to TNF inhibitor therapies in RA: results from a retrospective cohort analysis EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Aesthetic impairment in patients with systemic sclerosis: a case control study using a semi-quantitative scale for body image Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) assessment. Laboratory ratios: a subrogate biomarker for detection of infection in SLE patients.
DIFFERENCES IN CLINICAL MANIFESTATION AND DISEASE ACTIVITY OF PEDIATRIC BEHÇET DISEASE: A CROSS- SECTIONAL COHORT COMPARISON BETWEEN TURKEY AND UNITED STATES Impact of joint destruction in the hands, the wrists and the ankles on the ultrasound assessment and the functional outcomes in rheumatoid arthritis in remission
Is nutritional follow-up in patients living with rheumatoid arthritis better with teleconsultation? - Experience before and after pandemic Evaluation of coping strategies in rheumatoid arthritis patients
CORRELATION BETWEEN EXPRESSION LEVELS OF MIR-155 AND MIR-223 IN SYNOVIAL FLUID AND ULTRASOUND SCORES FOR ACTIVE SYNOVITIS IN RHEUMATOID ARTHRITIS PATIENTS The course of coronavirus disease 2019 (COVID‑19) in patients with Sjogren’s syndrome treated with anti-CD20 monoclonal antibody (rituximab) The Relationship of Mast Cell Activation Syndrome and Hypermobile Ehlers-Danlos Syndrome in Hospitalized Patients in the United States
Challenges of Egyptian patients with Systemic Lupus Erythematosus during COVID-19 Pandemic
Application of the new ACR/EULAR 2019 classification criteria of Systemic Lupus Erythematosus to a inception, monocentric cohort of Undifferentiated Connective Tissue Diseases population at onset of the disease. Assessing relevant joints for monitoring CPPD disease: A Systematic Literature Review of imaging techniques by the OMERACT Ultrasound – CPPD subgroup
Optimizing a Referral Strategy for Patients with a High Probability of Axial Spondyloarthritis: the Role of Age and Symptom Duration
Reduction in monocyte count predicts sustained remission in rheumatoid arthritis patients treated with anti-TNF therapy Distribution of comorbidities in spondyloarthritis with regard to the phenotype and the presence of psoriasis: data from the ASAS- COMOSPA study. Psoriatic Disease – a heterogenous disease who needs a multidisciplinary care! EULAR Recommendation-based Quality Indicators (QIs) for Systemic Lupus Erythematosus (SLE): Elaboration, Final Set, Performance and Initial Validation Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events in patients with psoriatic arthritis: a time-dependent Cox regression analysis. Obesity phenotypes in early rheumatoid arthritis
Reproducibility of a new automatic system (CAPILLARY.IO) in the analysis of Nailfold Capillaroscopy images Rheumatologic diseases as presentations of primary immunodeficiency diseases Optical spectral transmission (HandScan) in patients with psoriatic arthritis: first data on diagnostic value and associations with clinical and ultrasound disease activity markers. EPIDEMIOLOGICAL AND CLINICAL DIFFERENCES BETWEEN ANTI-MDA5 PHENOTYPES: DATA FROM A LARGE COHORT (MEDRA5) STUDY Long-term efficacy and safety of canakinumab in patients with Familial Mediterranean Fever (FMF) - Interim analysis of the RELIANCE Registry Prevalence of chondrocalcinosis in patients with inflammatory rheumatic diseases – frequently found in patients with rheumatoid arthritis and vice versa Central sensitization has major impact on quality of life in patients with axial spondyloarthritis Left ventricular geometric abnormalities associated with higher titers of rheumatoid factor and anti-cyclic citrullinated peptide antibodies in Rheumatoid Arthritis patients
Duration of starting bDMARDs are almost 3 times longer in RA patients than PsA patients: HUR-BIO real life results
The associated factors of ultrasonographic tenosynovitis in patients with rheumatoid arthritis in remission IMPACT OF A PRE-EXISTING INTERSTITIAL LUNG DISEASE ON SEVERITY OF COVID-19 IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES
The Journey of Patients from First Symptoms to Diagnosis of Systemic Lupus Erythematosus (SLE): An Observational Study
Risk factors for the development of diabetes mellitus in patients with gout according to a 6-year prospective follow-up study. Is active synovitis of metacarpophalangeal joints a neuropathic condition in rheumatoid arthritis patients? Results from a ultrasound study at level of the palmar digital nerves
A nationwide cohort study on clinical and laboratory manifestations in children with multisystem inflammatory syndrome (MIS-C) Do biologics improve fatigue in patients with rheumatoid arthritis?
Association of body fat mass and its distribution with disease activity, pain and disability in rheumatoid arthritis.
Telemedicine and Management of the patient affected by giant cell arteritis during the COVID-19 pandemic - TELEMACOV The impact of tumour necrosis factor-alpha inhibitor treatment on Wnt signaling inhibitors, noggin and cytokine levels in axial spondyloarthritis Preliminary results of long-term follow-up of the health status of patients using csDMARDs and b/tsDMARDS for rheumatic diseases during the COVID-19 pandemic Clinical characterization of Portuguese patients with Antisynthetase syndrome Treatment knowledge and preferences for Black people with hip and knee osteoarthritis: A Systematic Literature Review and Meta- analysis EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
CONCORDANCE BETWEEN THE QUANTIFERON-TB GOLD IN-TUBE AND TUBERCULIN TEST FOR THE DIAGNOSIS OF Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH RHEUMATIC DISEASES
A CITIZEN SCIENCE APPROACH TO CAPTURE POOR MENTAL HEALTH RELATED TO COVID-19 IN RHEUMATIC PATIENTS AFTER CONFINEMENT DURING PANDEMIC IN ITALY The effect of M694V homozygosity on the carotid intima-media thickness and flow mediated dilatation in patients with FMF related amyloidosis Missing the window of opportunity: early arthritis clinics in times of COVID-19 Algorithm for differential diagnosis of arthropathies using osteoscintigraphy
Direct comparison of effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis in real-world settings
The impact of non-persistence on resource utilization costs in immune-mediated rheumatic diseases
Fascial ultrasound: the context for dry needling trigger points in treatment of myofascial pain, postural imbalance
Clinical characteristics, imaging phenotype, and long-term outcomes of Takayasu arteritis patients with hypertension
Validation of the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for systemic lupus erythematosus (SLE) in Hong Kong Chinese
Triple-positivity and Antinuclear Antibodies, insights on disease activity: a retrospective cohort study of Colombian RA patients Early factors associated with the initiation of treatment with biologics in patients with Axial Spondyloarthritis – results from a single centre retrospective cohort study.
Treatment of Uveitis Associated With Juvenile Idiopathic Arthritis: a Seven Years' Single-Centre Experience Development of a diagnostic algorithm for the differential diagnosis of interstitial lung disease: preliminary data from a multicenter retrospective case-control study Adverse drug reactions in tuberculosis and management Interleukin-37: associations of plasma levels and genetic variants in gout Infection risk among rheumatic patients receiving denosumab therapy: single centre experience
Favourable Short-Term Course of COVID-19 in Patients with Familial Mediterranean Fever Using Biologic Agents THE ROLE OF MUSCULOSKELETAL ULTRASOUND IN PREDICTING THE RESPONSE TO JAK INHIBITORS: RESULTS FROM A LARGE MONOCENTRIC COHORT Defining ear chondritis: Data from 685 patients with relapsing polychondritis
Comparison of carotid subclinical atherosclerosis and structural damage in axial spondylitis with and without concomitant inflammatory bowel disease. A multicenter study with 886 patients. . A multicenter study with 886 patients. TMT-based quantitative proteomics analysis of synovial fluid-derived exosomes in rheumatoid arthritis, axial spondyloarthritis, gout and osteoarthritis Procalcitonin in rheumatology High incidence and mortality of Pneumocystis jiroveci infection in anti-MDA5-antibody positive dermatomyositis: experience from a single center
Co prescription of Anti-acid therapy reduces the bio availability of mycophenolate mofetil in systemic sclerosis patients Both spondyloarthritis and psoriatic arthritis patients have strong family histories Clinical and radiological features of seropositive psoriatic arthritis Lupus nephritis: histological features and long term outcomes in a large single-centre cohort The role of urinary tract infections as a source of osteoarticular infections in a rheumatology department during the 2010-2020 period: a retrospective study. COVID-19 in patients with systemic sclerosis: one rheumatology center experience
MONOGENIC AUTO-INFLAMMATORY DISEASES IN ADULTS IN THE PRACTICE OF A RHEUMATOLOGIST
The association between bariatric surgery and Dupuytren disease: a cohort study from Swedish nationwide healthcare registries
Reactogenicity of SARS-CoV-2 Vaccines in Patients with Autoimmune and Inflammatory Disease Could be interstitial myocarditis a feature of the antisynthetase syndrome?
Anti-MDA5 and antisynthetase antibodies screening in severe SARS-CoV-2 pneumonia. Be aware of false positive results. Comparison of numerical rating scale (NRS) and visual analogue scale (VAS) in the patient reported outcome measures of 3VAS and 4VAS in Psoriatic Arthritis The effect of arthritis treatment on the course of rheumatoid arthritis-associated interstitial lung disease focusing on biologic DMARDs: from a prospective cohort study (Part 5) Developing a Tool to Measure the Learning Curve: Enthesitis Ultrasound in Psoriasis Arthritis
COVID-19 in Italian patients with rheumatic autoimmune systemic diseases: results of a nationwide survey study
Aberrant Th17 cells expansion and risk factors in ankylosing spondylitis patients complicated with cardiovascular events
The association between social stressors and disease remission among men and women with early rheumatoid arthritis
Comparison of the efficacy and safety of original and biosimilar adalimumab molecules in childhood rheumatic diseases
Regulation of intestinal flora restores immune balance in patients with undifferentiated spondyloarthritis EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Usefulness of synovial biopsy in the differential diagnosis and as possible predictor of response to treatment in juvenile idiopathic Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) arthritis
Latent tuberculosis infection in rheumatic diseases: a real-life study of three Apulian centres. Data from BIOPURE registry ANTIPHOSPHOLIPID ANTIBODIES AND COVID-19: TREND OVER TIME
The impact of anti-Ro antibodies in pregnant patients with Systemic Lupus Erythematosus and Sjögren’s Syndrome
Asymptomatic Enthesitis and Dominant Side Related Patterns in Spondyloarthritis – The Role of Ultrasonography in Everyday Practice
Clot lysis time predicts recurrent digital ulcers in systemic sclerosis after one year of follow-up: A nested case-control study Local adaptation of recommendation-based materials for shared decision-making and management of comorbidity in rheumatoid arthritis
Treatment survival on biologics in patients with axial spondyloarthritis – data from Moscow Unified Arthritis Registry (MUAR) FERTILITY AND PREGNANCY OUTCOMES IN TAKAYASU’S ARTERITIS
Serum uric acid to creatinine ratio is associated with urinary uric acid excretion in patients with gout Spinal location of tuberculosis: what has changed over the last years? Number and co-expression of TNF receptors type 1 and 2 on immunocompetent cells are associated with stability of remission in rheumatoid arthritis patients Investigation on the effect and mechanism of abnormally activated CD8+ T cells from bone marrow on hematopoietic stem cells in patients with systemic lupus erythematosus Changing expression profiles of long noncoding RNAs, miRNAs, mRNAs and circular RNAs in labial salivary glands of primary Sjögren’s syndrome (pSS) Fibroblasts are not just fibroblasts - clear differences in ECM production between dermal and lung fibroblasts in response to growth factors Sustained 2-year remission of the disease in a clinic of excellence in rheumatoid arthritis. Experience of the clinical registry in Colombia. The formula to predict tacrolimus concentration according to genotyping of CYP3A5 is useful for effective treatment in interstitial lung disease with dermatomyositis HYPOGAMMAGLOBULINEMIA IS A SIGNIFICANT RISK FACTOR FOR MORTALITY IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS AND COVID-19 Improved survival in Systemic Sclerosis patients during last decade: current findings and comparison with different previous Italian cohorts. Dose-dependent Relationship Between History of Dental Caries And Increased Risk of Newly-onset Systemic Lupus Erythematosus: A Nationwide Population-Based Cohort Study The patient global assessment (PGA) of disease activity collects different information in early compared to established rheumatoid arthritis. Predictors of Endothelial Dysfunction in Ankylosing Spondylitis
SEVERE RESPIRATORY INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS WITH BIOLOGIC THERAPY. COMPARATIVE STUDY BETWEEN VACCINATED AND NON VACCINATED PATIENTS. EULAR RECOMMENDATIONS ON GIANT CELL ARTERITIS IN REAL LIFE Single dose tocilizumab pharmacokinetics in glucocorticoid pre-treated COVID-19 patients during cytokine storm syndrome hyperinflammatory episode: less is more Self- and shared-management interventions for children, young people, and families living with rheumatic and musculoskeletal diseases: An integrative review
Does time to remission differ depending on route of administration of Methotrexate in an Early Arthritis Treat to Target (T2T) cohort? How does obesity influence the features of knee osteoarthritis ?
Detection of the gene expressions in peripheral blood involved in the progression of pulmonary vessel disease at the subclinical stage of pulmonary hypertension associated with systemic sclerosis.
Infectious Risk During Biologic Therapy For Inflammatory Rheumatic Diseases: Data From The Tunisian BINAR Registry
ASSESSMENT OF DAREA AND MODIFIED DAREA IN AN ARGENTINIAN-GUATEMALAN REACTIVE ARTHRITIS COHORT Rheumatoid arthritis is an inflammatory disease with a high cardiovascular risk. WHEN DO THE ACTIVE SACROILIITIS MRI FINDINGS LOSS IN ANKYLOSING SPONDYLITIS? A RETROSPECTIVE, CROSS- SECTIONAL, OBSERVATIONAL STUDY APLs-associated Retinal Vasculopathy as a Presentation of Thrombotic Microangiopathy The Enhanced Liver Fibrosis (ELF) score as a biomarker of skin fibrosis in systemic sclerosis
Safety of anakinra in patients with cryopyrin associated periodic syndromes (CAPS) using a graduated pre-filled syringe
ROLE OF SYSTEMIC AUTOINMUNE CONDITIONS IN HOSPITAL ADMISSIONS RELATED TO COVID-19 ASSESSMENT OF EMOTIONAL WELL-BEING IN RHEUMATIC PATIENTS DURING COVID-19 LOCKDOWN THROUGH A WEB- BASED SURVEY APPROACH Circulating Exosomes Promote Lupus Nephritis in MRL-lpr Mice A Cohort Study On The Risk of Developing Obstructive Sleep Apnea, Temporomandibular Joint Disorders and Craniofacial Deformities In Patients With Juvenile Idiopathic Arthritis Adiponectin induces synovial angiogenesis in rheumatoid arthritis through metabolic remodeling Psoriatic arthritis with hyperuricemia: more peripheral, destructive and challenging to treat Molecular profiling of radiographic axial spondyloarthritis patients reveals an association between innate and adaptive cell populations and therapeutic response to adalimumab EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Evaluation of the effect of mTOR expression on the clinical manifestations of knee osteoarthritis in obese and normal weight patients. Post-immunization with collagen V confers a disadvantageous immune matrices microenvironment for early lung fibrosis in a SSc mouse model Long-Term Clinical Outcomes of Patients with Lupus Nephritis treated with an Intensified B-Cell Depletion Protocol: A Prospective Study Factors associated with severe SARS-CoV-2 infection in patients with inflammatory rheumatic diseases in Madrid: results from REUMA-COVID SORCOM registry
Ultrasonography of the median nerve in patients with rheumatoid arthritis under suspicion of carpal tunnel syndrome Current registries in PsA do not well reflect the profiles of patients with PsA because they originate in similar countries : a systematic literature review of 27 registries, or 16183 patients WORK ABSENCE DUE TO MUSCULOSKELETAL SYMPTOMS IN PATIENTS AT-RISK OF RHEUMATOID ARTHRITIS IS COMPARABLE TO THOSE WITH ESTABLISHED DISEASE Antiphospholipid related large vessel lesions: not only thrombosis LONG TERM OUTCOME OF MULTIPLE ULTRASOUND GUIDED SUPRASCAPULAR NERVE BLOCK IN TREATMENT OF FROZEN SHOULDER IN DIABETIC PATIENTS COVID-19 from the patients’s perspective: preliminary results of online survey
Subclavian arteries involvement in patients with giant cell arteritis: do we need a modified Halo Score? INCREASED BDNF LEVELS AS A PREDICTOR OF CENTRAL SENSITIZATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS Does experience in Systemic Lupus Erythematosus influence the Physician Global Assessment scoring? A cross-sectional study on two European cohorts. Identifying Mechanisms Underlying the Association between Rheumatoid Arthritis and Periodontitis Using in Silico Analysis of Canonical Pathways
Anti-IL-1 Therapies in Colchicine-Resistant or İntolerant Patients with Familial Mediterranean Fever: Single Center Experience
Performances of Different Classification Criteria for Systemic Lupus Erythematosus in a Single Center Cohort from Turkey HYDROXYCHLOROQUINE CARDIOTOXICITY: A CASE-CONTROL STUDY COMPARING PATIENTS WITH COVID19 AND PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Clinical presentation and outcomes of the antiphospholipid syndrome (APS) in southern Chinese patients: the Hong Kong APS registry
Correlation of Peripheral CD4+GranzB+CTLs with Disease Severity in Patients with Primary Sjögren’s Syndrome A cohort study of COVID-19 related multisystem inflammatory syndrome in children and adolescents from multiple tertiary care centres in south India The impact of the COVID-19 pandemic on Physical Functioning and Mental Wellbeing in 824 patients with Rheumatic Disease over 8 months: Physical Functioning Declines The discordance between patient-reported and clinical/biological outcomes could help in predicting future disease impact in patients with rheumatoid arthritis
Algorithm identifying chronic inflammatory diseases treated by biotherapy and/or targeted synthetic treatments in outpatient care in France: feasibility, preliminary results, and impact of COVID-19 Influence of demographic and disease related factors on efficacy of infliximab or golimumab in rheumatoid arthritis. A meta-analysis on randomized placebo- controlled trials.
SKIN LESIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME Musculoskeletal variant of Familial Mediterranean Fever May Have More Severe Disease
BASELINE FACTORS ASSOCIATED WITH LUPUS FLARES: A POST-HOC ANALYSIS OF PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS ENROLLED IN A 48 WEEK PHASE II RANDOMIZED CLINICAL TRIAL Engineered glove to evaluate the speed of the hands’ movements in rheumatoid arthritis Assessment of risk factors for hospitalization of autoimmune and rheumatic disease patients with COVID-19 – A single centre observational study.
Performance of major salivary gland ultrasound for the diagnosis of Sjögren’s Syndrome in clinical practice Anti-TNF drugs and cardiovascular events in patients with spondyloarthritis. Efficacy of intra-articular corticosteroid injections in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.
COVID-19 in patients with rheumatic diseases: survey-based assessment of the risk of hospitalization
Transcranial electrical stimulation is safe and efficient in patients with systemic autoimmune myopathies
Validity and psychometric characteristics of the Psoriatic Arthritis Quality of Life (PsAQoL) Questionnaire in Turkish population Macrovascular dysfunction and its clinical implication in systemic sclerosis Daily Activity Impairment is Mediated by Both Oral Dryness and Oral Health Related Quality of Life in Patients with Primary Sjögren’s Syndrome
PREDICTORS OF END STAGE RENAL DISEASE IN THE RENAL BIOPSY PROVEN LUPUS NEPHRITIS Impact of COVID-19 pandemic on disease activity and emotional well-being among Rheumatoid Arthritis patients: a telemedicine study
Predictive factors for response to treatment in a long-term cohort of patients with juvenile idiopathic arthritis-associated uveitis EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Disorders of urodynamics and parenchyma concentration function in patients with arterial hypertension and gout
A systematic review of international guidelines regarding the role of radiography in the diagnosis of osteoarthritis
EFFECTS OF ACUTE EXERCISE ON SERUM BDNF LEVEL IN PATIENTS WITH RHEUMATOID ARTHRITIS Catastrophizing in patients with rheumatoid arthritis Clinical characteristics of the pulmonary artery involvement in patients with Behçet’s syndrome: A single-centre experience of 61 patients
COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES ON CHRONIC USE OF HYDROXYCHLOROQUINE IN A LARGE BRAZILIAN COHORT – A 24-WEEK PROSPECTIVE STUDY Arthritis in adult IgA vasculitis The impact of age on discontinuation of biologic DMARDs in patients with Rheumatoid Arthritis Some parameters of endothelial function in patients with idiopathic avasclar necrosis Retrospective analysis of pregnancy outcomes in patients with obstetric antiphospholipid syndrome (OAPS), non-criteria OAPS (NC- OAPS) and antiphospholipid carriers
The effect of platelet inhibitors on digital ulcers in systemic sclerosis - a derivation and validation EUSTAR study
Predictors of durable clinical response to tofacitinib 11 mg once daily with or without methotrexate in patients with rheumatoid arthritis: post hoc analysis of data from a Phase 3b/4 methotrexate withdrawal study
MONITORING C3 AND C4 VARIATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS PREGNANCIES IS USEFUL TO RECOGNIZE COMPLICATIONS. DATA FROM 2 ITALIAN CENTERS
A Reliability Exercise Using Consensual Definitions for the Ultrasonography of the Shoulder in Rheumatoid Arthritis Baseline calprotectin and visfatin levels predict radiographic spinal progression after 2 years in ankylosing spondylitis patients on TNF inhibitor therapy
RHEUMATOID ARTHRITIS AND ORAL MICROBIOME: PREDICTORS OF DISTURBANCES AND ITS IMPLICATIONS. RESULTS FROM A COHORT AT TREATMENT WITH cs/b/tsDMARD
Hepcidin is potential biomarker to distinguish between iron deficiency anemia and anemia of inflammation in rheumatoid arthritis IMMUNE-MEDIATED DISEASES (IMID) AND CORONAVIRUS DISEASE 2019 (COVID-19): RESULTS FROM AN OBSERVATIONAL RETROSPECTIVE MULTICENTER STUDY
Young versus Late-Onset Rheumatoid Arthritis: a prospective 12 month-follow-up cohort study in an early arthritis cohort Pulse pressure as an indicator of subclinical atherosclerosis in Rheumatoid Arthritis
SURVIVAL OF THE FIRST COURSE OF BIOLOGIC OR JAK INHIBITOR IN RHEUMATOID ARTHRITIS: ASSOCIATION WITH THE CHOICE OF AGENT AND CONCOMITANT CONVENTIONAL SYNTHETIC DMARDS
Early infectious risk in patients with newly-diagnosed anti-neutrophilcytoplasmic antibody-associated vasculitis according to the remission-inductiontherapy: a French monocentric retrospective study including 145 patients
Differences in proinflammatory and lipid profile between psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis The comparative 3-year retention rate of targeted-synthetic and biologic drugs for rheumatoid arthritis: real-life data from the Italian GISEA Registry An investigation of joint inflammation defined by comprehensive ultrasound assessment and pain sensitisation in patients with active RA
Hyperlipidemia in psoriatic disease: higher prevalence in psoriatic arthritis and inverse association with systemic therapy Comparison of Injection Site Reactions and Injection Site Erythema between YLB113 and etanercept reference product from Phase 3 active comparator study (Study No. YLB113‑002) Demographics, comorbidities, and renal function of uncontrolled gout patients who received pegloticase: finding from a large US claims database
Differences in treatment satisfaction, patient preferences, and treatment patterns between European, South American, and Japanese patients with suboptimally controlled rheumatoid arthritis: A subgroup analysis of the SENSE study
The Efficacy and Safety of Tocilizumab in Patients With Giant Cell Arteritis: A Systematic Review and Meta-Analysis The Different Subtypes of Giant Cell Arteritis by Ultrasound: Results from a fast-track clinic Effect of Upadacitinib on Reducing Pain in Patients With Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti- inflammatory Drugs Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study
Voluntary wheel running model in mice to mechanically stimulate the enthesis of the Achilles tendon Brucellar spondylodiscitis: Clinical and magnetic resonance imaging findings ULTRASOUND FOR PANNICULITIS. CAN INTERLEUKIN 33 (IL-33) BE CONSIDERED A VALUABLE BIOMARKER IN THE EARLY STAGES OF SYSTEMIC SCLEROSIS? ANALYSIS OF A MONOCENTRIC COHORT JIA patients do not have more osteoporosis than healthy age and sex-matched controls but lower bone mass density is found at total hip and cortical compartment Analysis of 5-year Hospitalization data of Patients with Systemic Lupus Erythematosus: Damage is a risk factor for frequent and longer stays EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Upadacitinib as Monotherapy and in Combination with non-biologic DMARDs for the Treatment of Psoriatic Arthritis: Subgroup Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Analysis from Two Phase 3 Trials
Association between antibiotic use and knee pain and function in OA: data from the Osteoarthritis Initiative Use of telemedicine for follow-up of SLE patients with nephritis in the COVID-19 outbreak (“TeleSLE”): the 6-month results of a randomized controlled trial Serum biomarkers before and after a six months structured weight loss intervention in patients with psoriatic arthritis and obesity compared with controls. Filgotinib-treated rheumatoid arthritis patients with high baseline neutrophil-to-lymphocyte ratio show better clinical response rates and patient-reported outcomes
Conduction and Rhythm Disorders among Patients with Systemic Sclerosis: A US Population Based Study Autoimmune liver disease in anticentromere antibody positive primary Sjogren’s syndrome De novo lupus nephritis following the introduction of Belimumab. Fibrocytes in Early and Longstanding Rheumatoid Arthritis: A 6-month trial with repeated synovial biopsy, imaging, and lung function test. Predictors of hospitalization in patients with systemic lupus erythematosus: a 10-year cohort study of 398 patients from a tertiary centre
Identifying potential classification criteria for calcium pyrophosphate deposition disease (CPPD): results from the initial phases Costs and factors affecting health service utilisation in patients with gout: a longitudinal, population-level linked data study in Western Australia.
UNDERSTANDING PRESCRIPTION BEHAVIOR ACROSS HEALTHCARE PROFESSIONALS IN TREATING KNEE OSTEOARTHRITIS BEFORE AND DURING THE 2020 COVID-19 PANDEMIC Cytokine Biomarkers in Common Low Back Pain Risk of serious infections in offspring exposed in utero to ustekinumab or vedolizumab Hyperinflammation and clinical outcomes for patients with systemic rheumatic diseases hospitalized for COVID-19: A comparative cohort study Blood-derived DNA methylation epi-signatures associated with Ankylosing Spondylitis
Low Incidence of Gastrointestinal-related and Overall Serious Adverse Events Among Guselkumab-treated Patients: Pooled Analyses of VOYAGE 1 & 2 and DISCOVER 1 & 2 Through 1-Year
A single dose of zoledronate induces modifications of serum VEGF in osteoporotic postmenopausal women.
SPECIFIC MITO-NUCLEAR INTERACTIONS AND mt16519C VARIANT AS PREDICTIVE BIOMARKERS FOR THE RAPIDLY PROGRESSIVE OSTEOARTHRITIS OF THE KNEE. DATA FROM THE OSTEOARTHRITIS INITIATIVE.
Risk factors of non-protective levels of antibodies to vaccines in patients with juvenile idiopathic arthritis. Body composition and frequency of sarcopenia in patients with systemic sclerosis Peripheral arthritis and higher disease activity lead to more functional impairment in axial spondyloarthritis: longitudinal analysis from ESPAXIA
Quality of life in chronic back pain patients, a 2-year comparison between patients with and without a diagnosis of axial spondyloarthritis: Data from the SpondyloArthritis Caught Early Cohort Self-reported SARS-CoV2 testing and COVID-19 disease in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis in a Swiss observational cohort Extracellular matrix protein turnover markers are associated with axSpA– a comparison with control subjects with or without pelvic, buttock or back pain
Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post hoc Analysis of a Phase 3 Study Geographic Variation of Efficacy in the Filgotinib Rheumatoid Arthritis Program
IN SPONDYLOARTHRITIS PATIENTS THE PRESENCE OF COMORBIDITIES IS AN INDEPENDENT PREDICTOR OF INSUFFICIENT RESPONSE TO THERAPY WITH BIOLOGIC AGENTS AND TREATMENT DISCONTINUATION Efficacy of ixekizumab through 52 weeks for improving peripheral joint involvement among patients with radiographic-axial spondyloarthritis Cardiovascular risk status and obesity in gout compared to healthy Mexican subjects: a case-controls study with a propensity score- matched analysis.
RITUXIMAB THERAPY IN THE INTERSTITIAL LUNG DISEASE OF RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW.
The Effect of Filgotinib on Enthesitis: 100-week Data from an Open-label Extension Study in Patients with Active Psoriatic Arthritis
More Frequent and Earlier Hip Involvement in Spondyloarthritis Associated with Familial Mediterranean Fever
Preliminary findings of the PROTECT clinical trial: pegloticase efficacy and safety in kidney transplant recipients
Dual Energy CT Has Prognostic Value in Gout Beyond Standard Clinical Measures: A Best Evidence Synthesis Physician and Patient Reported Effectiveness Outcomes are similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada ULTRASOUND ASSESSMENT OF SUB-CLINICAL HAND JOINT SYNOVITIS: A COMPARATIVE STUDY BETWEEN PSORIATIC AND RHEUMATOID ARTHRITIS COVID-19 vaccine hesitancy among rheumatology patients receiving influenza vaccine EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Performance of 2019 EULAR/ACR classification criteria for Systemic Lupus Erythematosus in a pediatric population – a multicenter Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) study
Higher serum uric acid is associated with increased risk of obesity in Chinese adults: A longitudinal data analysis Musculoskeletal manifestations in a cohort of 234 inflammatory bowel disease patients Rheumatologist and patient perspectives on implementing cardiovascular risk prevention in the management of psoriasis: A qualitative study
Risk Factors for Polyarticular Gout Flares—Analysis of a Longitudinal Online Gout Follow-Up Study
THE IMPACT OF COVID-19 QUARANTINE ON MENTAL HEALTH OF PATIENTS WITH FIBROMYALGIA The therapeutic target is reached more often in RA patients starting TNF inhibitors with moderate activity than with high disease activity –an analysis from the ATTRA registry Lifestyle and Mood Changes in AxSpA Patients During the Quarantine Period
Responsiveness of spinal mobility measurements in axial spondyloarthritis using conventional and advanced metrology: a pilot study Patient Characteristics & Clinical Features Associate With Health-Related Quality of Life in Bio-naïve Patients With Active Psoriatic Arthritis Through Week 24 of the DISCOVER-2 Study Prevalence of sleep disturbance in patients with ankylosing spondylitis within the Australian Clinical Setting (ASLEEP study): A Real- World Observational Study using the OPAL Dataset.
Epidemiology and trends in survival of systemic sclerosis in Olmsted County: A population-based study (1980-2018) Effect of emotional triggers on the frequency of PFAPA attacks - a multicenter study
Biosimilar infliximab therapy in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a long-term follow-up study on infliximab-naïve patients and patients switched from the originator to the biosimilar CT-P13
Diagnostic delay in axial spondyloarthritis: results from the National Early Inflammatory Arthritis Audit
Importance of body mass measurement and the grip strength test to predict falls in patients with rheumatoid arthritis
Effect of Argentine tango practice on total physical activity time in patients with chronic inflammatory rheumatism: a pilot study. Visual ischemia during relapse and follow-up of giant cell arteritis: a systematic review Incidence, prevalence, and mortality of chronic periaortitis: a population-based study Meaningful Improvement and Worsening in Patients Who Do Not Achieve LDA and Switch Therapy to a New Biologic or Targeted Therapy: Results from the CORRONA Registry COMORBID INFECTIONS IN PATIENTS WITH SPONDYLOARTHRITIS. Chronic low back pain: therapeutic strategies and clinical outcomes in a military population Ankylosing Spondylitis in West African patients: A series of 37 cases reported in Togo Rheumatology patient attendance to the paediatric emergency department
Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated Patients with Ankylosing Spondylitis The development and validation of a risk stratification questionnaire to screen for medication related Osteonecrosis of the jaw risk in osteoporotic patients
Relationship between Changes in Lipid Levels and Improvement in Disease Activity Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib Treatment: Pooled Analysis of Data from Two Phase 3 Studies
Characteristics and outcomes in a real-world cohort of rheumatoid arthritis patients with COVID-19
Differences in drug survival between Originator and Biosimilar products among first users of each molecule
Association Between Pain Severity and Healthcare Utilization in an Osteoarthritis Population: An 18-Year Retrospective Cohort Study
Prevalence of rheumatoid cachexia and its association with serum fetuin-A levels in Caucasian patients with rheumatoid arthritis. Geographic Variation of Safety in the Filgotinib Rheumatoid Arthritis Program Responsiveness of conventional, semi-automatic and full-automatic methods to quantify marrow bone edema lesions in MRI of axial spondyloarthritis patients: a pilot study. Efficacy of tofacitinib on dactylitis in individual digits in patients with active psoriatic arthritis Relationship between psychological factors and measures of rheumatoid arthritis activity Presence and Associated Factors of Fatigue in Patients in Patients with Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS).
Monomeric C Reactive Protein (mCRP) Regulates Inflammatory Responses in Human and Mouse Chondrocytes
Review of the impact of COVID-19 pandemic on Rheumatology Services at a large tertiary care centre in Wales, UK Anatomical Locations and Correlates of Calcium Pyrophosphate Crystal Deposits of the Spine – Pathologic Examination of 77 Surgical Cases "Extra"- criteria antiphospholipid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data) Relationship of Anifrolumab PK With Efficacy and Safety in Patients with SLE Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK2/DYRK1A Inhibitor That Modulates the Wnt Pathway, as a Potential Treatment for Meniscal Injuries
Are there gender differences in axial spondyloarthritis: data from a Portuguese spondyloarthritis cohort
MEDITERRANEAN DIET IN AXIAL SPONDYLOARTHRITIS: A NUTRITIONAL INTERVENTION STUDY EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Baseline Skin Severity: A Subgroup Analysis of Two Phase III Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Trials
The assessment of fracture risk and osteoporosis rate among patients over 50 years old undergoing medical rehabilitation LARGE VESSEL-GCA: A DIAGNOSTIC CHALLENGE ANKLE ARTHRITIS IN JUVENILE IDIOPATHIC ARTHRITIS: DON’T MISS TENOSYNOVITIS. CLINICAL AND SONOGRAPHIC FEATURES OF ANKLE TENOSYNOVITIS IN JIA. Fluorescence optical imaging (FOI) detects subclinical inflammation in hands of patients diagnosed with fibromyalgia syndrome and other rheumatic diseases Impact of Concomitant Glucocorticoids on the Clinical Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: An Ad Hoc Analysis of Data from Three Phase 3 Studies SUICIDAL BEHAVIOUR IN SLE PATIENTS: A SYSTEMATIC LITERATURE REVIEW
Factors Associated with Switching from one anti-TNF Agent to Another Anti-TNF, or IL17 Agent in Patient with Ankylosing Spondylitis Idiopathic, rheumatoid arthritis and diabetes mellitus associated carpal tunnel syndrome: evaluation of the depth of the carpal tunnel by ultrasonography Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Number of Prior Biologic Disease-modifying Anti-rheumatic Drugs Concomitant Use of Statins in Filgotinib-Treated Patients with Rheumatoid Arthritis Presence of tophi is associated with a rapid decline in the renal function in patients with gout Cardiovascular risk in different clinical variants of spondyloarthritis
Response to Sequential Lines of Biological Therapy in Psoriatic Arthritis: A single centre cohort study
Agreement between Vertebral fracture Assessment and radiographic scans for the diagnosis of vertebral fracture
Different clinical characteristics of IgG4-RRD patients and non-IgG4-RRD patients: a large Chinese cohort study Correlation between skin involvement, joint involvement and enthesitis in patients with active psoriatic arthritis: post-hoc analysis of EQUATOR/EQUATOR2 COVID-19 ACROSS RHEUMATOLOGY: A BIBLIOMETRIC STUDY
Evidence based practice: What is the evidence that British Society for Rheumatology guidelines are evidence based? Salivary gland ultrasonography and the Clinical features using ESSDAI in patients of early-onset versus late-onset with primary Sjögren's syndrome Comparison of carotid subclinical atherosclerosis and structural damage in axial spondylitis with and without concomitant anterior uveitis. A multicenter study with 886 patients.
Decline in forced vital capacity (FVC) in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the SENSCIS trial versus hypothetical reference subjects without lung disease The long-term clinical course of muscular vasculitis depending on the anti-neutrophil cytoplasmic antibody status: a retrospective observational study Autoimmune diseases associated with chronic liver diseases Diagnostic Value of High-Resolution peripheral quantitative computed tomography compared to conventional radiography for detecting erosive disease in Rheumatoid Arthritis. Usual interstitial pneumonia during rheumatoid arthritis: Prevalence and associated factors Assessment of the COVID-19 Pandemic from the Perspective of People with Rheumatic Musculoskeletal Diseases in Europe. Results from the REUMAVID Study (Phase 1)
Patient-Reported Impact of Axial Spondyloarthritis on Working Life. Results from the Spanish Atlas
Correlates of testing positive for SARS-CoV-2 in patients with rheumatic ad musculoskeletal diseases Ixekizumab improves signs, symptoms and quality of life of ankylosing spondylitis in patients irrespective of HLA-B27 status: pooled results from the COAST-V and COAST-W trials
Gout patients in remission, and their perspectives on urate lowering therapy treatment stop or continuation strategies IMPLEMENTATION OF THE OMERACT PSAMRIS IN A PHASE IIB, RANDOMISED PLACEBO-CONTROLLED STUDY OF ABATACEPT IN PSORIATIC ARTHRITIS Efficacy, Safety and Characteristics of Iguratimod-based Therapy in the Treatment of UA, ERA and RA Patients for 24 Weeks: A Prospective Cohort Study Panniculitis as a manifestation of an autoimmune/autoinflammatory disease
Pain in children with Juvenile Idiopathic Arthritis treated to target: 24 month results from a randomised trial Using Hip Structural Analysis Measurements to Predict Fracture in Rheumatoid Arthritis Mental health outcomes among health care workers during the coronavirus-19 pandemic Prevalence and Severity of Stress at Home among patients with Rheumatoid Arthritis: single centre results from the PRIME registry cohort Epidemiology of Cocaine and hallucinogen use disorder hospitalizations in Rheumatic Diseases Safety of ixekizumab in patients with psoriatic arthritis: an integrated analysis of 4 clinical trials
Factors associated with fertility outcomes in women with Systemic Lupus Erythematosus: a systematic review.
Psychiatric disorders in patients with different phenotypes of neuropsychiatric systemic lupus erythematosus (NPSLE) Early Identification of Axial Spondyloarthritis in a Multi-Ethnic Asian Population EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) BILAG-2004 Index Active Disease predicts development of damage Prevalence and Associated Factors of Sleep Disorders in Patients with Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS) Prevalence, incidence and antirheumatic drug use in psoriatic arthritis (PsA) in Norway
Personal Experiences with Diagnostic Delay Among Axial Spondyloarthritis Patients – A Qualitative Study
The serum iron level might be useful in determining the severity of malnutrition in patients with rheumatoid arthritis A short delay in arthritis care is associated with higher disease activity - lessons from the coronavirus disease 19 (COVID-19) pandemic. IMMUNOGENICITY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH SPONDYLOARTHRITIS. Comparison of FMF clinical features between Turkish and Crimean Tatar children.
How HLA B27 prevalence in the population influence on features of juvenile idiopathic arthritis: data from Sakha Republic (Yakutia).
A New questionnaire and Score (MISA) for Assessing Methotrexate Intolerance in Rheumatoid Arthritis
Rapid and Concurrent Improvements in Patient-Reported Outcomes of Rheumatoid Arthritis with Baricitinib in RA-BEAM Association between individual and country-level socioeconomic factors and health outcomes in axial and peripheral spondyloarthritis: analysis of the ASAS perSpA study
The relationship between sedentary behavior and sleep in Rheumatoid Arthritis: a cross-sectional study INCONSISTENCY OF THE DEGREE OF CARDIOVASCULAR RISK WHEN ASSESSED USING DIFFERENT INDICES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
Guselkumab-Treated Patients With Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured With PROMIS-29 Through 52 Weeks: Results From the Phase 3 DISCOVER-1 Trial
The relevance of osteoporosis diagnosis and treatment for doctors working in the field of physical and rehabilitation medicine Importance of lateral spine view in DXA bone densitometry in patients with spondyloarthritis ABATACEPT IN MONOTHERAPY VERSUS COMBINED IN INTERSTITIAL LUNG DISEASE OF RHEUMATOID ARTHRITIS. MULTICENTER STUDY OF 263 CAUCASIAN PATIENTS Risk factors of total hip arthroplasty in juvenile arthritis with hip involvement Enhancing osteoporosis management: The contribution of FRAX® and VFA in Tunisian women
Self-protection strategies, health behavior and disease activity during the first wave, re-opening and second wave of the COVID-19 pandemic in >7000 Danish patients with inflammatory arthritis
Behçet`s disease and course of pregnancy - Results from the nationwide pregnancy register RevNatus White matter hyperintensities lead to reduced psychomotor speed in patients with systemic lupus erythematosus and neuropsychiatric symptoms
Do social factors impact on biologics costs in rheumatoid arthritis? Results from the Moroccan RBSMR registry Giant cell arteritis treatment patterns and rates of serious infections
The Italian prospective SIRENA study: focus on early psoriatic arthritis cohort and gender differences ABATACEPT IN USUAL AND IN NON-SPECIFIC INTERSTITIAL PNEUMONIA ASSOCIATED TO RHEUMATOID ARTHRITIS. NATIONAL MULTICENTER STUDY OF 190 PATIENTS
Long-term safety and efficacy of upadacitinib in patients with rheumatoid arthritis: 3-year results from the SELECT-EARLY study Predictors of Hospitalisation in Patients with Rheumatic Disease and COVID-19 in Ireland: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
PHYSICAL FUNCTION IN PATIENTS WITH RA, STRATIFIED BY SEROSTATUS AND TREATMENT LINE, FOLLOWING SC ABATACEPT: POST HOC ANALYSIS OF AN OBSERVATIONAL, 2-YEAR STUDY CONDUCTED IN ROUTINE CLINICAL PRACTICE (ASCORE) A retrospective cohort study in Chinese patients with adult polymyositis and dermatomyositis: risk of comorbidities and subclassification using machine learning
The COVID-19 pandemic prompts isolation and behavioral changes in patients with chronic rheumatic diseases leading to reduced physical activity, increased pain, disease activity, and low seroprevalence of SARS-CoV2 antibodies. Real word experience with tofacitinib in patients with rheumatoid arthritis : an interim analysis from a French prospective observational study DeFacTo
DISEASE ACTIVITY IN PATIENTS WITH RA BY SEROSTATUS AND TREATMENT LINE, FOLLOWING TREATMENT WITH ABATACEPT: RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY
The need for information among patients with ANCA associated vasculitis differs between groups.
The therapeutic effects of omega-6 PUFA (Pinolenic acid) on the transcriptomic profile of activated peripheral blood mononuclear cells isolated from healthy controls and Rheumatoid arthritis patients Lupus fog is not dissociative fog MYCOPHENOLATE MOFETIL IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: FIVE-YEARS DRUG SURVIVAL IN RENAL AND NON-RENAL INVOLVEMENT Retroperitoneal fibrosis in Erdheim-Chester disease has unique presenting and prognostic features: a single centre retrospective comparative cohort study EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start A Prospective, Longitudinal Study to Evaluate Real-World Patient Experiences and Treatment Satisfaction With Secukinumab for Wednesday, 2 June 2021 08:00:00 18:00:00 Posters Viewing (blank) (blank) Psoriatic Arthritis
THE USE OF CANNABIDIOL IN THE TREATMENT OF PAIN RELATED TO SCLERODERMA DIGITAL ULCERS
Discontinuation Rate of Tofacitinib as Monotherapy is Similar Compared to Combination therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from two Rheumatoid Arthritis Registries in Canada Profile of lumbar spine degenerative pathology in rheumatologic consultation in Northen Togo The prevalence and factors related to sleep apnoea in ankylosing spondylitis
Effects of rituximab in patients with rheumatoid arthritis-related interstitial lung disease: A single-centre experience from Turkey
Risk factors for progression of rheumatoid arthritis-associated interstitial lung disease: reassuring impact of methotrexate Psoriatic arthritis and physical activity, a systematic review Power and spectral Doppler Ultrasound as a screening tool in the diagnostic course of suspected axial spondyloarthritis: preliminary data from a large monocentric cohort.
Subclinical dactylitis: comparative study of therapeutic response with TNF inhibitors, secukinumab and ustekinumab.
Drug survival of biologics with respect to combination with methotrexate in treatment of polyarticular JIA. FRAX and the effect of teriparatide on bone mineral density in secondary osteoporosis Quantifying the Psychosocial Impact of Undifferentiated Connective Tissue Disease (UCTD)
Etanercept-associated new onset uveitis in patients with juvenile idiopathic arthritis under biological therapy: single center experience Long-term outcome of SSc associated ILD: improved survival in PPI treated patients The PsABio study in Italy: a real-world comparison of the persistence, effectiveness and safety of ustekinumab and tumour necrosis factor inhibitors in patients with psoriatic arthritis
Effects of cholecalciferol and calcifediol in osteoporotic women with secondary hyperparathyroidism due to severe vitamin D deficiency undergoing zoledronic acid treatment: a randomized-controlled trial Collagen Turnover Markers are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial
13:00:00 14:00:00 Room 1 no session group Opening Plenary session (blank) 13:00:00 Opening by the President of EULAR
14:15:00 15:00:00 Room 1 What is New (WIN) What is new in axial spondyloarthritis? To learn most recent data on diagnosis, classification, outcome assessment, and Introduction treatment of axial spondyloarthritis (including radiographic and non-radiographic forms). 14:15:00 14:20:00 Non-radiographic or radiographic axial SpA – does it matter? 14:50:00 Q&A
15:45:00 Room 10 EULAR Projects What the rheumatologist needs to know to interpret studies in 2021 Methodology of clinical trials and observational studies has changed over time. The phenotype of patients that are studied has also changed over time. In this session, methodological aspects of study design and data analysis will be discussed. Topics like selection bias, propensity scores and ROC-curve analysis will be discussed. 14:15:00 Introduction 14:20:00 Patient profiles in the era of biological treatments - Implications for trial design and interpretation 14:40:00 Q&A 14:45:00 Measurements, composite scores and the art of 'cutting-off' 15:05:00 Q&A 15:10:00 How to improve your propensity score models? 15:30:00 Q&A
15:35:00 Dietary Hyperinsulinemic Potential and Risk of Incident Gout: 3 Prospective Cohort Studies of US Men and Women 15:42:00 Q&A Room 11 Joint, PARE Help! What do I need to cope with my RMD? To present what people with inflammatory diseases should know about managing their disease. To give an overview of various digital solutions for monitoring and coping strategies. 14:15:00 Introduction 14:20:00 What my newly diagnosed patient should know about the disease, its risk factors and comorbidities 14:35:00 Foot problems and foot healthcare for people with RMDs 14:50:00 The influence of physical activity and sports on inflammation 15:05:00 Self-Management 4.0 15:20:00 Debate Room 12 Practical skills New assessments in clinical practice To learn which measures are the best for the heart function in Rheumatic diseases in clinical practice to learn the value of Patient reported outcome measures in Rheumatic Diseases to learn about clinical importance of BASDAI and ASDAS to learn about the added value and clinical importance of composite index measurement of disease activity.
14:15:00 How to assess heart function in Rheumatic diseases? 14:37:00 Value of Patient reported outcome measures in Rheumatic Diseases EULAR 2021 SCIENTIFIC PROGRAMMEPresentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Wednesday, 2 June 2021 14:15:00 15:45:00 Room 12 clinical practice to learn the value of Patient reported outcome measures in Rheumatic 14:55:00 Q&A 14:59:00 BASDAI and ASDAS: should we use both, or one should be preferred? 15:39:00 Q&A 15:17:00 Q&A 14:33:00 Q&A
15:21:00 Is there an added value of imaging to the Composite index measurement of disease activity in patients with Rheumatoid Arthritis? Room 13 Practical skills Meet the EULAR Editors Obtain answers to pertinent issues related to paper submissions and EULAR journal processes Develop skills of self-judgement regarding suitability of manuscripts for the EULAR journals. 14:15:00 Introduction 14:20:00 Issues related to RMD 14:30:00 Issues related to ARD 14:40:00 Publication ethics and scientific conduct 14:50:00 Group discussion Room 2 Joint EULAR Recommendations 2021 Through all its taskforces, EULAR launches every year a number of recommendations or points to consider which impact greatly on the wider rheumatology community. EULAR is proud to present this year’s recommendations in a session in which you will be efficiently summarised with the most up to date evidence in topics as diverse as from how to manage tissues to work related issues. 14:15:00 EULAR Recommendations 2021
14:20:00 EULAR recommendations on the management of RMDs in the context of SARS-CoV-2: an update of the process 14:30:00 Q&A 14:58:00 Q&A 15:16:00 The Gender Equity in Academic Rheumatology EULAR taskforce
15:30:00 EULAR Points to consider for minimal reporting requirements in synovial tissue clinical applications and research in rheumatology 15:40:00 Q&A 15:12:00 Q&A
EULAR Recommendations for the management of 2 groups of Autoinflammatory diseases, IL-1-mediated and Type-I Interferonopathies, and 15:02:00 for the early management of suspected Macrophage Activation Syndrome/Hemophagocytic Lymphohistiocytosis 14:44:00 Q&A
14:34:00 EULAR Points to consider on COVID-19 pathophysiology and immunomodulatory therapies from the Rheumatology Perspective 15:26:00 Q&A Preliminary Points to Consider for the measurement and reporting of IFN assays in clinical research and practice: report from a EULAR 14:48:00 TaskForce Room 3 Clinical Science Treating SLE to target: remission or low disease activity? Remission is the target of treatment in SLE. However a complete remission might be a Introduction difficult target to reach. In this session the steps toward a common definition of remission in SLE will be described as well as the characteristics of the Lupus Low disease Activity State. 14:15:00 14:20:00 Toward a common definition of remission: the DORIS project 14:36:00 Q&A 14:41:00 The Lupus Low Disease Activity State 15:02:00 Physician global assessment in the definition of targets in SLE management: yes or no? 14:57:00 Q&A 15:18:00 Q&A 15:23:00 Is remission achievement possible with the today's drugs? 15:39:00 Q&A Room 4 From Bench to Bedside New perspectives on therapeutic immune tolerance To understand how tolerogenic strategies may lead to paradigm shifts in autoimmunity. 14:15:00 Introduction 14:19:00 The potential of co-stimulation blockade 14:38:00 Tolerising with peptides – routes and results 14:53:00 Q&A 15:16:00 CD3 antibodies: beyond expectations 15:35:00 ImmTOR nanoparticles enhance the tolerogenic environment of the liver in mice 15:42:00 Q&A 15:12:00 Q&A 14:34:00 Q&A 14:57:00 Low-dose IL2 15:31:00 Q&A EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Wednesday, 2 June 2021 14:15:00 15:45:00 Room 5 Challenges in Clinical Practice Multi-disciplinaryWhich are the main patient professions care: needed the new for era a holisticof Rheumatology rheumatic patient approach? (e.g. psychologist, physiotherapist, occupational therapist, nurse, rheumatologist) To define their individual role in rheumatic patient care Ways of effective collaboration and goals. Case 1 Adriana is a 40 year old woman who was diagnosed with RA 14 months ago. She has been seen regularly by the rheumatologist and treated with Methotrexate and a short course of corticosteroids. She is responding to medical treatment, with current low disease activity (DAS-28 3.1). However, she reports that she still has pain and swelling in her dominant wrist, pain and stiffness in her small hand joints and painful feet. She also feels tired all the time. She has difficulties to use her computer during her work as an administrator at a local school (4 days per week) and is exhausted at the end of her working days. She also experiences problems with household tasks such as preparing and cooking meals. Due to fatigue and joint complaints, she did not continue her weekly fitness lessons and regular walks with friends. She is overweight and is diagnosed with diabetes and dyslipidemia. Adriana lives in a detached house with her husband, who works full-time as an engineering advisor, and two teenage children (12 and 14 years old). Case 2 The term ‘co-morbidities’ implies the presence of co-existing conditions alongside an ‘index’ disease. In Rheumatology, the ‘index’ disease is usually the rheumatic and musculoskeletal disease (RMD) the patient is diagnosed with. Comorbidities have originally been described as distinct clinical entities, although in recent years it has become increasingly known that some of these entities share common underlying pathophysiological mechanisms with the index disease. Many of these comorbidities arise from uncontrolled extra-articular inflammation affecting other organs such as the heart or lungs and causing additional disease. On the other hand, the term multimorbidity tends to take the emphasis away from an ‘index’ disease and considers all conditions including the index RMD to be of at least similar importance. Multimorbidity thus inherently suggests a more holistic approach, keeping the patient right at the centre 14:15:00 Case 1 (presentation): Why rheumatologists need a multi-disciplinary team? - An example from the practice 14:30:00 Case 1 (discussion): How to build a successful multi-disciplinary team in rheumatology practice? 14:45:00 Discussion Case 2 (presentation): From co-morbidities to multi-morbidities. A case presentation illustrating the challenges for the future generation of 15:00:00 rheumatologists 15:15:00 Case 2 (discussion): Are comorbidities and difficult-to-treat patients different sides of the same coin? 15:30:00 Discussion Room 6 Innovation EULAR and the EMA: From approval to safety and drug supply To gain an understanding on the approval process and policies/practice of post- marketing drug surveillance To understand how the drug supply can be maintained in the pandemic situation. 14:15:00 Introduction: EU, EMA and rheumatology 14:20:00 How does EMA work? The approval process for new drugs. 14:30:00 How are EMA safety recommendations developed? 14:40:00 How can we assure drug supply? - The public view. 14:50:00 How can we assure drug supply? - The industry's view. 15:00:00 Podium discussion Room 7 Basic and Translational Science Autoimmune diseases by abnormal T cell function To understand current concepts of T cell mediated autoimmune diseases 14:15:00 Introduction 14:19:00 Monogenic autoimmune diseases 14:36:00 Q&A 14:58:00 Q&A 15:20:00 Q&A 15:32:00 Q&A 15:35:00 Autoreactive CD4+ T cells and their TCR repertoire in PR3-ANCA associated vasculitis 15:42:00 Q&A 14:41:00 The environment as the trigger for autoimmune T cell activity 15:03:00 The dysbalance of regulation and aggression – T cells "out of control" 15:25:00 Autoimmune and inflammatory manifestations in common variable immunodeficiency disorders Room 8 The Young Rheumatologist Implementation of immunological knowledge in rheumatology research and practice To identify the role of general and more deep understanding and knowledge of immunology in the practice of rheumatologists. To get clinical examples of how the knowledge of immunology could be implemented. To highlight the learning opportunities in immunology for rheumatologists and to describe a path of translational research scientist. 14:15:00 Introduction 14:20:00 It’s never lupus! 14:36:00 Q&A 14:41:00 From the clinic to translational research 15:02:00 Gathering knowledge and experience in immunology as rheumatologist 14:57:00 Q&A 15:18:00 Q&A 15:23:00 Immuno-oncology for rheumatologists: not just checkpoint inhibitors 15:39:00 Q&A Room 9 Health Professionals in Rheumatology (HPR) HPR Welcome session: The value of Diversity Delegates will be aware of top publications of HPR since last EULAR know how to navigate the congress in order not to miss any interesting presentation or networking event have knowledge on main challenges that HPR are facing currently and their solutions in current practice have seen examples on good multidisciplinary clinical teamwork, from different centres in Europe and beyond. 14:15:00 Introduction 14:20:00 Appetizer: TOP year news from HPR 14:35:00 Q&A 14:40:00 Entree: Making the best use of the EULAR Congress EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Wednesday, 2 June 2021 14:15:00 15:45:00 Room 9 navigate the congress in order not to miss any interesting presentation or networking 14:55:00 Q&A 15:00:00 Main: The challenges and the opportunities of HPR nowadays; how can we shape the world? 15:15:00 Q&A 15:20:00 Dessert: Brilliant examples of multidisciplinary teamwork in rheumatology 15:35:00 Q&A 15:00:00 15:45:00 Room 1 How to Treat (HOT) How to treat spondyloarthritis To provide an update on the newest evolutions in management of spondyloarthritis in gut Introduction and joint 15:00:00 15:05:00 Strategies towards early and longterm remission in spondyloarthritis and beyond the joint 15:35:00 Q&A
16:15:00 17:45:00 Room 1 Oral Abstract Presentations Opening Plenary Abstract session (blank) 16:15:00 Introduction Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID- 16:20:00 19 Global Rheumatology Alliance MUC5B promoter variant and long-term incidence of interstitial lung disease in patients with rheumatoid arthritis: a population biobank study of 16:30:00 250,000 individuals A randomized, double-blind, placebo-controlled phase III trial of IVIG 10% in patients with Dermatomyositis. The ProDERM study: Results on 16:40:00 Efficacy and Safety 16:47:00 Q&A Successful patient education on COVID-19 vaccine safety in a large rheumatology cohort using interactive mobile-phone video technology: 16:50:00 context, results, and next steps. Integration of flow and digital cytometry in early treatment-naïve rheumatoid arthritis identifies distinct immunophenotypes in peripheral blood and 17:10:00 disease tissue
17:20:00 Association between passive smoking in childhood and adulthood, and rheumatoid arthritis: results from the French E3N-EPIC cohort study 17:30:00 Sex differences in autoimmune disease susceptibility; a multi-omic approach 16:57:00 Q&A 17:37:00 Q&A 17:07:00 Q&A 17:17:00 Q&A 17:27:00 Q&A 16:37:00 Q&A 16:27:00 Q&A
17:00:00 Efficacy and safety of faecal microbiota transplantation for active peripheral psoriatic arthritis: a randomised sham-controlled trial Room 10 Oral Abstract Presentations Education
Learn the newest in the areas of education and educational cases. 16:15:00 A framework of potential interventions to accelerate gender-equitable career advancement in academic rheumatology 16:25:00 Evaluation of a virtual reality teaching concept for medical students during the SARS-CoV-2 pandemic
16:35:00 How to self-examine for tender and swollen joints: co-development of a training video for people with rheumatoid arthritis 16:45:00 The EMerging EUlar NETwork (EMEUNET): an international survey reflecting on a ten-year journey 16:52:00 Q&A 16:55:00 High median nerve lesion secondary to severe giant cell arteritis (GCA) 17:02:00 Q&A 17:15:00 Osteopoikilosis in patient with ankylosing spondylitis. 17:12:00 Q&A 16:32:00 Q&A 16:22:00 Q&A 16:42:00 Q&A 17:22:00 Q&A 17:32:00 Q&A 17:05:00 Limb Girdle Muscular Dystrophy Type 2B - A rare myositis mimic A Case of Atypical Mycobacterium Infection Complicating Extra-Nodal Rosai-Dorfman Disease in a Patient with Systemic Lupus Erythematosus 17:25:00 (SLE) Room 11 PARE Challenges for Patients and Patients’ Organisations in Times of the Pandemic To give an overview of organisations' activities for people with RMDs. To outline challenges organisations have faced and how they have tried to overcome these. To give an update on Sars-Cov2 research. 16:15:00 Supporting patients: information, helpline, coping support, shielding support [UK experience] 16:30:00 Q&A 16:35:00 Supporting patients: information, helpline, coping support, shielding support [German experience] 16:50:00 Q&A 16:55:00 Economic challenges for patient organisations and how to overcome them 17:10:00 Q&A 17:15:00 Coronavirus research + discussion 17:30:00 Q&A
17:35:00 The effect Covid-19 has on the mental health of people living with Rheumatic diseases. From data to interventions. 17:42:00 Q&A Room 12 Oral Abstract Presentations The origins of pain in RMDs Learn the newest in the areas of Basic and translational pain science, Pain in rheumatic diseases, including fibromyalgia and Spine, mechanical musculoskeletal problems, local soft tissue disorders. 16:15:00 Introduction 16:20:00 Infectious and autoinflammatory Modic type 1 changes have different pathomechanisms
16:30:00 Central Mechanisms Trait predicts persistent knee osteoarthritis pain at 24-months: data from the Osteoarthritis Initiative EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start 17:45:00 diseases, including fibromyalgia and Spine, mechanical musculoskeletal problems, local Wednesday, 2 June 2021 16:15:00 Room 12 soft tissue disorders. 16:40:00 Altered expression of neurotrophins and their receptors in the skin of patient with complex regional pain syndrome (CRPS) 16:47:00 Q&A Gender influence on clinical manifestations, depressive symptoms and Brain-Derived Neurotrophic Factor (BDNF) serum levels in patients 16:50:00 affected by Fibromyalgia
17:10:00 A Cohort Study On The Bidirectional Relationship Between Fibromyalgia And Periodontitis Over A 15-year Follow-up
17:20:00 Do pain catastrophizing reduce the likelihood of remission in patients with chronic inflammatory joint disorders? 16:57:00 Q&A 17:07:00 Q&A 17:17:00 Q&A 17:27:00 Q&A 16:37:00 Q&A 16:27:00 Q&A
17:00:00 COMORBIDITIES IN HAND OSTEOARTHRITIS PATIENTS: PREVALENCE AND IMPACT ON PAIN AND PAIN SENSITIZATION Room 13 Oral Abstract Presentations Infection-related rheumatic and orphan diseases Learn the newest in the areas of infection-related rheumatic and orphan diseases. 16:15:00 Classification of Patients with Relapsing Polychondritis Based on Somatic Mutations in UBA1 TREATMENT OF OCULAR SARCOIDOSIS. STUDY OF 65 PATIENTS OF A SERIES OF 384 PATIENTS FROM A SINGLE UNIVERSITY 16:25:00 HOSPITAL. Long-Term Safety and Effectiveness of Canakinumab in cryopyrin-associated periodic syndromes (CAPS) – 30-month data from the 16:35:00 RELIANCE Registry 16:45:00 Retention rate of IL-1 inhibitors in patients with Schnitzler’s syndrome 16:52:00 Q&A 16:55:00 Pulmonary arterial hypertension in Adult-Onset Still’s Disease: a case series of 13 patients 17:02:00 Q&A Exposure to dengue infection do not raise risk of rheumatoid arthritis: findings from the Malaysian Epidemiological Investigation of Rheumatoid 17:15:00 Arthritis (MyEIRA) case-control study 17:12:00 Q&A 16:32:00 Q&A 16:22:00 Q&A 16:42:00 Q&A 17:22:00 Q&A 17:32:00 Q&A Non-gonococcal pyogenic arthritis of native joints in Western Australia. A longitudinal population-based study of frequency, risk factors and 17:05:00 outcome. LISTERIA MONOCYTOGENES. DESCRIPTION AND ANALYSIS OF CASES IN AN IMMUNODEPRESSED POPULATION BY RHEUMATIC 17:25:00 DISEASES. Room 2 Oral Abstract Presentations Genomics, genetic basis of disease and functional genomics Learn the newest in the areas of genomics, genetic basis of disease and functional genomics. 16:15:00 HLA associations in patients with juvenile idiopathic arthritis associated uveitis and clinical subtypes. 16:25:00 Genomic risk score for advanced osteoarthritis in older adults 16:35:00 Identification of functional variants in the rheumatoid arthritis associated JAZF1 locus in synovial fibroblasts
16:45:00 Validation of GWAS-identified variants for anti-TNF drug response in rheumatoid arthritis: a meta-analysis of three large cohorts 16:52:00 Q&A
16:55:00 Predicting responses to anti-TNF treatments in rheumatoid arthritis patients from genetic and clinical data using a machine learning approach 17:02:00 Q&A
17:15:00 Homeobox D transcription factors shape differential joint environment between anterior finger joints and thumb 17:12:00 Q&A 16:32:00 Q&A 16:22:00 Q&A 16:42:00 Q&A 17:22:00 Q&A 17:32:00 Q&A Defining Systemic Lupus Erythematosus Molecular Taxonomy Through Data-driven Restratification and Identification of Cluster-tailored Drugs 17:05:00 for a Personalized Medicine Approach 17:25:00 Identification of differentially expressed genes in early rheumatoid arthritis patients responding to tocilizumab. Room 3 Oral Abstract Presentations Adaptive immunity (T cells and B cells) in rheumatic diseases and Innate immunity in rheumatic diseases Learn the newest in the areas of Adaptive immunity (T cells and B cells) in rheumatic diseases and Innate immunity in rheumatic diseases. 16:15:00 Rho expression facilitates T cell migration to lymph nodes in response inflammation 16:25:00 Generation of PT101, a highly selective IL-2 mutein for treatment of autoimmune diseases Decreased Levels of T Follicular Helper (CD4+CXCR5+) Cells and CD27+CD38+ and CD27+CD38- B Cells in Ankylosing Spondylitis Patients 16:35:00 Correlate with Marker of Inflammation
16:45:00 CD209+/CD14+ Dendritic Cells are enriched and activated at the site of inflammation and are modulated by JAK/STAT signalling. 16:52:00 Q&A 16:55:00 IGF1R dependent cell interaction and regulation of autoantibody production in rheumatoid arthritis 17:02:00 Q&A
17:15:00 CD206+CD163+ pathogenic macrophages enriched in Rheumatoid Arthritis synovial tissue with distinct transcriptional signatures. 17:12:00 Q&A 16:32:00 Q&A 16:22:00 Q&A 16:42:00 Q&A EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Wednesday, 2 June 2021 16:15:00 17:45:00 Room 3 diseases and Innate immunity in rheumatic diseases. 17:22:00 Q&A 17:32:00 Q&A
17:05:00 AS-related TCR beta clonotypes are present in different inflamed tissues of patients with spondyloarthropathies Neutrophil Extracellular Traps in Giant Cell Arteritis inflamed temporal arteries: localization, co-expression of inflammatory cytokines and 17:25:00 association with disease extension Room 4 Oral Abstract Presentations Of mice and man: insights into pathophysiology of rheumatoid arthritis and spondyloarthritis Learn the newest in the areas of Rheumatoid arthritis - aetiology, pathogenesis and Treatment of Non-biologic-DMARD-IR PsA Patients With Upadacitinib or Adalimumab Results in the Modulation of Distinct Functional animal models and Spondyloarthritis - etiology, pathogenesis and animal models. 16:15:00 Pathways: Proteomics Analysis of the SELECT-PsA 1 Phase 3 Study
16:25:00 Shared and distinct gut microbiome signatures in patients with axial spondyloarthritis and its related immune-mediated diseases
16:35:00 Single cell analysis of Spondyloarthritis regulatory T cells identifies distinct synovial gene expression patterns and clonal fates
16:45:00 Regulatory T cell CD39 expression as a predictor of early remission-induction with methotrexate in new-onset rheumatoid arthritis 16:52:00 Q&A
16:55:00 STP938, a novel, potent and selective inhibitor of CTP Synthase 1 (CTPS1) demonstrates efficacy in rodent models of inflammation and arthritis 17:02:00 Q&A IL-6 activates Yes-associated protein (Yap) in fibroblasts and induces Yap-Snail complex formation to drive synovial lining pathology in 17:15:00 inflammatory arthritis 17:12:00 Q&A 16:32:00 Q&A 16:22:00 Q&A 16:42:00 Q&A 17:22:00 Q&A 17:32:00 Q&A 17:05:00 Assessment of the intestinal permeability in patients with rheumatoid arthritis using colonic tissues and sera
17:25:00 ABATACEPT AND OTHER DMARDS HAVE COMMON TRANSCRIPTOMIC EFFECTS ON RA SYNOVIAL TISSUE Room 5 Oral Abstract Presentations Molecular mechanisms in Connective Tissue Disease Learn the newest in the areas of SLE, Sjögren’s and APS - etiology, pathogenesis and animal models. 16:15:00 Spliceosome alterations in leucocytes from APS, SLE and SLE+APS patients are closely related to their main clinical features. ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus 16:25:00 Erythematosus (SLE) and Other B Cell-Related Autoimmune Diseases
Hippocampal Immune Cell Trafficking and a Myeloid Predominant Inflammatory Response with Enhanced Antigen Presentation and Decreased 16:35:00 Levels of Neurotransmitters Underly the Neuropsychiatric Phenotype of the NZW/NZB Murine Lupus Model Saliva and serum levels of CXCL13: association with the severity of salivary gland lesions and lymphoma in patients with Sjögren’s syndrome 16:45:00 (SS) 16:52:00 Q&A 16:55:00 Blocking of CD103+ tissue resident memory T cells (TRM) as a therapeutic strategy in Sjogren’s syndrome 17:02:00 Q&A
17:15:00 ANA positivity is associated with complex immune disturbance even in individuals who do not develop clinical autoimmune disease. 17:12:00 Q&A 16:32:00 Q&A 16:22:00 Q&A 16:42:00 Q&A 17:22:00 Q&A 17:32:00 Q&A
17:05:00 Increased risk of severe infections and mortality in patients with newly diagnosed systemic lupus erythematosus: A population-based study 17:25:00 NLRP12 Involves in the Lupus with Positive Interferon Signature Room 6 Oral Abstract Presentations Clinical aspects of axial spondyloarthritis – science meets daily practice
Learn the newest in the area of spondyloarthritis - clinical aspects (other than treatment). 16:15:00 Can patients with axial spondyloarthritis indicate whether pain is mainly related to inflammation or structural damage?
Identification of Clinical Phenotypes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis According to 16:25:00 Peripheral Musculoskeletal Manifestations: a Cluster Analysis in the International ASAS-PerSpA Study.
16:35:00 Diagnosing axial spondyloarthritis: estimation of the disease probability in patients with a priori different likelihoods of the diagnosis
Comparison of Baseline Disease Activity and Patient (Pt)-Reported Outcomes (PROs) Between Pts With Psoriatic Arthritis and Axial 16:45:00 Involvement (Axial PsA) and Axial Spondyloarthritis (Axial SpA) From the Corrona PsA/SpA Registry 16:52:00 Q&A Two-year diagnostic consistency in patients with chronic back pain suspected of axial spondyloarthritis in protocolised follow-up: Data from the 16:55:00 Spondyloarthritis Caught Early Cohort 17:02:00 Q&A EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start 17:45:00 Wednesday, 2 June 2021 16:15:00 Room 6 Learn the newest in the area of spondyloarthritis - clinical aspects (other than treatment). 17:15:00 Factors associated with remission at 5 years of follow-up in early onset axial spondyloarthritis: results from the DESIR cohort 17:12:00 Q&A 16:32:00 Q&A 16:22:00 Q&A 16:42:00 Q&A 17:22:00 Q&A 17:32:00 Q&A 17:05:00 Looking Beyond BASDAI Total Scores: Analysis of the BASDAI on the Basis of Sex
Impact of correcting CRP threshold according to BMI on diagnosis, disease activity, indication of biological treatment and prediction of 17:25:00 therapeutic response, in patients suspected of axial spondyloarthritis. Results from DESIR cohort. Room 7 Oral Abstract Presentations Vasculitis - I Learn the newest in the area of vasculitis. 16:15:00 New role for proteinase 3 in IL-16 bioactivity control in granulomatosis with polyangiitis 16:25:00 Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis 16:35:00 Plasma microvesicles as liquid biopsies of the arterial wall in large vessel vasculitis
16:45:00 A personalised rituximab retreatment approach based on clinical and B-cell biomarkers in ANCA-associated vasculitis 16:52:00 Q&A Cardiovascular and cerebrovascular risk in patients with small vessel vasculitides: a comparative analysis between aortic stiffness, carotid 16:55:00 sonography and SCORE. 17:02:00 Q&A COMPARATIVE STUDY ON ANTI-TNF VS TOCILIZUMAB FOR TREATMENT OF REFRACTORY UVEITIC CYSTOID MACULAR EDEMA 17:15:00 DUE TO BEHCET'S DISEASE. MULTICENTER STUDY OF 49 PATIENTS 17:12:00 Q&A 16:32:00 Q&A 16:22:00 Q&A 16:42:00 Q&A 17:22:00 Q&A 17:32:00 Q&A Mavrilimumab (anti GM-CSF receptor α monoclonal antibody) Reduces Risk of Flare and Increases Sustained Remission in a Phase 2 Trial of 17:05:00 Patients with Giant Cell Arteritis A Proof-Of-Concept Study To Assess The Efficacy Of Tocilizumab Monotherapy after Ultra-Short Glucocorticoid Administration To Treat Giant 17:25:00 Cell Arteritis - the GUSTO Trial Room 8 Oral Abstract Presentations Vasculitis - II Learn the newest in the area of vasculitis. 16:15:00 Cytokine producing B cells skew macrophages towards a pro-inflammatory phenotype in giant cell arteritis 16:25:00 Single centre experience of the clinical spectrum, aetiologies and management of non-infectious aortitis
16:35:00 TOCILIZUMAB IN CRANIAL AND EXTRACRANIAL REFRACTORY GIANT CELL ARTERITIS: A MULTICENTER STUDY OF 312 CASES TOCILIZUMAB IN VISUAL INVOLVEMENT OF GIANT CELL ARTERITIS. MULTICENTER STUDY OF 312 PATIENTS OF CLINICAL 16:45:00 PRACTICE 16:52:00 Q&A
16:55:00 Metabolic profile and comorbidities in Giant Cell Arteritis and Polymyalgia Rheumatica patients before and after treatment 17:02:00 Q&A
17:15:00 The role of positron emission tomography/computed tomography (PET/CT) in disease activity assessment in patients with large vessel vasculitis 17:12:00 Q&A 16:32:00 Q&A 16:22:00 Q&A 16:42:00 Q&A 17:22:00 Q&A 17:32:00 Q&A
17:05:00 Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: Multicenter worldwide retrospective study of 209 patients. 17:25:00 Onset to Diagnosis Time Predicts Survival Rate in Takayasu Arteritis Room 9 Health Professionals in Rheumatology (HPR), EULAR Projects Like a gearwheel: HPR’s research, education, and practice Delegates will be able to discuss the process and outputs of research supported by EULAR HPR grants recognise different projects managed by the HPR School of Rheumatology discuss the importance of quality of care and difficulties of harmonising its measurement describe the key steps of the implementation process and relate these to service improvement. 16:15:00 Introduction 16:20:00 HPR Research: Overview of the EULAR (and other) grants and future directions 16:28:00 HPR Education: Activities in course to reduce disparities across countries 16:36:00 HPR Quality of care: should we aim for a common audit in Europe? 16:44:00 Building all up: Key steps on implementation science 16:52:00 Roundtable discussion
17:35:00 Pilot implementation of enhancements in supervised group exercise for people with axial spondyloarthritis (axSpA) in the Netherlands 17:42:00 Q&A EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Wednesday, 2 June 2021 16:15:00 18:15:00 19:45:00 Room 7 Basic and Translational Science New toys in rheumatology: single cell RNA and epigenetic sequencing, the holy grail? Learning the power of single cell analyses to improve our knowledge of rheumatic diseases, and patient stratification Learning the latest development in single cell transcriptome and epigenome analyses from experts in the field. 18:15:00 Introduction 18:20:00 Single cell analyses to identify predictive signatures of rheumatoid arthritis flares (PMID 32668112) 18:49:00 Q&A 19:05:00 Q&A 19:21:00 Q&A 18:33:00 Q&A 19:08:00 Detecting T cells involved in immune responses from immune repertoire sequencing data 19:41:00 Q&A 18:52:00 X chromosome inactivation and SLE pathogenesis: gender and epigenetics 19:31:00 Q&A 18:36:00 Single cell analyses: deciphering tissue biology in health and disease across time and space Single-cell transcriptomics uncovers defective bone marrow early B cell development in a subset of lupus patients associated with aggravated 19:24:00 inflammation 19:34:00 Single cell sequencing reveals clonally expanded cytotoxic CD4+ T cells in the joints of ACPA+ RA patients Room 9 Health Professionals in Rheumatology (HPR) HPRs experience on distance health care: reshaping after the Pandemic Delegates will be aware of efficacious interventions to provide remote care, namely to promote adherence to the treatment plan be able to describe practicalities required to provide remote care gain a better understanding about psychological distress in Pandemic times. 18:15:00 Introduction 18:20:00 Mapping: Efficacious interventions and required competences to provide remote care in rheumatology 18:35:00 The Basics still work: Telephone help lines 18:42:00 Future today: Innovative models for physical care delivery 18:49:00 The essentials: Providing first mental aid - from identification to referral 18:56:00 Debate
Thursday, 3 June 2021 08:15:00 09:45:00 Room 7 Basic and Translational Science Immunodeficiency and autoimmune disease To appreciate the association of primary immunodeficiency with autoimmunity To enhance the understanding of monogenic / polygenic immune defects in the development of autoimmune diseases To dissect the role of the different immune cell network in the development of autoimmune diseases in patients with known primary immunodeficiency and to heighten the awareness of rheumatologists of disease / drug induced immunosuppressed state. 08:15:00 Introduction 08:20:00 Autoimmunity and primary immunodeficiency 09:20:00 Q&A 08:59:00 Q&A 08:38:00 Q&A 09:41:00 Q&A 09:23:00 Secondary immunodeficiency in patients with autoimmune disease 08:41:00 Genetic basis of primary immunodeficiency syndromes: implications in autoimmunity 09:02:00 Self-tolerance, immunodeficiency and autoimmunity
10:15:00 11:00:00 Room 1 What is New (WIN) Fatigue in Arthritis, SpA & systemic rheumatic diseases Understand the impact of fatigue on patients with chronic inflammatory rheumatic conditions Appreciate pharmacological and non-pharmacological management strategies of fatigue in these patients. 10:15:00 Introduction 10:20:00 Fatigue in Arthritis, SpA & systemic rheumatic diseases 10:50:00 Q&A
11:45:00 Room 10 Oral Abstract Presentations Advances in Pediatric Rheumatology PREDICTIVE VALUE OF MUSCULOSKELETAL ULTRASOUND IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS IN CLINICAL Learn the newest in the area of Pediatric Rheumatology. 10:15:00 REMISSION 10:25:00 ETANERCEPT RESPONSE CLUSTERS IN JUVENILE IDIOPATHIC ARTHRITIS
10:35:00 Comparative analysis of etanercept biosimilar and originator use in clinical practice: data from the German BIKER-Registry
11:05:00 Disease Activity in Children with Juvenile Idiopathic Arthritis after Simultaneous PCV13 and Hib Vaccination: A Cohort Study 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A Risk for uveitis events after withdrawal of disease modifying antirheumatic drugs in the treatment of patients with extended oligoarthritis or 10:55:00 rheumatoid factor negative polyarthritis 11:25:00 The role of vascular inflammation markers in deficiency of adenosine deaminase 2
10:45:00 Long-term safety of anakinra in patients with systemic juvenile idiopathic arthritis from the Pharmachild registry 11:15:00 The role of lung ultrasound in the diagnosis of interstitial lung disease in children with dermatomyosistis EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Thursday, 3 June 2021 10:15:00 11:45:00 Room 11 PARE Challenges for working people with RMDs in pandemic times To address the impact on working conditions and safety To outline how legal measures support to stay at work, enable better social protection and prevent work disability (align with other chronic conditions) To highlight the importance of disease prevention and health promotion in the working environment. 10:15:00 Introduction 10:20:00 Impact of the pandemic on work of people with RMDs - results of European surveys 10:35:00 A patient organisations' actions to support employees with an RMD 10:50:00 Empowered2work: healthy workplaces at home 11:05:00 EU OSHA Campaign on healthy work-places focuses on musculoskeletal disorders 11:20:00 Q&A Development of Points to Consider when supporting persons with reumatic and musculoskeletal diseases to participate in healthy and 11:35:00 sustainable paid work. 11:42:00 Q&A Room 12 Oral Abstract Presentations Progress in myositis and scleroderma research - I Decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) with and without dyspnoea: Learn the newest in the areas of scleroderma, myositis and related syndromes. 10:15:00 data from the SENSCIS trial
10:25:00 Phase 3 Trial of Lenabasum, a CB2 Agonist, for the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc)
10:35:00 Brentuximab vedontin for skin involvement in refractory diffuse cutaneous systemic sclerosis, interim results of a phase IIb open-label trial 11:05:00 International Multicentric Prospective Study on PREgnancy in Systemic Sclerosis (IMPRESS-2) 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A 10:55:00 Subclinical interstitial lung disease is frequent and progresses across different connective tissue diseases
11:25:00 Presence and Severity of Digital Occlusive Arterial Disease predicts Digital ischemic complications in Systemic sclerosis 10:45:00 Reduction of skin fibrosis in systemic sclerosis on rituximab treatment. Long-term follow-up 11:15:00 Ultrasound (US) evaluation of bowel vasculopathy in Systemic Sclerosis (SSc) Room 13 Oral Abstract Presentations Rheumatoid arthritis - prognosis, predictors and outcome Learn the newest in the area of rheumatoid arthritis - prognosis, predictors and outcome. 10:15:00 Association between environmental air pollution and rheumatoid arthritis flares Discontinuation rate of Tofacitinib is similar when compared to TNF inhibitors in Rheumatoid Arthritis Patients: Pooled Data from two 10:25:00 Rheumatoid Arthritis Registries in Canada IMPACT OF RF AND ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS ON 2-YEAR RETENTION OF ABATACEPT IN 10:35:00 PATIENTS WITH RA Identification of a subgroup of people with rheumatoid arthritis characterised by high disability over 10 years, despite low inflammation: Results 11:05:00 from two European prospective cohort studies 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A 10:55:00 In RA patients in remission, which biomarkers predict successful tapering of csDMARDs? Radiographic progression despite persistent LDA or remission is influenced by current smoking rather than the respective DAS 28 level, results 11:25:00 of the Swiss rheumatoid arthritis register (SCQM) 10:45:00 Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort
11:15:00 Phenotyping of molecular signatures in the synovial tissue of rheumatoid arthritis by integrative systems analysis Room 2 Oral Abstract Presentations Rheumatoid arthritis - comorbidity and clinical aspects - I
Learn the newest in the areas of rheumatoid arthritis - comorbidity and clinical aspects. 10:15:00 Polypharmacy is associated with a poorer treatment response and increased risk of adverse events in early rheumatoid arthritis EPIDEMIOLOGY AND MORTALITY OF RA-ASSOCIATED INTERSTITIAL LUNG DISEASE: DATA FROM A FRENCH ADMINISTRATIVE 10:25:00 HEALTHCARE DATABASE The influence of comorbidity on mortality in patients with Rheumatoid Arthritis 1980-2015: A longitudinal population-based study in Western 10:35:00 Australia 5-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients who received Treat-to-Target Management: a population-based cohort 11:05:00 study EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Thursday, 3 June 2021 10:15:00 11:45:00 Room 2 Learn the newest in the areas of rheumatoid arthritis - comorbidity and clinical aspects. 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A 10:55:00 Decline in Excess Risk of Heart Failure in Patients with Rheumatoid Arthritis in Recent Years
11:25:00 Feasibility and usefulness of mapping biologic registries to a common data model: illustration using comorbidities. 10:45:00 Rheumatoid arthritis disease activity over time and subsequent cardiovascular risks. Differences in Low-density lipoprotein (LDL) particle composition and oxidation may underlie the paradoxical association of low LDL with higher 11:15:00 coronary atherosclerosis burden in rheumatoid arthritis Room 3 Oral Abstract Presentations Bone & Joints The associations between bariatric surgery and hip or knee arthroplasty, and hip or knee osteoarthritis: a cohort study from Swedish nationwide Learn the newest in the areas of osteoarthritis and osteoporosis. 10:15:00 healthcare registries 10:25:00 Clinical efficacy of romosozumab in patients with rheumatoid arthritis for 12 months Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK2/DYRK1A Inhibitor That Modulates the Wnt Pathway, Provided Cartilage- 10:35:00 Protective Effects in an Animal Model of Post-traumatic OA
11:05:00 PLASMA PROTEOMICS IDENTIFIES CRTAC1 AS BIOMARKER FOR OSTEOARTHRITIS SEVERITY AND PROGRESSION 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A
10:55:00 A Cohort Study On The Bidirectional Relationship Between Periodontitis And Osteoarthritis Over A 15-year Follow-up Female reproductive factors and risk of joint replacement arthroplasty of knee and hip due to osteoarthritis in postmenopausal women: a 11:25:00 nationwide cohort study of 1.36 million women 10:45:00 Cartilage Lesions of the Knee: gagCEST Imaging at 3 T MRI and Intraoperative Validation 11:15:00 Factors associated with osteoporosis care of men: a real-life study on a nation-wide dataset Room 4 Oral Abstract Presentations Rheumatoid arthritis - biological DMARDs
Short- and longer-term risks for acute coronary syndrome in patients with rheumatoid arthritis starting treatment with disease-modifying anti- Learn the newest in the areas of rheumatoid arthritis - biological DMARDs. 10:15:00 rheumatic drugs. A collaborative observational head-to-head study across five Nordic rheumatology registers
Efficacy and Safety of ABBV-3373, a Novel Anti-TNF Glucocorticoid Receptor Modulator Antibody Drug Conjugate, in Patients With Moderate 10:25:00 to Severe Rheumatoid Arthritis Despite Methotrexate Therapy: a Phase 2a Proof of Concept Study
10:35:00 Elderly patients are not at increased risk of serious infections when receiving bDMARDs or JAK inhibitors compared to csDMARD treatment
11:05:00 Should we use bioDMARDS in first intention in early Rheumatoid Arthritis? : Results at 5 years from the ERA Louvain Brussels cohort 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A Effect of withdrawing etanercept or methotrexate on patient-reported outcomes in rheumatoid arthritis patients in remission on combination 10:55:00 therapy: Results from the SEAM-RA trial Real-world effectiveness of TNFi versus non-TNFi biologics on disease activity in patients with rheumatoid arthritis: data from the ACR’s RISE 10:45:00 registry
11:15:00 Duration of Clinical Efficacy Following Treatment with VIB4920 in Subjects with Moderate to Severe Rheumatoid Arthritis Room 5 Oral Abstract Presentations Rheumatoid arthritis - non biologic treatment and small molecules Learn the newest in the areas of rheumatoid arthritis - non biologic treatment and small molecules. 10:15:00 Comparative effectiveness of JAKi versus bDMARDs; a nationwide study in RA SAFETY PROFILE OF JAK-INHIBITORS VERSUS TNF-INHIBITORS IN REAL-WORLD CLINICAL PRACTICE: DATA FROM A 10:25:00 MULTICENTER REGISTER Effects of nintedanib in patients with progressive fibrosing interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in the INBUILD 10:35:00 trial Confounding effects of continued methotrexate in placebo arms (PLC) of rheumatoid arthritis (RA) clinical trials – a post-hoc analysis of two 11:05:00 randomized controlled trials (RCTs) 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A 10:55:00 Infections and Serious Infections in the Filgotinib Rheumatoid Arthritis Program
10:45:00 Tofacitinib in rheumatoid arthritis-associated interstitial lung disease: Efficacy and safety analysis from TReasure real-life data EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start 11:45:00 Learn the newest in the areas of rheumatoid arthritis - non biologic treatment and small Integrated laboratory abnormality profiles of upadacitinib with up to 4.5 years of exposure in patients with rheumatoid arthritis treated in the Thursday, 3 June 2021 10:15:00 Room 5 molecules. 11:15:00 SELECT phase 3 program Room 6 Oral Abstract Presentations SLE, Sjögren’s and APS - treatment and SLE, Sjögren’s and APS - clinical aspects (other than treatment) Learn the newest in the areas of SLE, Sjögren’s and APS - treatment and SLE, Sjögren’s and APS - clinical aspects (other than treatment). 10:15:00 Composite of Relevant Endpoints in Sjögren’s Syndrome (CRESS): a comprehensive tool for clinical trials Belimumab after rituximab significantly reduced IgG anti-dsDNA antibody levels and prolonged time to severe flare in patients with systemic 10:25:00 lupus erythematosus
10:35:00 Anifrolumab Effects on Rash and Arthritis in Patients With SLE and Impact of Interferon Signal in Pooled Data From Phase 3 Trials NOVEL INTERFERON GENE EXPRESSION SCORES PREDICT REFRACTORY SEVERE CUTANEOUS DISEASE FOLLOWING 11:05:00 RITUXIMAB THERAPY IN SLE 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A 10:55:00 The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use
Rituximab prevents the progression of B-cell driven inflammatory infiltrate in the minor salivary glands of Primary Sjogren’s 11:25:00 Syndrome by downregulating immunological pathways key in ectopic germinal centre organization: results from the TRACTISS trial Effect of Iberdomide on Cutaneous Manifestations in Systemic Lupus Erythematosus: Results of a 24-Week, Placebo-Controlled, Phase 2 10:45:00 Study
SAFETY AND EFFICACY OF SUBCUTANEOUS BELIMUMAB AND INTRAVENOUS RITUXIMAB COMBINATION IN PATIENTS WITH 11:15:00 PRIMARY SJÖGREN’S SYNDROME: A PHASE 2, RANDOMISED, PLACEBO-CONTROLLED 68-WEEK STUDY Room 7 Oral Abstract Presentations Spondyloarthritis - treatment Tumor Necrosis Factor Inhibitors Show a Delayed Effect on Radiographic Sacroiliitis Progression in Patients with Early Axial Spondyloarthritis: Learn the newest in the area of spondyloarthritis - treatment. 10:15:00 10-Year Results from the German Spondyloarthritis Inception Cohort Feasibility of progressive anti-TNF tapering in axial spondyloarthritis patients in low disease activity: results from the multicenter non-inferiority 10:25:00 prospective randomized controlled trial SPACING. A Time-Shifted Effect of Tumor Necrosis Factor Inhibitors on Radiographic Spinal Progression in Patients With Axial Spondyloarthritis: Long- 10:35:00 term Results From the German Spondyloarthritis Inception Cohort NETAKIMAB REDUCES ANKYLOSING SPONDYLITIS ACTIVITY IN PATIENTS WITH OR WITHOUT SACROILIITS ON MRI: RESULTS OF 11:05:00 SUBANALYSIS OF PHASE 3 ASTERA TRIAL 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A
10:55:00 Effects of filgotinib on spinal lesions in ankylosing spondylitis: Magnetic resonance imaging data from the TORTUGA trial Efficacy and Safety of Upadacitinib in Patients With Active Ankylosing Spondylitis: 1-Year Results From a Randomized, Double-Blind, Placebo- 11:25:00 Controlled Study With Open-Label Extension Biologic refractory disease in axial spondyloarthritis - definition, prevalence and patient characteristics. A collaboration between five Nordic 10:45:00 biologic registries Impact of Adalimumab versus Non-Biologic Therapy on Disease Activity and Patient-Reported Outcomes in Ankylosing Spondylitis over 24 11:15:00 Months – Results of the COMPLETE-AS Canadian Observational Study Room 8 Oral Abstract Presentations Diagnostics and imaging procedures Learn the newest in the areas of diagnostics and imaging procedures. 10:15:00 Differential diagnosis of RA and PsA using neural networks on three-dimensional bone shape of finger joints Tenosynovitis, synovial hypertrophy and feet bursitis are useful ultrasound biomarkers for predicting arthritis development in a population at-risk 10:25:00 for rheumatoid arthritis
10:35:00 Rheumatic? - A Digital Diagnostic Decision Support Tool for Individuals Suspecting Rheumatic Diseases: A Multicenter Validation Study Machine learning approaches for risk modelling in interstitial lung disease associated with systemic sclerosis using high dimensional image 11:05:00 analysis 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A Reliability and responsiveness of two OMERACT whole-body MRI scores of entheseal and joint inflammation in the knee region in 10:55:00 spondyloarthritis
11:25:00 COMPARISON OF DIAGNOSTIC CRITERIA IN BEHÇET DISEASE AND SENSITIVITY IN DIAGNOSING SEVERE MANIFESTATIONS. 10:45:00 Spatiotemporal dynamics of bone loss before and after the onset of rheumatoid Arthritis. 11:15:00 Autoantibodies against dense-fine-speckled 70 (DFS70) do not entirely exclude connective tissue diseases Room 9 Health Professionals in Rheumatology (HPR), Oral Abstract Presentations HPR Abstract Session (I) EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start 11:45:00 Bridging gaps across levels of care in rehabilitation of patients with rheumatic- and musculoskeletal diseases: results from a stepped wedge Thursday, 3 June 2021 10:15:00 Room 9 To discuss the results of some of the best abstracts submitted to the congress. 10:15:00 cluster randomised controlled trial 10:25:00 Feasibility of a web-based, peer-supported exercise program for people with hip or knee osteoarthritis
10:35:00 Remote management of rheumatoid arthritis vs routine outpatient follow-up: a prospective, longitudinal real-world study 11:05:00 The fall prevention programme ‘Sicher durch den Alltag’ is effective and cost-effective 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A
10:55:00 Changes in pain and hand function after multimodal occupational therapy and/or surgery in patients with carpometacarpal osteoarthritis Preferences for treatments to prevent rheumatoid arthritis: Discrete choice survey of general populations in United Kingdom, Germany, and 11:25:00 Romania The effect of a person-centered smoking cessation program in rheumatoid arthritis patients in a rheumatology outpatient clinic setting – results 10:45:00 of an interventional feasibility study. Impact of non-pharmacological interventions targeting sleep disturbances or disorders in patients with inflammatory arthritis: A systematic review 11:15:00 and meta-analysis of randomised trials 11:00:00 11:45:00 Room 1 How to Treat (HOT) Treatment of severe lupus nephritis Understand the prevalence and definition of severe lupus nephritis Appreciate the clinical diagnosis, followup and monitoring of patients with severe lupus nephritis Appreciate treatment and management options for severe lupus nephritis. 11:00:00 Introduction 11:05:00 Treatment of severe lupus nephritis 11:35:00 Q&A
11:50:00 13:30:00 Poster Tours no session group Adaptive immunity (T cells and B cells) in rheumatic diseases
(blank) 12:20:00 NX-5948, a Selective Degrader of BTK, Significantly Reduces Inflammation in a Model of Autoimmune Disease 12:38:00 The relationship between different IgG and IgA anti-modified protein autoantibodies in rheumatoid arthritis T-cell repertoire of synovial fluid in spondyloarthropathies exhibits hallmarks of HLA-dependent clonal expansions and remains stable over 1.5 12:08:00 years
12:44:00 CD38+ memory T cells are a functionally distinct subset that is expanded in SLE and associated with lupus nephritis. 12:32:00 Identification and Characterization of HisRS+ CD4+ T cells patients with Idiopathic Inflammatory Myopathies PI16 represses Foxp3 expression in T regulatory cells and exacerbates autoimmune arthritis via inhibiting the K48-linked polyubiquitin 11:56:00 degradation of Bmi-1 12:14:00 The effect of LKB1 inhibition in RA pathogenesis
12:26:00 Loss of balance between protective and pro-inflammatory synovial tissue T cell polyfunctionality predates clinical onset of Rheumatoid Arthritis Phenotype and functional characteristics of antigen-specific, auto-reactive B cell responses reveal differential immunological activity in patients 11:50:00 with systemic sclerosis 12:02:00 Rituximab therapy in systemic lupus erythematosus – transient effects on age associated B-cells Epidemiology and treatment of pain in RMDs
(blank) 12:20:00 The evaluation of functional abilities of patients with osteoporotic vertebral fractures as a basis for rehabilitation programs developing
12:38:00 PREDICTORS OF SUSTAINED 6 MONTHS REMISSION AND FLARE IN PATIENTS WITH POLYMYALGIA RHEUMATICA
12:08:00 Time-trends in Cocaine and hallucinogen use disorder hospitalizations in Rheumatic Diseases: A National Time-Trends study Efficacy and safety of secukinumab in patients with rotator cuff tendinopathy: a 24-week, randomised, double-blind, placebo-controlled, phase II 12:44:00 proof-of-concept trial
12:32:00 Investigating Virtual Immersive Experiences in the Management of Chronic Pain – The VIPA Study (Preliminary Results) 11:56:00 Epidemiology of Fibromyalgia Hospitalizations in the United States 12:14:00 Prevalence of Neuropathies in Rheumatic and Musculoskeletal Diseases IMC-1, a fixed dose combination of famciclovir and celecoxib, improves common symptoms associated with fibromyalgia in addition to pain: post 12:26:00 hoc analysis of a Phase 2a trial
11:50:00 The association between bariatric surgery and carpal tunnel syndrome: a cohort study from Swedish nationwide healthcare registries 12:02:00 Musculoskeletal manifestations in patients with endocrine diseases in tertiary service Imaging in axial spondyloarthritis Does Imaging of the Sacroiliac Joint Differ in Patients Presenting with Undiagnosed Back Pain and Psoriasis, Acute Anterior Uveitis, and Colitis: (blank) 12:20:00 An Inception Cohort Study One in twenty inflammatory bowel disease patients who underwent abdominopelvic computed tomography have undiagnosed axial 12:08:00 spondyloarthritis 12:32:00 MRI lesions in SpA: a comparison with age and sex matched participants with non-inflammatory back pain In radiographic axial spondyloarthritis, bridging syndesmophytes increase risk of facet joint ankylosis on the same vertebral level while facet joint 11:56:00 ankylosis does not increase risk of same level syndesmophytes AN ARTIFICIAL INTELLIGENCE MODEL IN RHEUMATOLOGY: INTERPRETATION OF THE SACROILIAC JOINT GRAPHY IN 12:14:00 ANKYLOSING SPONDYLITIS The influence of age on the prevalence of inflammatory and post-inflammatory MRI lesions in the sacroiliac joints of patients with and without 12:26:00 axial spondyloarthritis
11:50:00 Scoring MRI structural Lesions in Sacroiliac Joints of Patients with Axial Spondyloarthritis: How Many Slices are Optimal? Radiographic entheseal lesions at hip and pelvic region are associated with longer disease duration, higher BMI and more severe spinal and hip 12:02:00 radiographic damage in patients with ankylosing spondylitis EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Thursday, 3 June 2021 11:50:00 13:30:00 Poster Tours Molecular and structural changes of bone turnover during inflammatory disease (blank) 12:20:00 Least significant change in bone densitometry in patients with obesity Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing 12:08:00 spondylitis patients 11:56:00 The gasotransmitter hydrogen sulfide (H2S) is protective against calcific tendinopathy (CT) 12:14:00 T315 suppresses osteogenic differentiation in Saos-2 cells by inhibiting phosphorylation of Akt
12:26:00 Micro-CT analysis of sacroiliac joint as a new tool for studying trabecular bone and osteo-articular lesions in murine models THE DECREASE IN BONE MINERAL DENSITY DEPENDS ON THE CONCENTRATIONS OF ANGIOPOIETIN-LIKE PROTEIN TYPE 4 IN 11:50:00 PATIENTS WITH RHEUMATOID ARTHRITIS 12:02:00 Notch 1 inhibition increases osteoclast progenitor activity in the mouse model of rheumatoid arthritis New Developments in COVID research
(blank) 12:20:00 Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. 12:38:00 SARS-CoV-2 outbreak in autoimmune diseases: The Euro-COVIMID study Are patients with Immune Mediated Inflammatory Diseases (IMID) more likely to receive COVID-19 tests and test positive for SARS-CoV-2? A 12:08:00 matched population-based study
Anxiety and concerns related to the work situation during the COVID-19 pandemic in >5,000 patients with inflammatory rheumatic disease 12:44:00 followed in the Danish DANBIO registry, results from a nationwide questionnaire
12:32:00 The impact and outcome of COVID-19 on systemic sclerosis patients from the European Scleroderma Trial and Research group (EUSTAR) Seroprevalence of anti-SARS-CoV-2 antibodies in rheumatic patients treated with biological and targeted therapy living in Lombardy, 11:56:00 Italy (MAINSTREAM project)
12:14:00 The impact of COVID-19 on rheumatology training: Results from the COVID-19 Global Rheumatology Alliance trainee survey Rheumatoid arthritis and the risk of COVID-19 diagnosis, hospitalisation and death: a population-based multi-state cohort analysis including 12:26:00 5,586,565 people in Catalonia, Spain. 11:50:00 Outcomes in Inflammatory Arthropathy Patients Hospitalized for COVID-19 12:02:00 SARS-CoV-2 infection in children with rheumatic disease: experience of a tertiary referral center PARE Poster Tour (blank) 12:20:00 Real-World Patient Experience and Treatment Preferences in Patients With Psoriatic Arthritis Health Impact of Overweight and Obesity in patients with Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis 12:38:00 (EMAS) 12:08:00 Rheumatoid Arthritis in Norway: a survey-based patient experience 12:44:00 Rehabilitation with kinesiotherapy in muscle function and weight loss improving in obesity patients 12:32:00 Design of an innovative mHealth solution for fighting stigma associated with chronic pain 11:56:00 Increasing preeclampsia knowledge in SLE with a specific educational tool: Preliminary results
12:14:00 How do the Complications of Spondyloarthritis (SpA*) Impact the Quality of Life (QOL) of Patients Living with SpA? IMPLEMENTING SHARED DECISION MAKING TO ADVANCE PATIENT CENTRED RHEUMATOID ARTHRITIS CARE: A ROLE FOR A 12:26:00 PATIENT ORGANISATION
11:50:00 Summary of patient/parent organisation services promoting self- and shared-management of JIA in the UK and Ireland 12:02:00 Delay To diagnosis In axial Spondyloarthritis – Time for a Gold Standard approach Pediatric Rheumatology – Basic and translational science (blank) 12:20:00 Comprehensive immune profiling of 20 children with multisystem inflammatory syndrome 12:08:00 Population pharmacokinetics of infliximab in children with Juvenile Idiopathic Arthritis 12:32:00 Can we predict the development of nephritis in pediatric IgA vasculitis patients?
11:56:00 High levels of Porphyromonas gingivalis and Prevotella intermedia antibodies in children with juvenile idiopathic arthritis 12:14:00 Is anti-NXP2 autoantibody a risk factor for calcinosis and poor outcome in juvenile dermatomyositis patients? Association of SAA1 gene polymorphism -13T/C (rs12218) with cryopyrin associated periodic syndromes (CAPS), but not familial 12:26:00 Mediterranean fever (FMF). HIGH DEGREE OF INTER-PATIENT HETEROGENEITY IN SYNOVIOCYTE HYPERPLASIA AND IMMUNE CELLS INFILTRATION IN THE 11:50:00 SYNOVIUM OF JUVENILE IDIOPATHIC ARTHRITIS PATIENTS Increased T cell responses, metabolic activity and fibroblast invasive capacity in children with Down's syndrome-associated arthritis compared to 12:02:00 juvenile idiopathic arthritis Rheumatoid arthritis - non biologic treatment and small molecules - PART 1
(blank) 12:20:00 Off-target profiling of Janus Kinase (JAK) inhibitors in rheumatoid arthritis: a computer-based approach for drug safety studies and repurposing AZD9567 versus prednisolone in patients with active rheumatoid arthritis: a phase 2a, randomised, double-blind, parallel-group efficacy and 12:08:00 safety study Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 years From the SELECT- 11:56:00 COMPARE Study
12:14:00 Risk of QT Interval Prolongation Associated With Chronic Use of Hydroxychloroquine in Rheumatic Patients and the Effect of Cotreatments 12:26:00 Herpes Zoster in the Filgotinib Rheumatoid Arthritis Program
Analysis of disease activity measures in the context of a methotrexate withdrawal study among patients with rheumatoid arthritis treated with 11:50:00 tofacitinib 11 mg once daily + methotrexate: post hoc analysis of data from ORAL Shift 12:02:00 Efficacy of Janus Kinase inhibitors for difficult-to-treat RA in clinical practice Rheumatoid arthritis - prognosis, predictors and outcome
(blank) 12:20:00 The influence of the activity of rheumatoid arthritis to infectious and wound complications after total hip and knee arthroplasty.
12:08:00 Splenic metabolic uptake in FDG-PET/CT predicts risk of future cardiovascular thrombosis events in patients with rheumatoid arthritis Vitamin D level in rheumatoid arthritis patients starting a biologic disease-modifying drug and its correlation with disease activity and response to 12:32:00 treatment Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomized, double-blind, 11:56:00 placebo-controlled trial 12:14:00 Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
Clinical remission in rheumatoid arthritis patients treated with tofacitinib is associated with low baseline expression of genes related to energy Thursday, 3 June 2021 11:50:00 13:30:00 Poster Tours (blank) 12:26:00 metabolism and with cellular capacity of their upregulation during follow-up Heterogeneity in adverse event assessment between countries participating in an international collaboration of registries of rheumatoid arthritis 11:50:00 patients using Janus Kinase Inhibitors (the JAK-pot study) DEVELOPPING A SCORE TO PREDICT PRECLINICAL INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS – 12:02:00 A CROSS-SECTIONAL STUDY FROM THE ESPOIR COHORT Translating vasculitis
Renal and overall outcomes of double-positive (ANCA and anti-GBM antibodies) patients compared to ANCA-associated vasculitis patients with (blank) 12:20:00 severe renal involvement: A multicenter retrospective study with systematic renal pathology analysis
12:38:00 Incidence of malignancies in patients with granulomatosis with polyangiitis and microscopic polyangiitis diagnosed between 1988 and 2020.
12:08:00 RISK FACTORS FOR CORONARY HEART DISEASE AND ATHEROSCLEROSIS IN PATIENTS WITH BECHET’S DISEASE
12:44:00 Response of eosinophilic granulomatosis with polyangiitis to mepolizumab according to disease manifestations. A single centre experience
12:32:00 Renal involvement and need of renal replacement therapy in ANCA associated vasculitis in a Spanish single-center study 11:56:00 BAFF-APRIL-BAFFR pathway on the pathogenesis of Immunoglobulin-A vasculitis 12:14:00 HEART RATE VARIABILITY IN PATIENTS WITH BEHCETS DISEASE
12:26:00 A worldwide pharmacoepidemiological update of drug-associated ANCA-associated vasculitis at the time of targeted therapies 11:50:00 CD8+ T-cell infiltration is associated with lesional GM-CSF overexpression in GCA 12:02:00 Aberrant monocyte subsets in patients with Behçet’s disease
13:40:00 Poster Tours no session group Epidemiology: Big Questions - Big studies (blank) 12:20:00 Association between RA disease activity and tooth loss: results of two national cohorts 12:38:00 Incidence and treatment penetration of rheumatoid arthritis in Norway – a nationwide register linkage study 12:50:00 The prevalence of inflammatory back pain and HLA-B27 in a large population-based cohort in the Netherlands ESTIMATED PREVALENCE, INCIDENCE AND HEALTHCARE COSTS OF SJÖGREN’S SYNDROME IN FRANCE: A NATIONAL CLAIMS- 12:08:00 BASED STUDY 12:44:00 SARCOIDOSIS INCIDENCE IN A NORTHERN SPANISH HEALTH REGION. 12:32:00 Defining the prevalence of unmet need in SLE: data from a large multinational longitudinal SLE cohort Pharmacovigilance Pregnancy Data in a Large Population of Patients with Chronic Inflammatory Disease Exposed to Certolizumab Pegol: 11:56:00 Pregnancy Outcomes and Confounders Incidence rates and point prevalence of seropositive and seronegative rheumatoid arthritis in Denmark: a nationwide register-based study from 12:14:00 1998 to 2018 using four different case criteria Secular trends in baseline characteristics, treatment retention and response rates in 27189 bio-naïve axial spondyloarthritis patients initiating 12:26:00 TNFi – results from the EuroSpA collaboration
11:50:00 Intermetatarsal bursitis, a novel feature of juxta-articular inflammation in early rheumatoid arthritis: results from a longitudinal MRI-study Racial/Ethnic and Regional Differences in Multimorbidity Between Patients with Rheumatoid Arthritis and Comparators in a Large Nationwide 12:02:00 US Study Pediatric Rheumatology - Clinical (blank) 12:20:00 Tofacitinib treatment in children with rheumatic diseases: single-center experience
12:38:00 Useful experience of rheumatologists for understanding of the disease origin and approaches to therapy in Fibrodysplasia ossificans progressiva Evaluation of duration of clinical remission in children with non-systemic juvenile idiopathic arthritis after withdrawal of anti – Tumor Necrosis 12:50:00 Factor - alpha Therapy 12:08:00 Cross-sectional analysis of interferon signature in pediatric systemic lupus erythematosus 12:44:00 Septic arthritis in children. A longitudinal population-based study in Western Australia.
12:32:00 Performances of the risk factors and pediatric vasculitis activity scores for disease severity in children with Multisystem Inflammatory Syndrome S100A8/A9 AND S100A12 AS POTENTIAL PREDICTIVE BIOMARKERS OF ABATACEPT RESPONSE IN POLYARTICULAR JUVENILE 11:56:00 IDIOPATHIC ARTHRITIS Patients with juvenile systemic sclerosis have a distinct pattern of organ involvement.Results from the juvenile systemic sclerosis inception 12:14:00 cohort. www.juvenile-scleroderma.com 12:26:00 Clinical Features of Pediatric Behçet’s Disease in China
11:50:00 Safety and efficacy of Golimumab for the treatment of polyarticular juvenile idiopathic arthritis - an update from the BiKeR registry Physical activity and sport participation: A comparison between children and adolescents with juvenile idiopathic arthritis (JIA) and the German 12:02:00 general population SLE, Sjögren's and APS - clinical (blank) 12:20:00 BILAG-2004 LDA and BST LDA are valid treat to target in SLE 12:38:00 Identification of Primary Sjogren’s syndrome subtypes by Machine Learning 12:50:00 Development of damage and mortality in an inception cohort of SLE patients 12:08:00 ESSDAI and its association with patient outcomes in Sjögren’s syndrome: A real-world survey in the US
12:44:00 Association of miR-155 and miR-34a expression in lupus nephritis renal tissue with disease onset and outcomes 12:32:00 Plasma Mitochondrial DNA as a Biomarker in Diagnosis and Follow-up of Systemic Lupus Erythematosus
11:56:00 Go ask your patients! PSS-QoL reported perception of dryness correlates with lacrimal and salivary flow in primary Sjögren’s Syndrome
12:14:00 Predictors of flare in SLE patients attaining Lupus Low Disease Activity State: A real-life cohort study of 292 patients with 36-month follow-up 12:26:00 Tapering belimumab in patients with SLE: a single center experience
11:50:00 Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus 12:02:00 C3 and C4 variations in SLE pregnancies: preliminary results from the GR2 study. EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Thursday, 3 June 2021 11:50:00 13:30:00 14:15:00 Room 1 What is New (WIN) WIN Giant Cell Arteritis To understand current concepts in diagnosis, therapy and long-term management of Introduction patients with giant cell arteritis. 13:30:00 13:35:00 WIN: GCA 14:05:00 Q&A
15:00:00 Room 10 EULAR Projects Standing Committee on Clinical Affairs To learn, how development of new and updated EULAR recommendations is being performed To learn, how difficult-to-treat rheumatic diseases are being treated in an evidence-based manner To learn, how the various aspects of rheumatic diseases are handled in an evidence-based manner 13:30:00 Points to Consider on the Assessment of Competences in Rheumatology Training 13:45:00 Definition of difficult to treat rheumatoid arthritis 14:00:00 Points to Consider on Therapeutic Drug Monitoring in inflammatory arthritis 14:15:00 Development And Validation of a disease activity score in adult onset Still’s Disease: the “DAVID” project 14:27:00 Q&A 14:30:00 Points to Consider for Conducting Clinical Trials in Individuals at risk of Rheumatoid Arthritis Recommendations for cardiovascular risk management in Rheumatic and Musculoskeletal Diseases (including SLE and the antiphospholipid 14:45:00 syndrome) 14:57:00 Q&A 14:12:00 Q&A 14:42:00 Q&A 13:57:00 Q&A 13:42:00 Q&A Room 11 PARE Improving collaborative research and patients' participation in health decision- making To provide best practices examples of collaborative research and PPI, evidencing EULARs leading role and opportunities for PPI. To highlight the added value of patients' participation in health decision-making. 13:30:00 Introduction
13:35:00 Collaborative research: is it really evolving? The EULAR roadmap of Patient Research Partners: how far did we go? 13:50:00 Examples of patient involvement and engagement in research 14:05:00 From trainee to expert: An engaged route for involvement 14:20:00 RheumaMap – Prioritizing patients' unmet needs 14:35:00 Discussion
14:50:00 Development of a public and patient involvement (PPI) research network for people who have rheumatic conditions 14:57:00 Q&A Room 12 Practical skills Ultrasound basic in theory To be made aware of ultrasound pitfalls that may influence the scoring of arthritis in the hand to be introduced to ultrasound examination of the collateral ligaments of the fingers and how they may be affected in inflammatory and degenerative arthritis to be made aware of how different ultrasound approaches to the arthritic ankle may provide information on ankle involvement of the ankle to be introduced to the newly developed consensus-based ultrasound scoring system for monitoring crystal depositions in gout. 13:30:00 An overview of pitfalls in assessing synovitis and tenosynovitis of the hand + quiz 13:50:00 The involvement of collateral ligaments of the hand in arthritis + quiz 14:10:00 The clinical relevance of the medial and lateral ankle involvement in arthritis + quiz 14:30:00 The development and validation of the OMERACT scoring system for crystal deposits in gout + quiz 14:50:00 Q&A Room 13 Practical skills Problem solving: How to deal with Glucocorticoids in practice? To learn details of the benefit-risk ratio when using glucocorticoids in the treatment of inflammatory rheumatic diseases; To understand better how to improve this benefit-risk ratio; To understand in detail the relationship between rheumatic inflammation, glucocorticoid therapy and bone health and what results from this for clinical practice. 13:30:00 Presentation of an exemplary difficult case: Glucocorticoids, rheumatic diseases and bone 13:40:00 Guided interactive discussion and problem solving 14:00:00 Presentation of an exemplary difficult case: Glucocorticoids in vasculitis 14:10:00 Guided interactive discussion and problem solving 14:30:00 Presentation of an exemplary difficult case: Glucocorticoids in rheumatoid arthritis 14:40:00 Guided interactive discussion and problem solving Room 2 Clinical Science Oncorheumatology: the crossroads of cancer and musculoskeletal diseases To learn possible associations between rheumatology and oncology To understand the development of malignancies in inflammatory RMDs To determine the possible carcinogenicity of antirheumatic drugs To understand the development and management of immune-related adverse events due to immune-checkpoint inhibition. 13:30:00 Introduction 13:34:00 Eight pillars of oncorheumatology 13:48:00 The winding road from inflammation to cancer 14:02:00 Possible carcinogenicity associated with antirheumatic therapies 14:16:00 Immune-related adverse events of immune-checkpoint inhibitors: the EULAR points to consider 14:30:00 Discussion Changes in circulating B cell levels and immunophenotype are associated with development of arthritis following treatment with checkpoint 14:40:00 inhibitors 14:47:00 Q&A
14:50:00 Incidence of malignancy in Japanese patients with rheumatoid arthritis: data from the Japanese IORRA patient registry 14:57:00 Q&A Room 3 Clinical Science EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Thursday, 3 June 2021 13:30:00 15:00:00 Room 3 Shedding new light on Fibromyalgia: is it a matter of Hard or Software? To understand the neurobiological features and abnormalities of fibromyalgia. To explore the relationship between the psycho-social and the neurobiological features of fibromyalgia. To critically appraise the impact of psychotherapy in fibromyalgia and how this relates to the biological underpinnings. To apply all these concepts to clinical practice. 13:30:00 Introduction 13:35:00 Hardware: The neurobiological signature(s) of Fibromyalgia 13:50:00 Q&A 14:38:00 The evidence base for managing fibromyalgia: current data and future directions 14:53:00 Q&A 13:56:00 Software: An integrative model of the neuro-psycho-social features of Fibromyalgia 14:32:00 Q&A 14:17:00 Rewiring in Fibromyalgia: soothing the threats 14:11:00 Q&A Room 4 From Bench to Bedside Stem cells – bridging the understanding of the pathogenesis and treatment of rheumatic diseases To understand the roles and applications of stem cells in immunological disease To study the role of stem cells in the pathogenesis of rheumatoid arthritis To appreciate the therapeutic applications of stem cells in degenerative rheumatic diseases. 13:30:00 Introduction 13:35:00 Stem cells in immunological disease: Focus on mesenchymal stem cells 13:52:00 Q&A 14:13:00 Q&A 14:38:00 Stem cell therapy for degenerative arthritis 14:55:00 Q&A 14:34:00 Q&A 13:56:00 Stem cells in immunological disease: Focus on expanded potential stem cells
14:17:00 Aberrant haematopoietic stem and progenitor cells in systemic lupus erythematosus: implications on disease aetiology and treatment Room 5 Challenges in Clinical Practice Identifying new genetic inflammatory diseases: the example of DADA2 and type I interferonopathiesTo provide information about genetics and pathophysiology of DADA2 and to highlight its main diagnostic clues and the optimal therapy. To present an overview of the group of type I interferopathies and to illustrate their typical clinical and laboratory manifestations and the new therapeutic advances. Case 1 INTRODUCTION Adenosine Deaminase 2 (ADA2) deficiency is an autosomal recessive autoinflammatory disease caused by loss of function mutations in ADA2 gene, located on chromosome 22q11.1. The clinical spectrum of the disease is heterogeneous ranging from multisystemic inflammation with vascular and multiorgan involvement to immunodeficiency and immune-dysregulation. A certain percentage of patients, despite a consistent phenotype and lack of ADA2 enzymatic activity, have an incomplete or negative genotype. OBJECTIVES To describe the disease course and define the genetics underlying ADA2 deficiency in a 9 years old girl with a complete clinical phenotype and deficient enzymatic activity but without any mutation in the coding region of ADA2 gene. METHODS Whole exome sequencing (WES) was performed in the proband and the asymptomatic parents by using Illumina’s Nextera Rapid Capture Expanded Exome libraries and Illumina Hiseq2000 Instrument with 75bp paired-end reads. Since no coding mutation was identified as potentially candidate to account for the clinical phenotype, whole Genome Sequencing (WGS) by TruSeq Nano DNA Library Prep kit and HiSeq 3000 Instrument with 150bp paired-end reads. Structural variants were identified with Manta. RESULTS At the age of 3 months, the patient began to suffer from intermittent episodes of fever and livedo reticularis. At 1- year old inflammatory symptoms become persistent and the patient developed hypertension and a severe dilatative myocarditis, responsive to high doses of steroids. Anakinra was not effective, hence steroid therapy could not be suspended for years. Hypogammaglobulinemia was also present, together with recurrent upper airways infections. At the age of 6, following the withdrawal of steroids, the patients presented two episodes of ischemic and hemorrhagic stroke. Sanger analysis did not detect any 13:30:00 Introduction 13:35:00 Case 1: The diagnostic challenge of DADA2 13:45:00 Discussion: The diagnostic challenge of DADA2 14:05:00 Q&A 14:27:00 Discussion: The emerging spectrum of interferonopathies 14:47:00 Q&A 14:17:00 Case 2: The emerging spectrum of interferonopathies Room 6 EULAR Debate Is ethics in clinical management and research of Covid19 patients adequately addressed? Non-Covid19 patient care and research have suffered from the shift in resources to Covid19 patients. What could be the ethical implications of this shift in resources for patients, doctors, researchers, and the overall community? There might be a second theme in case we have time left. If that happens, we might deliberate on the ethical implications of treatments with compassionate use drugs without proper permits or indications as a standard procedure due to clinical urgency. To ponder around these issues, Prof Van Laar and Prof Machado would share their respective positions by following an ethical school of thought, using the utilitarian method and the deontological/Rights (Kantian) approach, respectively. 13:30:00 Introduction 13:35:00 Deontological ethical approach 13:50:00 Utilitarian ethical approach 14:05:00 Q&A 14:20:00 Debate Room 7 Basic and Translational Science Mechanobiology and joint disease: balancing between health and disease? To understand the relation between mechanical stress in musculoskeletal system in Introduction health and disease and implications thereof to rheumatic disease 13:30:00 EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start To understand the relation between mechanical stress in musculoskeletal system in Thursday, 3 June 2021 13:30:00 15:00:00 Room 7 13:35:00 Tenocytes: gatekeepers of tendon homeostasis health and disease and implications thereof to rheumatic disease 13:53:00 Q&A 14:14:00 Q&A 14:35:00 Q&A 14:38:00 Tendinopathy: from pathophysiology to treatment 14:56:00 Q&A 13:56:00 Mechanoinflammation and osteoarthritis 14:17:00 Mechanostress in tendons: gateway to rheumatic disease? Room 8 The Young Rheumatologist Biobanking in Rheumatology The multi-omics technologies are becoming every day more economically sustainable and widespread in rheumatology research aiming to a better understanding of disease pathogenesis and the identification of predictors of response and novel therapeutic targets. Side by side with the rise of the systems approach to rheumatic diseases, the availability of high-quality, harmonized biological samples coming from the disease affected sites paired with curated clinical information is becoming the bottleneck in biomedical research. The young rheumatologist, particularly if working in small peripheric centres, is likely to be frightened away by the complexity of data acquisition and analysis required by with "-omics" technologies. However, the establishment of a diffuse network of biobanks can be instrumental for the research in rheumatology. The participation of young rheumatology to larger international consortiums is instrumental for both research progress and personal career development. Learning objectives To provide insights on the ethical, logistic and legal aspects associated with human tissue biobanking To review some of the successful experiences and examples of the possibilities offered by biobanking of the most affected tissues in rheumatic diseases To get informed about the current and future opportunities offered by international consortium aiming to translational research in rheumatology. 13:30:00 Introduction 13:35:00 Biobank & registries: ethics and law 13:50:00 Patients perspective and public engagement 14:05:00 Q&A 14:10:00 Genomic sampling 14:25:00 Beyond the blood: biological samples in rheumatology research 14:40:00 International consortia and the young rheumatologist: challenges and opportunities 14:55:00 Q&A Room 9 Joint Joint Session EULAR ESCMI and EANM (European Association of Nuclear Medicine) – State-of-the-art nuclear imaging in RMDs To learn about the most recent advances in nuclear imaging applicable to RMDs 13:30:00 Introduction 13:34:00 Where is the fire: immunoscintigraphy of TNF-driven inflammation in rheumatoid arthritis 13:52:00 Q&A 14:14:00 Q&A 14:36:00 Q&A Usefulness of 18F-fluorodeoxyglucose positron emission tomography in diagnosing polymyalgia rheumatica and large-vessel vasculitis: a case- 14:40:00 control study 14:47:00 Q&A
14:50:00 Macrophage PET/CT imaging of the feet can contribute to early prediction of therapy outcome in rheumatoid arthritis 14:57:00 Q&A 13:56:00 Beyond FDG: novel PET tracers for macrophage imaging in rheumatoid arthritis 14:18:00 SPECT versus PET: pick the right tool for the right job! 14:15:00 15:00:00 Room 1 How to Treat (HOT) Systemic sclerosis and lung involvement: diagnostic work-up and new treatment modalities To understand the minimally required work-up of SSc patients with suspected lung involvement To learn how to optimise treatment strategies for SSc-related lung disease. 14:15:00 Introduction 14:20:00 Systemic sclerosis and lung involvement: diagnostic work-up and new treatment modalities 14:50:00 Q&A
15:30:00 16:15:00 Room 1 What is New (WIN) SARS-CoV-2 related Multisystem Inflammatory Syndrome in Children To describe the features and pathophysiology of the paediatric multisystem Kawasaki- like inflammatory syndrome related to SARS-CoV-2 infection. 15:30:00 Introduction 15:35:00 SARS-CoV-2 related Multisystem Inflammatory Syndrome in Children 16:05:00 Q&A
17:00:00 Room 10 EULAR Projects EULAR Projects in Education and Training To inform the audience about current EULAR activities in Education and Training 15:30:00 Introduction 15:35:00 The EULAR School of Rheumatology: Introducing a new era in rheumatology education 15:53:00 Q&A 16:35:00 Q&A 15:56:00 New avenues in education: Mixing the formats 16:56:00 Q&A 16:17:00 EULAR activities in patient education 16:14:00 Q&A 16:38:00 How to navigate yourself in the EULAR School Platform EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Thursday, 3 June 2021 15:30:00 17:00:00 Room 11 Joint, PARE Fertility and family planning with an RMD: a blessing, but also a risk? To provide latest data and facts about fertility and pregnancy in people with RMDs. To share best practices to support (future) parents with an RMD. 15:30:00 Introduction 15:34:00 Patient: Fertility and family planning with an RMD: a blessing, but also a risk? 15:42:00 Patient: Fertility and family planning with an RMD: a blessing, but also a risk? 15:50:00 Rheumatologist: Fertility and family planning with an RMD: a blessing, but also a risk? 16:00:00 HPR: Fertility and family planning with an RMD: a blessing, but also a risk? 16:10:00 EMEUNET: Fertility and family planning with an RMD: a blessing, but also a risk? 16:20:00 Discussion 16:45:00 Take home messages, session summary and closing Room 12 Practical skills Problem solving: Therapeutically refractory myositis Learn about different clinical features of myositis Learn about approaches in patients with refractory myositis Learn how to perform a muscle biopsy. 15:30:00 Introduction 15:35:00 Demo 1: Case presentation - Refractory muscle weakness 15:50:00 Group discussion 15:55:00 Demo 2: How to perform a muscle biopsy 16:10:00 Group discussion 16:15:00 Demo 3: Case presentation - Myositis with difficult to treat interstitial lung disease 16:30:00 Group discussion 16:35:00 Demo 4: Case presentation - Myositis with refractory skin rash 16:50:00 Group discussion Room 13 Practical skills MRI in practice To learn how to best use MRI in osteoarthritis, suspected axial spondyloarthritis, challenging shoulder cases and in early inflammatory arthralgia and arthritides. 15:30:00 Recent advances in MRI in osteoarthritis 15:50:00 Differential diagnoses in suspected axial SpA 16:10:00 MRI of the shoulder and its challenges: Arthritis or overuse?
16:30:00 The earliest MRI findings in inflammatory arthralgia and arthritides – How to recognize them and their prognostic importance 16:50:00 Q&A Room 2 Clinical Science Comorbidities in gout and hyperuricaemia Review the evidence linking high uric acid to different comorbidities cardiovascular, renal, other Assess the current evidence linking different XOI (xanthine-oxidase inhibition) and cardiovascular risk Review the potential use of colchicine in cardiovascular risk Discuss the potential pathogenic effect of high urate levels on the progression of CKD Review current evidence on the use of ULT to prevent CKD progression. 15:30:00 Introduction 15:34:00 Comorbidities and hyperuricaemia – causality or association? 16:35:00 Q&A 16:40:00 Evaluation of the causal effects between gout and hypertension: a mendelian randomization study 16:47:00 Q&A
16:50:00 Incident gout and risk of first-time acute coronary syndrome: a prospective, population-based, cohort study in Sweden 16:57:00 Q&A 15:56:00 Gout therapies and cardiovascular risk 16:13:00 Q&A 15:51:00 Q&A 16:18:00 Hyperuricaemia and gout in chronic kidney disease Room 3 Clinical Science Lyme disease: Myths and reality Learn about Lyme pathogenesis How to recognize Lyme symptoms How to make the diagnosis of Lyme disease 15:30:00 Introduction 15:35:00 Persisting complaints after treatment for Lyme borreliosis 16:26:00 Q&A 16:54:00 Q&A 15:58:00 Q&A 16:31:00 Lyme arthritis, persisting infection or auto-immune disease? 16:03:00 Biological diagnosis of Lyme borreliosis, methods and interpretation Room 4 From Bench to Bedside Immune events with checkpoint inhibitors To understand what immune processes are taking place during therapy with check-point inhibitors and why are specific autoimmune diseases triggered and not others. 15:30:00 Introduction 15:34:00 Mechanisms underlying immune related adverse events from immune checkpoint inhibitors 16:36:00 Q&A
16:40:00 PLASMA CHECKPOINT PROTEIN LEVELS AND GALECTIN-9 IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS 16:47:00 Q&A
Generalized Immune Activation in Structures Related To PMR Or GCA On PET/CT Assessment Does Not Occur In Immune Checkpoint 16:50:00 Inhibitor-Treated Patients Who Do Not Go On To Develop Rheumatic Immune-Related Adverse Events 16:57:00 Q&A 15:56:00 Which are the most common immune-related adverse events of checkpoint inhibitors? 15:52:00 Q&A 16:18:00 Toxicities from immunotherapy: From clinical trials to real-world clinical practice 16:14:00 Q&A Room 5 Challenges in Clinical Practice Vaccinations for the immunosuppressed Rheumatological Patients EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start 17:00:00 Room 5 To get day to day guidelines in the prevention of infections in patients on immunosuppressive drugs. Case 1 A 54 year-old woman has a 6 year history of RF and ACPA positive rheumatoid arthritis. Other medical problems include diabetes treated with metformin and hypertension. Her rheumatoid arthritis is currently treated with methotrexate 25mg weekly, infliximab 10mg/kg every 6 weeks, and prednisone 7.5mg daily. She has been experiencing severe right knee pain with no response to injections. On exam she has 1 swollen joint, 3 tender joints, a patient global of 4/10, and a physician global of 2/10. The right knee has a small effusion without warmth. X-ray shows nearly complete joint space loss. She is referred to an orthopedist and the decision is made to pursue elective right total knee arthroplasty. You are asked how her immunosuppression should be managed in the perioperative period. In this session we will discuss the existing evidence to inform the optimal management of immunosuppression in patients with rheumatoid arthritis undergoing surgery, including a discussion of current guidelines. Case 2 Case involves a 50 year old female with PsA and COPD, who is failing a TNF blocker, MTX, and 5mg of daily prednisone. Rheumatologist is considering changing the TNF blocker to a JAK inhibitor (upadicitinib) and she is concerned about which vaccines Thursday, 3 June 2021 15:30:00 should be given and when. 15:30:00 Introduction 15:35:00 Case 1: How to adjust immunosuppressive treatment in RA patients who have planned surgery 15:45:00 Discussion: How to adjust immunosuppressive treatment in RA patients who have planned surgery 16:05:00 Q&A 16:47:00 Q&A Discussion: Which vaccinations are needed for RA patients on the respective therapies both in normal life and in a situation that they want to 16:27:00 visit the jungle Case 2: Which vaccinations are needed for RA patients on the respective therapies both in normal life and in a situation that they want to visit 16:17:00 the jungle Room 6 Clinical Science The aftermath of metabolic imbalance in OA The association between metabolic imbalance (MI) and OA is complex and highly intricated. Recent epidemiological studies indicate a significant role for MI in predicting increased knee pain after adjustment for BMI. In addition to systemic pro-inflammatory components of the two disorders, there are other molecular mechanisms that may link MI and OA pain. Interestingly, intra-articular fat tissue inflammation itself could play a key role in the pathogenesis of OA. Hence, both articular and systemic chronic, low-grade inflammation should be considered a therapeutic target in OA patients. 15:30:00 Introduction
15:34:00 Metabolic Syndrome and Osteoarthritis Pain: Common Molecular Mechanisms and Potential Therapeutic Implications 16:35:00 Q&A 16:40:00 Circulating level of IL-6 is associated with 10.7-year knee cartilage volume loss and worse pain trajectory 16:47:00 Q&A
16:50:00 Evaluation of the relationship of leptin with the metabolic phenotype of knee osteoarthritis in the context of obesity therapy. 16:57:00 Q&A 15:56:00 The role of joint fat tissue in OA 16:13:00 Q&A 15:51:00 Q&A 16:18:00 Chronic, low-grade, articular and systemic inflammation as a therapeutic target in OA Room 7 Basic and Translational Science From bedside to bench – unexpected results of clinical studies that changed our understanding of the disease To learn how unexpected results of clinical studies changed our understanding of the disease pathophysiology or optimal outcome measures and stimulated further clinical and basic research. 15:30:00 Introduction 15:35:00 From bedside to bench in SLE 16:26:00 Q&A 16:54:00 Q&A 15:58:00 Q&A 16:31:00 From bedside to bench in RA 16:03:00 From bedside to bench in SpA Room 8 Practical skills Raising the performance of your presentations As a result of participating, attendees will be better able to Analyse and describe what makes a presentation great Choose and create good supporting media Evaluate your own presentations and learn from others Access further resources. 15:30:00 Raising our Performance in presentations 16:30:00 Q&A Room 9 Health Professionals in Rheumatology (HPR) Monitoring and restoring health: Should we have a core set for multidisciplinary care in rheumatology? Delegates will be able to gain a better understanding of what a core set is have increased knowledge of existing core sets developed for multidisciplinary settings discuss pro and cons of an international core set for multidisciplinary care in RMDs. 15:30:00 Introduction 15:35:00 What is a core set, how and when to use it? 15:50:00 Q&A 15:53:00 Results from a Norwegian core set for RMDs 16:08:00 Q&A 16:11:00 Expected outcomes of multidisciplinary interventions – the patient perspective 16:26:00 Q&A 16:29:00 Expected benefits of a core set for monitoring the delivery of multidisciplinary care in RMDs 16:44:00 Q&A
16:47:00 A structured model for OA care in primary healthcare is a cost-effective alternative compared to usual care for people with hip and knee OA 16:54:00 Q&A EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Thursday, 3 June 2021 16:15:00 17:00:00 Room 1 How to Treat (HOT) Cytokine storm syndromes To understand the rationale for immunomodulatory therapy in cytokine storm syndromes To gain information on the use of anti-cytokine agents in cytokine storm syndromes associated with rheumatic diseases To discuss the role of anti-rheumatic medications in the management of COVID-19-related cytokine storm syndrome 16:15:00 Introduction 16:20:00 Advances and challenges in the management of cytokine storm syndromes 16:50:00 Q&A
17:30:00 19:00:00 Room 7 Basic and Translational Science Emerging molecular targets in OA Molecular pathogenesis of OA is a rapidly evolving area. Considerable insight has come from preclinical models which are concordant with outcomes of human trials. New preclinical targets are emerging and bring with them a completely new way to view future therapeutic targeting in OA. 17:30:00 Introduction 17:35:00 How drugable is pain in OA in 2021? 18:25:00 Panel discussion 18:50:00 Ex vivo biomarker profiling identifies Oncostatin-M as spine osteoarthritis-specific osteoimmunological target 18:40:00 Blocking ROR2 improves cartilage integrity and provides pain relief in osteoarthritis 18:00:00 Structure modification in OA, reality or myth? 18:47:00 Q&A 18:57:00 Q&A
Friday, 4 June 2021 08:15:00 09:45:00 Room 7 Basic and Translational Science Origin and role of myeloid cells during homeostasis and inflammation Understand origin and role of macrophages and neutrophils. 08:15:00 Introduction 08:20:00 Origin and maintenance of macrophages 08:40:00 Q&A 08:45:00 Development and homeostasis of macrophage subsets 09:05:00 Q&A 09:10:00 Tissue surveillance and protection by resident macrophages 09:30:00 Q&A 09:35:00 Dynamic changes in O-GlcNAcylation regulate osteoclast differentiation and bone loss in arthritis 09:42:00 Q&A
10:15:00 11:00:00 Room 1 What is New (WIN) Imaging in the assessment of connective tissue diseases Imaging techniques are becoming very important in the assessment of patients with Introduction CTDs. In the present section the most recent advances on the use of imaging in the assessment of rare and complex disease will be discussed. 10:15:00 10:20:00 Which is the role of imaging in the assessment of connective tissue diseases? 10:50:00 Q&A
11:45:00 Room 10 Oral Abstract Presentations Progress in myositis and scleroderma research - II
Learn the newest in the areas of scleroderma, myositis and related syndromes. 10:15:00 Short-term changes in the radiographic extent of interstitial lung disease predict long-term mortality in systemic sclerosis
10:25:00 Treatment status affects how pulmonary biomarkers predict progression of systemic sclerosis-related interstitial lung disease A combined clinical and biomarker algorithm to predict FVC decline in Systemic Sclerosis associated Interstitial Lung Disease: results from an 10:35:00 international multicentre observational cohort 68Ga-FAPI-04 PET/CT study extension for the assessment of fibroblast activation and risk evaluation in Systemic Sclerosis-related interstitial 11:05:00 lung disease 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A 10:55:00 Juvenile Localized Scleroderma: A Large Retrospective Cohort Study from a Tertiary Care Center Efficacy of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) and internal organ involvement: data from 11:25:00 the SENSCIS trial
10:45:00 LONG-TERM EFFICACY AND SAFETY OF BOSENTAN IN PATIENTS WITH DIGITAL ULCERS RELATED TO SYSTEMIC SCLEROSIS
11:15:00 The Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) in a Systemic Sclerosis cohort with 10-years follow-up. Room 11 Oral Abstract Presentations, PARE PARE Abstract session From abstract to concrete – the variety of activities of PARE organisations 10:15:00 Introduction
10:20:00 Evaluation of patient satisfaction for telehealth (phone and video) in rheumatology outpatients during COVID-19 pandemic EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start MetabERN, the European Reference network for Rare Hereditary diseases: Structure, objectives, metabolic RMDs and the roles of European Friday, 4 June 2021 10:15:00 11:45:00 Room 11 From abstract to concrete – the variety of activities of PARE organisations 10:50:00 Patient Advocacy Groups (ePAGs) Providing support to families of children newly-diagnosed with childhood arthritis: A patient and parent-led pilot study to develop and assess ‘A 11:00:00 Little Box Of Hope’ support packs
11:20:00 A mindfulness program dosing study to evaluate improvement in emotional distress among people with rheumatic disease 10:40:00 Creating political levers to improve axial spondyloarthritis care 10:47:00 Q&A 10:27:00 Q&A 10:57:00 Q&A 10:37:00 Q&A 11:07:00 Q&A 11:17:00 Q&A 11:27:00 Q&A 11:10:00 Chronic Rheumatic Disease (CRD) and Sport
10:30:00 The Unacceptable Delay to Diagnosis in Axial Spondyloarthritis; Developing a Call to Action for a Global Healthcare Challenge Room 12 Oral Abstract Presentations New Developments in COVID-Research Learn the newest in the area of Covid-19. 10:15:00 Excess giant cell arteritis cases are associated with peaks in COVID-19 prevalence Rituximab associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicenter study in 1116 successive 10:25:00 patients receiving biologic agents 10:35:00 Does TNF-inhibition decrease the risk of severe COVID-19 in RMD-patients? Characteristics Associated with Severe COVID-19 Outcomes in Systemic Lupus Erythematosus (SLE): Results from the COVID-19 Global 11:05:00 Rheumatology Alliance (COVID-19 GRA) 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A COVID-19 hospitalizations, ICU admission, and Death among Patients with Immune Mediated Inflammatory Diseases (IMID) – A Population- 10:55:00 Based Study Machine Learning Algorithms to Predict COVID-19 Acute Respiratory Distress Syndrome in Patients with Rheumatic Diseases: Results from the 11:25:00 Global Rheumatology Alliance Provider Registry Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with RITUXIMAB: data from de French RMD COVID-19 10:45:00 cohort
11:15:00 Immunomodulatory therapies for severe forms of COVID-19: a systematic literature review to inform EULAR points to consider Room 13 Oral Abstract Presentations SLE, Sjörgen's and APS - Clinical Aspects
LLDAS (Low Lupus Disease Activity State), Low Disease Activity (LDA) and Remission (on- or off-treatment) Prevent Damage Accrual in Learn the newest in the areas of SLE, Sjörgen's and APS - clinical aspects. 10:15:00 Systemic Lupus Erythematosus (SLE) Patients in a Multinational Multicenter Cohort.
10:25:00 Clinical characteristics and prognosis of antiphospholipid syndrome patients based on cluster analysis: a 10-year cohort study 10:35:00 Severity of labial minor salivary gland focus score and future lymphoma development in Sjögren’s Syndrome 11:05:00 Sjögren’s Syndrome associated lymphomas: Clinical description and 10-year survival The SLE-DAS enables accurate and user-friendly definitions of remission and categories of lupus disease activity: Derivation and validation 11:35:00 study in 1190 SLE patients. 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A 10:55:00 Optimizing a tool to identify lupus flares in daily clinical practice: SLE-DAS flare versus SELENA Flare Index 11:25:00 The 2021 DORIS Definition Of Remission In SLE – Final Recommendations from an International Task Force Survey on the perceptions and experiences of Spanish lupus patients. Results about knowledge of the disease and relationship to disease- 10:45:00 FELUPUS SURVEY. GR2 multicentric prospective French study’s results: damage but not remission at first trimester predicts adverse pregnancy outcome in lupus 11:15:00 pregnancies. 11:42:00 Q&A Room 2 Oral Abstract Presentations Crystal diseases Does Excess Weight Affect Gout Risk Differently Among Genetically Predisposed Individuals? – Sex-Specific Prospective Cohort Findings over Learn the newest in the area of crystal diseases. 10:15:00 >26 Years 10:25:00 Gene-Diet Interaction on the Risk of Incident Gout among Women – Prospective Cohort Study over 32 Years Urate crystal depositions are associated with inflammatory markers and carotid plaques indicating subclinical inflammation in gout; baseline 10:35:00 results from the NOR-GOUT study 11:05:00 Association between dementia and gout : A nationwide population-based study 11:32:00 Q&A EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Friday, 4 June 2021 10:15:00 11:45:00 Room 2 Learn the newest in the area of crystal diseases. 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A
10:55:00 Association between female reproductive factors and gout: nationwide population-based cohort study of 1 million postmenopausal woemn
11:25:00 Sonographic estimation of monosodium urate burden predicts the fulfilment of the 2016 remission criteria for gout: a 12-month study. 10:45:00 Ultrasound-detected calcium pyrophosphate crystal deposition: which sites should be scanned? 11:15:00 ”Incident gout: risk of death and cause-specific mortality in western Sweden – a nested case control study” Room 3 Oral Abstract Presentations Rheumatoid arthritis - comorbidity and clinical aspects - II Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis - a matched Learn the newest in the areas of rheumatoid arthritis - comorbidity and clinical aspects. 10:15:00 cohort study from Sweden and Denmark Men diagnosed with inflammatory arthritis before the age of 40 years have a lower fertility rate than those diagnosed after the age of 40 years: 10:25:00 results of a large multicenter study (iFAME-Fertility)
10:35:00 Paternal inflammatory arthritis is associated with a higher risk of miscarriages: results of a large multicenter study (iFAME-Fertility)
11:05:00 Mental health, sleep and cognition characteristics in rheumatoid arthritis and associations with rheumatoid factor status in the UK Biobank 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A Impact of a multi-morbidity screening and prevention program in chronic inflammatory rheumatic diseases on the one-year hospitalization rate 10:55:00 based on an analysis of the French national health database. Is metacarpophalangeal-joint pain as an early symptom of patients at risk for progression to inflammatory arthritis explained by MRI-detected 11:25:00 subclinical inflammation? – a large observational study
10:45:00 Sex Differences in Multimorbidity Between Patients with Rheumatoid Arthritis and Comparators in a Large Nationwide US Study
11:15:00 Trends in Occurrence of Dementia in Patients with Rheumatoid Arthritis: a Population-based Cohort Study, 1980-2009 Room 4 Oral Abstract Presentations Unraveling the impact of PsA and comorbidity prevention Learn the newest in the area of psoriatic arthritis - clinical aspects (other than treatment). 10:15:00 Mortality in patients with psoriatic arthritis in Sweden
10:25:00 The Association of Psoriatic Arthritis with all-Cause Mortality and Leading Causes of Death in Psoriatic Arthritis Secular trends in baseline characteristics, treatment retention and response rates in 17453 bionaïve psoriatic arthritis patients initiating TNFi – 10:35:00 results from the EuroSpA collaboration Development and preliminary validation of ultrasonographic disease activity and damage scores in Psoriatic Arthritis patients: results from the 11:05:00 UPSTREAM (Ultrasound in Psoriatic arthritis TREAtMent) study. 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A The incidence of interstitial lung disease in psoriatic arthritis compared to rheumatoid arthritis. Data from over 89 000 bDMARD treatment 10:55:00 courses derived from five Nordic registers 11:25:00 Depressive symptoms in PsA: a cross-sectional analysis from the national German RABBIT-SpA registry
10:45:00 Targeted metabolomic profiling and prediction of cardiovascular events: A prospective study of patients with psoriatic arthritis and psoriasis Continuous composite measures for routine care in Psoriatic Arthritis: Thresholds of meaning and clinically important difference estimates for the 11:15:00 3 and 4 VAS scales from a UK multicentre study Room 5 Oral Abstract Presentations Psoriatic arthritis - treatment
Learn the newest in the area of psoriatic arthritis - treatment. 10:15:00 Towards development of an ultrasound enthesitis score in psoriatic arthritis: 24-week results from the phase III randomised ULTIMATE study Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active Psoriatic Arthritis in a 10:25:00 Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis, Including Patients With Inadequate Response or Intolerance to Biologic 10:35:00 Therapies: 24-Week Results From the Phase 3, Randomized, Double-blind, KEEPsAKE 2 Trial Differences in real-world patient characteristics of 8921 psoriasis patients with and without comorbid psoriatic arthritis using the UK BADBIR 11:05:00 database 11:32:00 Q&A EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Friday, 4 June 2021 10:15:00 11:45:00 Room 5 Learn the newest in the area of psoriatic arthritis - treatment. 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A
Efficacy and Safety of Guselkumab in Patients with Active Psoriatic Arthritis Who Demonstrated Inadequate Response to Tumor Necrosis 10:55:00 Factor Inhibition: Week 24 Results of a Phase 3b, Randomized, Controlled Study 11:25:00 Efficacy and Safety of Upadacitinib in Patients With Psoriatic Arthritis and Axial Involvement
10:45:00 The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment Recommendations 2021 Female versus male burden of psoriatic arthritis is higher and treatment persistence shorter after ustekinumab or tumour necrosis factor inhibitor 11:15:00 treatment: 1-year data from the PsABio study Room 6 Oral Abstract Presentations Epidemiology and public health Learn the newest in the areas of public health, health services research, and health RISK OF ACUTE MYOCARDIAL INFARCTION AMONG NEW USERS OF CHONDROITIN SULPHATE: A NESTED CASE-CONTROL economics. 10:15:00 STUDY 10:25:00 Pro-Inflammatory Diet and Risk of Incident Gout: 3 Prospective Cohort Studies of US Men and Women 10:35:00 The effect of UV-B radiation exposure on the risk of developing rheumatoid arthritis
11:05:00 Psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with active ankylosing spondylitis 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A Drug cost for biologic and targeted synthetic DMARDs for rheumatoid arthritis patients in Norway from 2010 to 2019 - A country with a national 10:55:00 tender system for drug prescription
11:25:00 Serious infection with tocilizumab compared to TNF-inhibitors and other bDMARDS in rheumatoid arthritis patients: Does line of therapy matter?
10:45:00 Exposure To Environmental Air Pollutants As A Risk Factor For Primary Sjögren's Syndrome: A Population-based Cohort Study Epidemiology, predictors of mortality and role of prophylaxis for Pneumocystitis jiroveci pneumonia among rheumatic patients: a territory-wide 11:15:00 study Room 7 Oral Abstract Presentations Systemic sclerosis, myositis - etiology, pathogenesis and animal models Learn the newest in the areas of s ystemic sclerosis, myositis - etiology, pathogenesis and animal models . 10:15:00 Effects of the autotaxin inhibitor ziritaxestat on skin and lung fibrosis in a murine graft-versus-host disease model of systemic sclerosis An approach combining transcriptomic and topographic analysis reveals a potential role of proteasome and autophagy deregulation in the 10:25:00 pathophysiology of dermatomyositis 28 new autoantibodies against GPCR, growth factors and growth factor receptors are associated with disease manifestations in systemic 10:35:00 sclerosis 11:05:00 In myositis muscle fibre plays a direct and critical role in therapeutic response to glucocorticoids 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A PREDICTIVE VALUE OF LABORATORY AND INSTRUMENTAL FINDINGS IN THE VERY EARLY DIAGNOSIS OF SYSTEMIC 10:55:00 SCLEROSIS. ROLE FOR CXCL4 CHEMOKINE 11:25:00 Serum proteomic biomarkers define patients with systemic sclerosis with interstitial lung disease Anti-S100A4 monoclonal antibody treatment ameliorates skin fibrosis in inflammatory and non-inflammatory pre-clinical models of systemic 10:45:00 sclerosis 11:15:00 Development of a 3D skin microtissue model for fibrotic diseases Room 8 Oral Abstract Presentations Imaging in axial spondyloarthritis – what is new? MRI vertebral corner inflammation and fat deposition are associated with whole spine low dose CT detected syndesmophytes: a multilevel Learn the newest in the area of spondyloarthritis - clinical aspects (other than treatment). 10:15:00 analysis
10:25:00 Data-driven Definitions Based on Inflammatory Lesions for a Positive MRI of the Spine Consistent with Axial Spondyloarthritis
10:35:00 Arthritis and enthesitis in the hip and pelvis region in spondyloarthritis – validation of two whole-body MRI methods 11:05:00 The Role of Pelvic Morphology in Axial Spondyloarthritis 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A
10:55:00 An artificial neural network for the detection of definite radiographic sacroiliitis with high specificity in the diagnostic setting EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Value of Color Doppler Ultrasound Assessment of Sacroiliac Joints in Non-radiographic Axial Spondyloarthritis:a Comparison with Ankylosing Friday, 4 June 2021 10:15:00 11:45:00 Room 8 Learn the newest in the area of spondyloarthritis - clinical aspects (other than treatment). 11:25:00 Spondylitis 10:45:00 Structural damage in axial Spondyloarthritis: is there a preferred way to assess progression over time? 11:15:00 Choose Wisely: Imaging for Diagnosis of Axial Spondyloarthritis Room 9 Health Professionals in Rheumatology (HPR), Oral Abstract Presentations HPR Abstract Session (II) Delegates will be able to identify new evidence to support HPR practice in terms of assessment, implementation and evaluation of interventions discuss the evidence and its application to practice apply the knowledge in service improvement for patient benefit. 10:15:00 Is there a subset of patients with Sjögren’s syndrome who are more at risk for sexual dysfunction? Results from a scoping review. 10:25:00 The effect of osteoarthritis on Healthy Working Life Expectancy at age 50 in England
10:35:00 Predictors of Work Participation in Patients with active Rheumatoid Arthritis after 12 Months of T2T Therapy Intervention
11:05:00 THE ROLE OF PHYSICAL EXERCISES IN REDUCING CHRONIC FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS 11:32:00 Q&A 10:32:00 Q&A 11:12:00 Q&A 10:52:00 Q&A 10:42:00 Q&A 11:22:00 Q&A 10:22:00 Q&A 11:02:00 Q&A The Neuro-QOL Upper Extremity Function Scale: New Opportunities to more reliably and precisely measure self-reported hand function and self- 10:55:00 care activities in people with RA
11:25:00 Impact of COVID-19 pandemic on rheumatology patients in Northern Ireland - A web based cross-sectional survey. 10:45:00 Perceived challenges at work and need for support among people with inflammatory arthritis “I literally convinced myself I was going to catch it and die”: Lived Experiences of the COVID-19 pandemic by people with rheumatic diseases 11:15:00 from four European countries 11:00:00 11:45:00 Room 1 How to Treat (HOT) Hydroxychloroquine: a multifaceted drug Antimalarial drugs are widely used in RMDs. The aim of this session is to review the Introduction mechanism of action of hydroxychloroquine, to discuss its use in RMDs as well as in other non rheumatic conditions. The story of HCQ and COVID19 will be also reviewed. 11:00:00 11:05:00 Hydroxychloroquine in rheumatic diseases: not only SLE 11:35:00 Q&A
11:50:00 13:30:00 Poster Tours no session group Rheumatoid arthritis - biological DMARDs GENDER DIFFERENCES IN RESPONSE TO BIOLOGICALS. WOMEN FARE WORSE ACROSS INFLAMMATORIY ARTHRITIS (blank) 12:25:00 DISEASES - DATA FROM THE BIOREG 11:50:00 Introduction
12:31:00 Association of First, Second, and Third-Line bDMARDs and tsDMARD with Drug Survival among Rheumatoid Arthritis Patients: A Cohort Study
DESIGN AND CHARACTERISATION OF A THERAPEUTIC BISPECIFIC TANDEM scFv-Fc FUSION PROTEIN WITH ANTI-TNF AND 12:13:00 SYNOVIUM-TARGETING SPECIFICITY FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
12:01:00 Autoantibodies and systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy in rheumatoid arthritis
11:55:00 Analyzing cord blood levels of TNF inhibitors to validate the EULAR points-to-consider for TNF inhibitor use during pregnancy. 12:19:00 Real-world retention of JAK inhibitors is longer than bDMARDs in rheumatoid arthritis
12:07:00 Amelioration of Endothelial Dysfunction with JAK Inhibition in Rheumatoid Arthritis: JAK CV-Risk Reduction Study Spondyloarthritis - treatment (blank) 12:20:00 Impact of Gender and comorbidities in enterophatic Spondyloarthritis: a cross-sectional study Secukinumab Retention and Safety in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis: 2 Year Interim Results of the 12:38:00 Observational SERENA Study Disease Activity and Inflammation Following Withdrawal of Certolizumab Pegol Treatment in Axial Spondyloarthritis Patients Who Did Not 12:08:00 Experience Flares during the C-OPTIMISE Study
12:44:00 Comparison of axial and peripheral manifestations in patients with psoriatic arthritis and ankylosing spondylitis in upadacitinib clinical trials 12:32:00 The efficiency of treatment of coxitis in axial spondyloarthritis: experience of real clinical practice 11:56:00 Should all patients trial subcutaneous methotrexate prior to commencing biologic therapy – a real world study
12:14:00 INTESTINAL MICROBIOTA CHANGES TNF-INHIBITORS INDUCED IN IBD-RELATED SPONDYLOARTHRITIS
Clinical Effectiveness of Adalimumab versus Non-Biologic Therapy in the Management of Extra-Articular Manifestations in Ankylosing 12:26:00 Spondylitis Patients over 24 Months – Results of the COMPLETE-AS Canadian Observational Study
11:50:00 Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylitis: 3-Year Results from a Phase 2b Study
Baseline characteristics and treatment response to ixekizumab categorised by sex in radiographic and non-radiographic axial spondylarthritis 12:02:00 patients through 52 weeks: Data from 3 phase III, randomized, controlled trials Central pain and other extra-articular associations to KOA (blank) 12:20:00 Association between hyperuricemia and osteoarthritis 12:38:00 Association between hypertension and osteoarthritis. 12:08:00 Calculating Risk of Hand Osteoarthritis Progression at Ten years through a Prediction Model
12:44:00 10-YEAR PROBABILITY OF A MAJOR OSTEOPOROTIC FRACTURES IN WOMEN WITH OSTEOARTHRITIS OF THE KNEE JOINT Association between osteoarthritis-related serum biochemical markers over 11 years and knee MRI-based imaging biomarkers in middle-aged 12:32:00 adults EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Neuropathic pain symptoms in inflammatory hand osteoarthritis(OA) lowers health related physical quality of life and may require another Friday, 4 June 2021 11:50:00 13:30:00 Poster Tours (blank) 11:56:00 approach than anti-inflammatory treatment 12:14:00 Early stage hand osteoarthritis in patients with the Ehlers-Danlos syndrome: an explorative study.
12:26:00 Physician and patient perceptions of surgical procedures for knee OA across Japan, the US and 5 EU countries: results of a real-world study The associations between disease modifying anti-rheumatic drugs and incident, and progression of, radiographic hand osteoarthritis in 11:50:00 rheumatoid arthritis patients 12:02:00 Quality of life for patients with knee osteoarthritis with or without pain sensitization Crystal arthritis (blank) 12:20:00 Cardiovascular risk associated with treatment of allopurinol and benzbromarone in patients with gout Urate-lowering therapy reduces non-episodic foot pain in patients who fail to meet ACR/EULAR 2015 gout classification criteria: An effect 12:38:00 predicted by ultrasound. Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout: A Phase II 12:08:00 Randomized Controlled Trial 12:44:00 Active screening for gout identifies a larger cardiovascular population at high mortality risk. Two-year reduction of urate load in Dual-Energy CT during a treat-to-target approach in gout patients: Results from a longitudinal study (NOR- 12:32:00 Gout) 11:56:00 Monosodium urate crystals reduce human ligament cells viability through increase of ROS production 12:14:00 Roles of autophagy in the pathogenesis of primary gouty arthritis 12:26:00 Altered risk of gout according to change of metabolic parameters in young adults 11:50:00 Is the intercritical gout really asymptomatic? The inflammatory role of the silent urate crystal deposition.
12:02:00 Increased Prevalence of Lumbar Spine Monosodium Urate Deposition Among Gout Patients on Dual-Energy CT. Fine-tuning strategies (beyond treatments) to reduce the impact of PsA (blank) 12:20:00 Analysis of venous thromboembolic risk among psoriatic arthritis patients
12:38:00 Being overweight is associated with not reaching low disease activity in women but not men with psoriatic arthritis PREDICTORS OF PSORIATIC ARTHRITIS DEVELOPMENT IN PSORIASIS PATIENTS: A SYSTEMATIC LITERATURE REVIEW AND 12:08:00 META-ANALYSIS 12:44:00 A practical guide for the assessment of psoriasis burden in patients with Psoriatic Arthritis.
12:32:00 Musculoskeletal pain in patients with psoriasis and the influence on health-related quality of life: results from a Danish population-based survey
11:56:00 Post-stress ultrasound assessment of the Achilles tendon is useful to differenciate psoriatic arthritis from the physiological adaptation to exercise. PERIPHERAL NEUROPATHY IN PSORIASIS AND PSORIATIC ARTHRITIS: A SINGLE BLIND, CONTROLLED, 12:14:00 ELECTROPHYSIOLOGICAL STUDY
12:26:00 Maternal and Neonatal Outcomes in Pregnant Women with Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-Analysis.
11:50:00 Minimal Disease Activity in Patients with Psoriatic Arthritis and Associated Factors: Real Life Data from a Single Center Novel application of optical coherence tomography angiography and nailfold capillaroscopy in psoriatic arthritis - Diagnostic and prognostic 12:02:00 accuracy in relation to Psoriasis and hand Osteoarthritis. HPR - Adapting and individualising care
(blank) 12:20:00 Construct validity of the OCTOPuS stratification algorithm for allocating patients with knee osteoarthritis into clinically relevant subgroups 12:38:00 The Care Process of Hip and Knee Osteoarthritis: Giving an Account of Patients' Experience.
12:08:00 Diaphragmatic Breathing Relaxation Technique to Decrease Anxiety During Joint Infiltration : A Randomized Controlled Trial
12:44:00 Barriers and facilitators related to self-management of shoulder pain: a systematic review and qualitative synthesis 12:32:00 Impact of sleep disturbances on elderly patients with rheumatoid arthritis 11:56:00 Identifying targets for behavioural interventions in Fibromyalgia: Physical activity behaviour ‘The right advice, in the right way and at the right time’: An Innovative Multidisciplinary Approach to Address Client-Identified Participation Needs 12:14:00 in Early Inflammatory Arthritis 12:26:00 Understanding nurse-led care in early RA: Interview study with rheumatology nurse specialists Remote clinical management: incorporating electronic assessment of patients with rheumatic diseases into standard clinical pathways during the 11:50:00 COVID-19 pandemic: a pilot study Factors facilitating the self- and shared-management of JIA by children, young people, their families, and professionals involved in their care: A 12:02:00 realist evaluation Metabolic bone disease / Osteoporosis (blank) 12:20:00 SECONDARY PREVENTION OF VERTEBRAL FRACTURES IN REAL PRACTICE 12:38:00 Improving Management of Glucocorticoid Induced Osteoporosis in Rheumatology Study of Vertebral and Femur Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra in an 12:08:00 Academic Hospital Setting
12:44:00 Underestimation of the fracture risk by the FRAX formula in chronic glucocorticoid users: a 10-year longitudinal validation study 12:32:00 Fetuin-A as a marker of osteoporosis and osteoporotic fractures in patients with rheumatoid arthritis Incident fracture risk prediction using the Fragility Score calculated by lumbar spine Radiofrequency Echographic Multi Spectrometry (REMS) 11:56:00 scans 12:14:00 Association of Trabecular bone score and Fat distribution in Moroccan rheumatoid arthritis patients BONE MINERAL DENSITY IN PATIENTS WITH MULTIPLE SCLEROSIS. A DESCRIPTIVE STUDY FROM A UNIQUE CENTER FROM THE 12:26:00 EAST OF SPAIN 11:50:00 Predictive factors of a new fragility fracture after wrist fragility fracture
12:02:00 The need for anti-osteoporotic intervention in postmenopausal women with rheumatoid arthritis based on the FRAX® fracture risk assessment Molecular profiles in connective tissue disease outcome POTENTIAL INVOLVEMENT OF IL-40 AND IL-40-PRODUCING CELLS IN PRIMARY SJOGREN'S SYNDROME (pSS) AND pSS- (blank) 12:20:00 ASSOCIATED LYMPHOMA Type I interferon dependent hsa-miR-145-5p downregulation modulates MUC1 and TLR4 overexpression in salivary glands from primary 12:38:00 Sjögren’s syndrome patients. 12:08:00 Association between biomarkers and therapeutic pathway in patients with SLE 12:32:00 Exploring the effects of A Two-score Interferon Signature and Responses to Interferon Stimulus EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Friday, 4 June 2021 11:50:00 13:30:00 Poster Tours (blank) 11:56:00 Metabolomic Profiling and Symptom Burden in Black Women with Systemic Lupus Erythematosus 12:14:00 Combining CXCL5 with conventional therapy provides durable immunosuppression in murine lupus nephritis
12:26:00 Gene signature fingerprints divide SLE patients in subgroups with comparable biological disease profiles: a multicentre longitudinal study
11:50:00 Thrombin Generation Assay and Lupus anticoagulant identify different populations of patients with antiphospholipid antibodies Immunophenotype of Sjögren´s syndrome and systemic lupus erythematosus patients identified two endotypes with potential therapeutic 12:02:00 implications. PsA treatment: what is new?
(blank) 12:20:00 Responsiveness of Ultrasound Synovitis and Clinical Outcomes in Psoriatic Arthritis Treated with Secukinumab: Data from the ULTIMATE Trial Clinical Characteristics & Outcomes Associate With Work Productivity in Bio-naïve Patients With Active Psoriatic Arthritis Through Week 24 of 12:38:00 the DISCOVER-2 Study
12:08:00 Guselkumab Treatment Modulates Core Psoriatic Arthritis Gene Expression in Two Phase 3 Clinical Trials (DISCOVER-1 and -2) Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide population-based study 12:44:00 using the French health insurance database 12:32:00 Time-series Analysis in Moderate to Severe Plaque Psoriasis under Different Biologics Treatments
11:56:00 DAS28-CRP guided treat-to-target tapering of tumor necrosis factor inhibitors in psoriatic arthritis: a retrospective cohort study. Upadacitinib in patients with psoriatic arthritis refractory to biologic disease-modifying antirheumatic drugs: 56-week data from the phase 3 12:14:00 SELECT-PsA 2 study Efficacy and Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Active Psoriatic Arthritis: Results From a 12:26:00 Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
11:50:00 PROGNOSTIC FACTORS ASSOCIATED WITH ACHIEVING MINIMAL DISEASE ACTIVITY IN EARLY PSORIATIC ARTHRITIS PATIENTS. ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB OR ADALIMUMAB: A POST HOC ANALYSIS 12:02:00 OF EXCEED Rheumatoid Arthritis - comorbidity and clinical aspects - Part 1
(blank) 12:20:00 Direct and conditional effects of epicardial adipose tissue volume on coronary plaque progression in rheumatoid arthritis 12:38:00 Tumor-necrosis factor inhibitors improve aortic stiffness in patients with longstanding rheumatoid arthritis. 12:08:00 20 year follow-up of cardiovascular event risk in rheumatoid arthritis compared to diabetes Effect of low-dose methotrexate on estimated glomerular filtration rate and kidney adverse events in the Cardiovascular Inflammation Reduction 12:44:00 Trial Pulse wave velocity elevation above individual reference values and aortic-brachial stiffness mismatch as early markers of arterial stiffness 12:32:00 increase in patients with rheumatoid arthritis
11:56:00 Predictors of progression and mortality in patients with prevalent rheumatoid arthritis and interstitial lung disease: a prospective cohort study. Association between C-reactive protein and 10-year risk of cardiovascular disease in rheumatoid arthritis using the ERS-RA score: a cross- 12:14:00 sectional analysis of the CORDIS cohort Greater high-density lipoprotein levels over time are linked to decreased coronary plaque formation and regression and stabilization of high-risk 12:26:00 lesions in rheumatoid arthritis 11:50:00 The Incidence and Risk Factors of Rheumatoid Arthritis-associated Interstitial Lung Disease Comparison of patient characteristics and treatment patterns across body mass index categories in patients with psoriatic arthritis and 12:02:00 rheumatoid arthritis Rheumatoid arthritis - non biologic treatment and small molecules - PART 2
(blank) 12:20:00 Risk of Major Cardiovascular Event Across Jak inhibitor Treated Patients: Analysis of a National Claim Database Patterns of Janus Kinase inhibitor cycling for the management of rheumatoid arthritis in real-world clinical practice: an analysis of the OPAL 12:08:00 Dataset. Comparison of Tofacitinib and baricitinib by inverse probability of treatment weighting analyses based on propensity score in patients with 11:56:00 rheumatoid arthritis in real clinical practice 12:14:00 Selectivity of clinical JAK inhibitors and the impact on Natural Killer (NK) cell functional responses 11:50:00 Integrated safety profile of upadacitinib with up to 4.5 years of exposure in patients with rheumatoid arthritis Predictors of response: Baseline characteristics and early treatment responses associated with achievement of remission and low disease 12:02:00 activity among upadacitinib-treated patients with rheumatoid arthritis
13:40:00 Poster Tours no session group PROMs and markers (blank) 12:20:00 Metabolomic signatures for knee cartilage volume loss over 10 years Serum IFNα concentrations measured with single-molecule array technology in Sjögren’s syndrome reflect blood interferon-stimulated gene 12:38:00 expression 12:50:00 The value of miR-20b, miR-22, miR-26a, miR-125b and miR-221 in rheumatoid arthritis. URINE-GALECTINE 3 BINDING PROTEIN (U-GAL3BP) IS A SENSITIVE MARKER OF KIDNEY INFLAMMATION AND RESPONSE TO 12:08:00 TREATMENT IN LUPUS.
12:44:00 Association between osteoarthritis-related serum biochemical markers over 11 years and knee symptoms in middle-aged adults
Disease activity outcome measures are only available in half of the electronic medical files of patients with axial spondyloarthritis followed in an 12:32:00 outpatient clinic: the results of an audit of a tertiary-care rheumatology department. Minimal clinically important improvement (MCII) and patient acceptable symptom state (PASS) for pain and function instruments in hand 11:56:00 osteoarthritis (OA)
12:14:00 Identification and validation of two novel serum biomarkers associated with the serological status of Rheumatoid Arthritis patients. The prognostic factors in predicting relapse for IgG4-related disease: A long-term study based on the clinical and pathological characteristics of 12:26:00 the patients 11:50:00 How fit are the Social Support instruments used in RMDs: A systematic review of validation studies 12:02:00 SIGLEC1 as a type I interferon biomarker in idiopathic inflammatory myopathies EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Friday, 4 June 2021 11:50:00 13:30:00 14:15:00 Room 1 What is New (WIN) What is new in Psoriatic Arthritis? To learn about the clinical practice outcome assessment as oppose to the ones issues in Introduction clinical trials. Benefits and disadvantages of the new and old clinical assessments. 13:30:00 13:35:00 “To Lump or to split? – PsA outcome assessment in clinical practice and trials” 14:05:00 Q&A
15:00:00 Room 10 EULAR Projects EULAR Projects in Paediatric Rheumatology To present the current and future research projects of PReS in collaboration with other research networks. To provide an overview of the ongoing activities of EMERGE and Working Parties. 13:30:00 Introduction 13:35:00 Collaborative projects between CARRA and PReS 13:52:00 The growing activities of EMERGE 14:09:00 Opportunities and challenges of participation in the ERN 14:26:00 The collaboration between PRINTO and PReS 14:40:00 Q&A 14:43:00 Report of the progresses of PReS Working Parties 14:57:00 Q&A 13:49:00 Q&A 14:23:00 Q&A 14:06:00 Q&A Room 11 Joint, PARE Myths and taboos around relationships: strategies for a sexy life To address self-esteem and disease related issues in sexual life of (young) people with RMDs. To highlight reproductive health issues as one of the major concerns for young people with RMDs. 13:30:00 Introduction 13:35:00 The impact of an RMD on interpersonal relationships 13:50:00 Q&A 13:55:00 My partner has an RMD 14:10:00 Q&A 14:15:00 How to communicate about intimacy with my patients 14:30:00 Q&A
14:35:00 Development of interactive Decision Aid Tool for motherhood and parenthood among patients living with autoimmune rheumatic diseases
14:45:00 It is not just about the sex: viewpoints of Dutch adult men with inflammatory arthritis regarding the impact of the disease on their sexual health 14:52:00 Q&A 14:42:00 Q&A Room 12 Practical skills CAPILLAROSCOPY Learners will be instructed to use a fast track algorithmin order to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". In addition, learners will appreciate the Very early nailfold capillaroscopic nonspecific abnormalities that may predict the progression to the scleroderma pattern. Learners will be informed about the most important risk factors that may induce the endothelial damage that start the Raynaud's phenomenon. The most common capillaroscopic patters will be explained and instructed onhow to be quantified, in addition the different tools available for the analysis will be described. The predictive and prognostic role of capillaroscopy in systemic sclerosiswill be explained and documented. Learners at the end of the session will have understood when a capillaroscopic pattern is pathologic and what to do. Learners will observe on live patients how the nailfold capillaroscopic analysis is done and will discuss with the tutors the diagnosis. 13:30:00 Introduction and State of Art 2021 13:35:00 A fast track algorithm to differentiate a 'scleroderma pattern' from a 'non-scleroderma pattern' 13:45:00 2021 update on methods and tools for quantization of the capillaroscopic morphological changes 13:55:00 Group discussion (Q&A) 14:00:00 Demo 1: Optimised use of the nailfold capillaroscope (with patient and videocapillaroscope) 14:05:00 Demo 2: Clinical Case 1 14:10:00 Group discussion (Q&A) 14:20:00 Reliability of capillaroscopic characteristics versus instrumental detection
14:30:00 Very early nailfold capillaroscopic nonspecific abnormalities may predict the progression to the scleroderma pattern and early disease EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Friday, 4 June 2021 13:30:00 15:00:00 Room 12 "scleroderma pattern" from a "non-scleroderma pattern". In addition, learners will 14:40:00 Demo 3: Clinical Case 2 14:45:00 Demo 4: Clinical Case 3 14:50:00 Group discussion (Q&A) Room 13 Practical skills I want to see that poster! As a result of participating, attendees will be better able to Analyse and describe what makes a poster great Choose and create good supporting media Evaluate your own posters and learn from others Access further resources. 13:30:00 Introduction 13:35:00 Making posters a learning experience 14:20:00 Demo 14:30:00 Q&A 14:40:00 Helping passers-by catch your message right 14:50:00 Q&A Room 2 Clinical Science Difficult to treat RA: definitions and mechanisms To understand the concept “difficult to treat rheumatoid arthritis”. To gain insight into selected factors contributing to difficult to treat RA. 13:30:00 Introduction 13:34:00 Difficult to treat RA: definitions and epidemiology 14:13:00 Q&A 14:35:00 Q&A
Are patients with psoriatic arthritis being treated optimally across the world? Disparities in health care for patients with psoriatic arthritis across 14:40:00 countries with different GDP’s, an analysis of 429 patients from 13 countries 14:47:00 Q&A
IN RHEUMATOID ARTHRITIS PATIENTS HIGHER NUMBER OF COMORBIDITIES PREDICTS 6-MONTH INSUFFICIENT RESPONSE TO 14:50:00 FIRST BIOLOGIC THERAPY AND EVENTUAL CATEGORIZATION OF THE DISEASE AS DIFFICULT-TO-TREAT 14:57:00 Q&A 13:56:00 What can the synovial tissue learn us about difficult to treat RA 14:18:00 The role of comorbidities in difficult to treat RA 13:51:00 Q&A Room 3 Clinical Science Quantitative imaging To get insight into recent advances in quantitative imaging and learn how novel Introduction approaches to assessing imaging can support therapy monitoring and clinical decision making in rheumatology. 13:30:00 13:35:00 Can quantitative PET imaging contribute to tailored therapy in rheumatology? 13:55:00 Q&A 14:00:00 Quantitative MRI assessment for therapy monitoring in rheumatology 14:20:00 Q&A 14:25:00 High-resolution CT in Arthritis 14:45:00 Q&A Use of thermography of hands and machine learning to quantify joint inflammation and estimate DAS28, CDAI, SDAI in patients with 14:50:00 rheumatoid arthritis. 14:57:00 Q&A Room 4 Clinical Science Let’s consider Biologic Immunogenicity To obtain the latest information on biologic drug immunogenicity, the practical implications of this information, and the pros and cons of therapeutic drug monitoring for biologic drugs in RA. 13:30:00 Introduction
13:35:00 Measuring drug levels and anti-drug antibodies - what do the data tell us and what are the practical consequences? 13:50:00 Getting to grips with pharmacokinetics of biologic drugs - what is the relevance? 14:05:00 Therapeutic drug monitoring in RA - aspirations and challenges 14:20:00 Therapeutic drug monitoring in RA – what do the data tell us? 14:35:00 Debate 14:50:00 Risk factors for anti-infliximab antibody formation: Results from the randomised controlled NOR-DRUM A trial 14:57:00 Q&A Room 5 Challenges in Clinical Practice Challenges of Planetary changes How much do we have to weight environment in our clinical predictions, both in terms of diagnosis and prognosis? Are we ready to incorporate the environment into our practice? Should we become planetary activists? For each one of the clinical challenges, a reasoned diagnostic prediction and targeted management will be proposed. Case 1 Simon is a 35-year old man with intermittent pain in the wrists. Because he has relatives with rheumatoid arthritis, the family doctor did an ACPA test, which was positive. He is slightly overweight and likes to go out with friends, but does not smoke. He returns to the GP to ask what he can do to prevent him from developing RA. He wants an intervention to be climate-friendly. “Doc, should I become a vegan?” Case 2 This talk will explore the links between planetary changes, physical activity, and musculoskeletal health, as well as the role novel technologies and advanced analytics to address some of the challenges. 13:30:00 Introduction 13:35:00 Will Simon get RA? Case presentation 13:45:00 How much does the environment weight in the prediction? 14:05:00 Q&A
14:27:00 Discussion: How will planetary health affect Simone’s joints: Challenges and Opportunities from a health informatics perspective 14:47:00 Q&A
14:17:00 How will planetary health affect Simone’s joints: Challenges and Opportunities from a health informatics perspective EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Friday, 4 June 2021 13:30:00 15:00:00 Room 6 EULAR Debate Patients' input in the target(s) Critically review the Pros and Cons of combining or separating measures of disease process and disease impact in the definition of treat-to-target Propose the most effective way of incorporating patient perspective into the treatment target(s). 13:30:00 Introduction 13:35:00 Making the case for replacing PGA 13:50:00 Making the case for keeping PGA 14:05:00 Q&A and debate Room 7 From Bench to Bedside SpA: Innovative techniques in Spondyloarthritis research – Is there light at the end of the tunnel for our patients? To learn about novel techniques in the exploration of the genetic background of spondyloarthritis. To understand the potency of single cell technology to unravel the underlying pathophysiology of immune-mediated disorders. To discuss the application of these novel techniques in future spondyloarthritis research. 13:30:00 Introduction 13:35:00 Is RNA sequencing the new holy grail? 14:26:00 Q&A 14:54:00 Q&A 14:31:00 How (and when) can Spondyloarthritis patients benefit from basic research breakthroughs? 13:58:00 Q&A 14:03:00 Functional genomics in Spondyloarthritis Room 8 Practical skills Laboratory course - from the clinic to the lab and back (from translation to prescription) This session will provide an interactive forum for colleagues with interest in the rheumatology lab. State of the art and new lab parameters and dection methods will be discussed for three main sections arthritides, connective tissue diseases including antiphopsholipd syndrome and vasculitides. 13:30:00 Introduction 14:02:00 Vasculitis, systemic autoimmunity 14:27:00 Q&A 14:56:00 Q&A 14:31:00 New trends in biomarkers in inflammatory joint disease 13:33:00 ANA diagnostic and antiphospholipid syndrome (APS) as inherited coagulation disorder 13:58:00 Q&A Room 9 Health Professionals in Rheumatology (HPR) Context matters: Placebo and nocebo effects for pain management Delegates will be able to describe the importance and mechanisms of placebo and nocebo effect discuss the role of the context around the treatment in rheumatology apply concepts of placebo and nocebo and context in their clinical practice. 13:30:00 Introduction 13:35:00 The individual healing experience 13:50:00 Q&A 13:53:00 Mechanisms, predictors, and interventions to prevent, minimize, or extinguish nocebo effects in pain 14:26:00 Q&A
14:47:00 Identifying the Contextual Factors in the Patient-Practitioner Encounter that have Therapeutic Effect: A Systematic Review and Meta-Analysis 14:44:00 Q&A 14:08:00 Q&A 14:11:00 Placebo, nocebo and context in clinical practice: How to make use of it 14:54:00 Q&A 14:29:00 The power of empathy 14:15:00 15:00:00 Room 1 How to Treat (HOT) HOT Gout Define the treatment objectives in gout Explore the treatment options in gout treatment to achieve said objectives Briefly discuss treatment limitations in selected complex cases (e.g. patients with renal insufficiency or high cardiovascular risk). 14:15:00 Introduction 14:20:00 HOT Gout 14:50:00 Q&A
15:30:00 16:15:00 Room 1 What is New (WIN) Osteoarthritis Clinical trials There are many phase II and III clinical trials in OA that have been published in the past 3 Introduction years. Several are resolutely negative (anti-cytokine), some are showing disease modifying promise. Session will include an overview of what we have learnt and where new treatments are likely to come from. 15:30:00 15:35:00 WIN in OA clinical trials 16:05:00 Q&A
17:00:00 Room 10 EULAR Projects EULAR Projects in musculoskeletal imaging To get updates from ongoing or recently completed EULAR projects in musculoskeletal imaging. 15:30:00 Introduction 15:35:00 EULAR recommendations for the reporting of musculoskeletal ultrasound studies in rheumatology 15:55:00 Q&A 16:00:00 EULAR Recommendations for the use of imaging to guide interventional procedures in patients with RMD 16:20:00 Q&A 16:25:00 EULAR-PReS Standardised procedures for Ultrasound Imaging in Paediatric Rheumatology EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Friday, 4 June 2021 15:30:00 17:00:00 Room 10 imaging. 16:45:00 Q&A The role of imaging to guide interventional procedures in rheumatic and musculoskeletal diseases: a systematic literature review to inform 16:50:00 EULAR recommendations 16:57:00 Q&A Room 11 PARE What's new: Latest advances in treatment and care in vasculitis and fibromyalgia To inform about the latest advances in treatment and care in vasculitis and fibromyalgia. 15:30:00 Introduction 15:40:00 What's new: Latest advances in treatment and care in vasculitis 16:00:00 Discussion 16:10:00 What's new: Latest advances in treatment and care in fibromyalgia 16:30:00 Discussion 16:40:00 The role of comorbid pathology in the progressive course of ANCA-associated systemic vasculitis 16:47:00 Q&A 16:50:00 GENDER AND FIBROMYALGIA SEVERITY: REAL LIFE DATA FROM THE ITALIAN REGISTRY. 16:57:00 Q&A Room 12 Practical skills ABCs of biopsies: when to perform and how to interpret Learn when and how to perform synovial, salivary gland and muscle biopsies Learn how to interpret synovial, salivary gland and muscle biopsies Understand the role of synovial, salivary gland and muscle biopsies in the diagnostic pathway. 15:30:00 Introduction 15:32:00 Synovial biopsy 15:50:00 Discussion 16:00:00 Muscle biopsy 16:20:00 Discussion 16:30:00 Salivary gland biopsy 16:50:00 Discussion Room 13 Practical skills Scientific Data Visualisation To choose the data visualisation that best fits the data. To identify the basics of table and graph design. To choose tables and graphs that tells the story in the data. To learn about poster design. 15:30:00 Workshop: Scientific Data Visualisation Room 2 Clinical Science tsDMARD therapy of rheumatoid arthritis To understand up to date developments of targeted synthetic oral therapies in rheumatic diseases 15:30:00 Introduction 15:35:00 JAKi in the news – side effects 16:26:00 Q&A 16:54:00 Q&A 15:58:00 Q&A 16:31:00 Ten years of JAKi in RA – Real life data from the SCQM registry 16:03:00 “Selective” JAKi on the verve – implications for therapy Room 3 Clinical Science Controversies on phenotypes in PsA To describe and discuss the clinical heterogeneity and personalized treatment strategies of psoriatic arthritis. To address the controversies related to the concept and classification of psoriatic arthritis in childhood. 15:30:00 Introduction 15:34:00 The clinical heterogeneity of psoriatic arthritis in adults 16:35:00 Q&A Validation of the Psoriasis Epidemiology Screening Tool (PEST) and the new Early Arthritis for Psoriatic patients (EARP) in pediatric population - 16:40:00 pilot study 16:47:00 Q&A 16:50:00 Etanercept and Adalimumab in the treatment of Juvenile Psoriatic Arthritis 16:57:00 Q&A 15:56:00 Towards personalized treatment strategies for psoriatic arthritis 16:13:00 Q&A 15:51:00 Q&A 16:18:00 Controversies around the concept and classification of psoriatic arthritis in children Room 4 From Bench to Bedside Pharmacology and Microbiota Understand how drug pharmacology and gut microbiota may influence each other Learn the effect of gut microbiota on drug effectiveness in cancer Understand how gut microbiota may influence drug therapeutic response in rheumatology. 15:30:00 Introduction 15:35:00 Drugs and gut microbiome: overview of the bidirectional interactions 15:55:00 Q&A 16:00:00 Gut microbiome and therapeutic response: experiences in the field of cancer 16:20:00 Q&A 16:25:00 Gut microbiome and therapeutic response: applications in rheumatology 16:45:00 Q&A
16:50:00 Gut microbiota and its relevance to peripheral lymphocyte subpopulation in patients with systemic lupus erythematosus 16:57:00 Q&A EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Friday, 4 June 2021 15:30:00 17:00:00 Room 5 Challenges in Clinical Practice Managing Chronic Pain Understand the challenges of managing chronic osteoarthritis pain and the opportunities to optimise outcomes using mechanism based treatment strategies Understand the challenges of managing chronic pain in RA and stratified approaches to treatment. Case 1 The case involves a 57 year old female who has been referred for a Rheumatology opinion for painful hand osteoarthritis. Her symptoms started two years ago, and she is tearful about the impact of pain on her life and her ability to work. Her family doctor has trialled oral analgesia and topical NSAID without benefit, referring to Rheumatology for further management of her hand symptoms. Case 2 Case involves a 45 year old female with previously diagnosed fibromyalgia who presents with tender and swollen small joints, not helped by her current analgesics. The case outlines her journey of rheumatoid arthritis complicated by known chronic pain; and the complexity of teasing out which symptoms/signs are attributable to inflammation and/or chronic pain that will guide the management. 15:30:00 Introduction 15:35:00 Case 1: Managing chronic pain in hand osteoarthritis 15:45:00 Discussion: Optimising pain management in osteoarthritis: mechanism based treatment strategies 16:05:00 Q&A 16:47:00 Q&A 16:27:00 Discussion: Stratified targeted treatment strategies for chronic pain in Rheumatoid Arthritis 16:17:00 Case 2: Managing chronic pain in Rheumatoid Arthritis Room 6 Innovation Artificial Intelligence and Machine Learning in Medicine To understand the potential of artificial intelligence to impact on medicine in the next decade How to analyse very big data Understanding complex networks The advance of robotic surgery. 15:30:00 Introduction 16:10:00 Q&A 16:15:00 Complex networks 16:36:00 From Robotics to Data: Beyond the learning curve 16:52:00 Q&A 15:54:00 Translating a trillion points of data into therapeutics 16:31:00 Q&A 15:49:00 Q&A 15:33:00 Artificial Intelligence in Medicine Room 7 Basic and Translational Science What can we learn from the tissue Participants will learn the importance of pathological tissue analyses in rheumatology and Introduction also recognize recent development of analyses. 15:30:00 15:35:00 What can we learn from the tissues of rheumatic diseases? 15:55:00 Q&A 16:00:00 Single cell analysis of lupus kidney 16:20:00 Q&A 16:25:00 Spatial transcriptomic for tissue analysis 16:45:00 Q&A 16:50:00 Senescent progenitor cells in the skin of lupus patients 16:57:00 Q&A Room 8 The Young Rheumatologist How to communicate effectively with the patients To learn how to communicate effectively with patients with autoimmune rheumatic diseases (RMDs), explain, in newly diagnosed patients, what are RMDs? How are treated and what is expected? Listen to the problems that are important for the patients and identify the unmet needs. Learn how to use all available resources for patients' benefit. 15:30:00 Introduction 15:35:00 What do we expect from an appointment with the doctor? 15:45:00 The role of HPRs as patients’ advocators 15:55:00 When I saw a patient with RMD for the first time' What has changed in my clinical practice during the years? 16:05:00 Challenges for young rheumatologists when communicating with patients 16:15:00 Roundtable discussion Room 9 Health Professionals in Rheumatology (HPR) HPR’s contribution to the excellence of care in this treat-to-target era: what about personalised goals? Delegates will be able to discuss the importance of treatment targets from the perspective of the clinician and that of the patient apply the principles of person-centred care and goal setting in rehabilitation illustrate in their own practice how both clinical and patient personal goals can be the treatment targets. 15:30:00 Introduction 15:35:00 The Dual-target proposal for rheumatic (and other) diseases: Why and how? 15:50:00 Q&A 16:11:00 Q&A 16:32:00 Q&A 15:56:00 How to establish and assess personalized goals? The Goal Attainment Scale and other tools 16:17:00 How to motivate and engage patients in making change 16:38:00 Wrap-up: Putting it into perspective regarding overall well-being 16:53:00 Q&A 16:15:00 17:00:00 Room 1 How to Treat (HOT) Management of osteoporosis in male patients current evidence To learn the most updated strategies for the management of men osteoporosis 16:15:00 Introduction 16:20:00 Management of osteoporosis in men 16:50:00 Q&A
17:30:00 19:00:00 Room 7 Basic and Translational Science Stress, inflammation & autoimmunity To learn the correlations between stress, inflammation and autoimmunity in RMDs 17:30:00 Introduction EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
Friday, 4 June 2021 17:30:00 19:00:00 Room 7 To learn the correlations between stress, inflammation and autoimmunity in RMDs 18:50:00 Metabolic reprogramming in memory CD4+ T cells is associated with reactive oxygen induced immune cell dysfunction during aging 18:08:00 Q&A 18:12:00 Stress response systems and inflammation 18:57:00 Q&A 18:27:00 Q&A 17:34:00 Stress, Inflammation, and Autoimmunity: The 3 Modern Erinyes 18:31:00 The role of stress in subclinical and active RA 17:49:00 Q&A 18:46:00 Q&A 17:53:00 Stress and autoimmune diseases
Saturday, 5 June 2021 08:00:00 09:00:00 Room 1 Oral Abstract Presentations Late Breaking Abstracts (blank) 08:15:00 COVID-19 vaccine safety in patients with rheumatic and musculoskeletal disease
Efficacy and Safety of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Primary Results from a Randomised, Double- 08:45:00 blind, Placebo-controlled, Treatment Withdrawal, Phase 3 Study (JUNIPERA) Mavrilimumab Improves Outcomes in Phase 2 Trial in Non-Mechanically-Ventilated Patients with Severe COVID-19 Pneumonia and Systemic 08:00:00 Hyperinflammation Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and 08:30:00 general population: a multicenter study
09:00:00 09:45:00 Room 3 What is New (WIN) Are we what we eat? – The role of dietary intervention in rheumatic and musculoskeletal diseases To learn the current evidence and ways of practical implementation of dietary intervention Introduction including fasting in the treatment of RMDs. 09:00:00 09:05:00 What should I tell my patients with RMDs about diet? 09:35:00 Q&A
10:30:00 Room 10 EULAR Projects Need advice on your research? EULAR can help! How EULAR supports researchers investigating rheumatic and musculoskeletal diseases Under the umbrella of EULAR Research, the Virtual Research Centre (VRC) provides research resources, infrastructure, services, and training to enable high-quality, interdisciplinary rheumatic and musculoskeletal disease research. In this virtual panel discussion, the speakers will reflect on the first months since the VRC’s launch and highlight how the Research Consultation Service in particular benefits RMD researchers across Europe. Moreover, participants of this session will be the first ones to know about new and upcoming VRC research support services! The session will close with a Q&A. 09:00:00 Introduction to the EULAR Virtual Research Centre 09:10:00 Current and upcoming services for RMD researchers 09:40:00 Q&A Room 11 PARE Taking control – Managing different expectations towards treatment outcomes To discuss the impact of different expectations in the management of the disease and treatment outcomes. To reflect upon strategies for overcoming poor disease control. 09:00:00 Introduction 09:05:00 Assessing treatment failure 09:10:00 Adherence and belief 09:15:00 Understanding the patient perspective / patient expectation on treatment outcomes 09:20:00 Patients’ education, expectations and outcomes 09:25:00 Discussion 10:05:00 Disease monitoring apps and digital solutions 10:25:00 Session summary and closing Room 4 Clinical Science Hyperinflammation and Covid19 Understand the mechanisms of hyperinflammation in Covid19 and other contexts Update current evidence supporting (or not) the use of therapies targeting hyperinflammation in the context of Covid19 Explore the particularities of Covid19-related hyperinflammation in children. 09:00:00 Introduction 10:05:00 Q&A 10:20:00 Preliminary Criteria for Macrophage Activation Syndrome Associated with Coronavirus Disease-19 09:48:00 Pediatric inflammatory multisystem syndrome 09:04:00 Mechanisms of hyperinflammation in Covid19 and beyond 10:10:00 DOCK8 mutations in COVID-19 and MIS-C Cytokine Storm Syndrome 10:27:00 Q&A 09:43:00 Q&A 09:21:00 Q&A 10:17:00 Q&A 09:26:00 Success and failures of therapies for hyperinflammation in Covid19 EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Saturday, 5 June 2021 09:00:00 10:30:00 Room 5 Challenges in Clinical Practice Is early treatment of RA better than wait and see What is the evidence that early treatment is relevant for disease modification. Case 1 Early treatment start has become the cornerstone of the management of early arthritis and Rheumatoid Arthritis (RA). The success of early treatment has resulted in an increasing interest in the period before swollen joints actually appear, with the underlying assumption that disease processes that are still developing are more susceptible to permanent modification. We present a case of a 47-year old lady who visited our Early Arthritis Recognition Clinic with symptoms of the MCPs for 2 months. She has morning stiffness, a negative family history for RA and experiences some difficulties with dressing in the morning. At physical examination she has no tender or swollen joints. At the right hand side the squeeze test of the MCPs is positive. We then see her at the regular outpatient clinic. Acute phase reactants are normal, ACPA (anti-CCP2) test is positive and US shows signs of synovitis. After the case presentation we will discuss the diagnosis, the accuracy of risk assessment and the evidence for treatment. Case 2 In this session, we will present the case of a patient with newly presenting inflammatory oligoarthritis. The differential diagnosis (including reactive arthritis and the early presentation of a condition that will evolve into a chronic inflammatory arthritis such as rheumatoid arthritis (RA)) will be reviewed. Approaches to predicting the development of RA will be discussed as will pharmacological and other management strategies. 09:00:00 Introduction
09:05:00 Case 1: Arthralgia of recent-onset with positive ACPA and synovitis at US: what is the diagnosis and how should we treat this patient?
09:15:00 Discussion: Arthralgia of recent-onset with positive ACPA and synovitis at US: what is the diagnosis and how should we treat this patient? 09:35:00 Q&A 09:47:00 Case 2: How to deal with oligo-arthritis 09:57:00 Discussion: How to deal with oligo-arthritis 10:17:00 Q&A Room 6 EULAR Debate Remote rheumatology In a debate the pro’s and cons of Remote Rheumatology (accelerated by COVID-19) will be discussed by patients, physicians and health professionals. Pro- and con-statements will be given by those six participants, thereafter a debate will be generated with input from the audience. 09:00:00 Introduction 09:05:00 Pro's and Con's of Remote Rheumatology 10:05:00 Q&A Room 7 Basic and Translational Science Metabolic pathways during the regulation of inflammation and immunity Understanding the mutual influence of cellular metabolism and the immune response; Learn about immunometabolic pathways in rheumatic diseases. 09:00:00 Introduction 09:05:00 Krebs Cycle-derived metabolites in the control of inflammation 09:25:00 Q&A 09:30:00 Metabolic basis of sarcoidosis 09:50:00 Q&A 09:55:00 Metabolic rewiring of innate lymphocytes 10:15:00 Q&A 10:20:00 Effector CD4 T cells require survivin for regulation of glucose metabolism and IFNg production 10:27:00 Q&A Room 8 Clinical Science Multiple issues in connective tissues - More than ‘just’ Hypermobility To discuss the clinical features of the heritable rheumatological connective tissue disorders using real case studies To highlight the red flags that should alert the physician to the presence of these conditions and discuss the indications for genetic testing To discuss common comorbidities To provide a forum to enable interested audience to increase their clinical skills and consider taking part in future research studies. 09:00:00 Introduction 09:05:00 Joint hypermobility .. Why bother? 09:28:00 Q&A 10:24:00 Q&A 09:56:00 Q&A
09:33:00 Beyond chronic pain and fatigue - The role of autonomic dysfunction and psychological concerns in complex cases 10:01:00 Vascular Disease in the Heritable Diseases of Connective Tissue Room 9 Joint Let's work. Together. To understand the challenges of achieving a fulfilling job if facing an RMD. To know the level of involvement, real and desirable, of all stakeholders in achieving a gratifying work. To explore EULAR and EU initiatives to improve the level of work and the relationship between workers with RMD and their employees. 09:00:00 Introduction 09:05:00 The impact of RMD on absenteeism and presenteeism 09:50:00 Q&A 10:16:00 Q&A 10:06:00 Q&A 09:21:00 The challenges of achieving a fulfilling job if facing an RMD 09:18:00 Q&A 10:26:00 Q&A Association between individual and country-level socioeconomic factors and work participation in peripheral and axial spondyloarthritis: analysis 10:09:00 of the ASAS perSpA study 09:34:00 Q&A EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Saturday, 5 June 2021 09:00:00 10:30:00 Room 9 level of involvement, real and desirable, of all stakeholders in achieving a gratifying work. 09:37:00 Can rheumatologists improve the work situation of persons with RMD? 09:53:00 Stakeholder involvement in the EU OSH policy development 10:19:00 The contemporary work-related burden of disease for people with rheumatic diseases in Greece 09:45:00 10:30:00 Room 3 How to Treat (HOT) Pregnancy in SLE and APS Discuss recommendations and treatment of pregnancy in SLE and APS 09:45:00 Introduction 09:50:00 Common issues in pregnancy management in lupus and anti-phospholipid syndrome 10:20:00 Q&A
10:30:00 12:10:00 Poster Tours no session group Diagnostics and imaging procedures (blank) 11:00:00 Diagnostic performance and clinical utility of two referral rules for inflammatory arthritis Towards a simplified fluid-sensitive MRI-protocol in small joints of the hand in early arthritis patients: reliability between mDixon and regular FSE 10:36:00 fat saturation MRI-sequences Ultrasound as an imaging biomarker of early response to tocilizumab and methotrexate In very early rheumatoid arthritis, TOVERA – a 10:48:00 longitudinal study 11:24:00 Clinical and ultrasonographic enthesitis in inflammatory bowel disease with and without psoriasis 11:12:00 Clinical relevance of DFS70 antibodies – a multicentre study
10:42:00 Real-time versus static scoring in musculoskeletal ultrasonography in patients with inflammatory hand osteoarthritis 10:30:00 Automated capillary detection and image analysis software in capillaroscopy: Capillary.io
10:54:00 Ultrasound assessment of hands and feet for synovitis prior to first clinical visit markedly reduces time to diagnosis - experience from routine care
The emerging role of Magnetic Resonance Imaging in Interstitial Lung Disease in Systemic Sclerosis: evidence for Ultra Short TE and 11:18:00 Compressed Sensing VIBE acquisitions as promising tools for the evaluation of parenchymal alterations.
11:06:00 Identifying erosive disease from radiology reports of veterans with inflammatory arthritis using natural language processing Systemic sclerosis, myositis - etiology, pathogenesis and animal models Lung targeted delivery of everolimus as a new treatment of scleroderma-related interstitial lung disease (SSc-ILD) developed by PSGL-1 KO (blank) 11:00:00 mice 10:36:00 Inactivation of aldehyde dehydrogenase 3A2 inhibits fibroblast activation and tissue fibrosis GASTROINTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS: PATHOGENETIC ROLE OF GUT MICROBIOME, CYTOKINES AND 10:48:00 ADIPOKINES 11:24:00 The potential role of IL13 in vasculopathy in systemic sclerosis patients 11:12:00 Altered macrophage polarization phenotypes in systemic sclerosis
10:42:00 Engrailed 1 coordinates cytoskeletal organization to promote myofibroblast differentiation and fibrotic tissue remodeling
10:30:00 ROLE OF THE IL-25 / IL-17RB AXIS IN TH9 POLARIZATION IN PATIENTS WITH PROGRESSIVE SYSTEMIC SCLEROSIS Nintedanib (tyrosine kinase inhibitor) downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro- 10:54:00 fibrotic activity 11:18:00 Interstitial lung inflammation with alveolar hemorrhage in autoimmune MRL/Mp-lpr/lpr mice 11:06:00 Endothelial activation in systemic sclerosis vasculopathy: role of long non-coding RNA H19X Clinical aspects of spondyloarthritis
Validation of the Ankylosing Spondylitis Disease Activity Score with a quick quantitative C-reactive protein assay (ASDAS-qCRP) in patients with (blank) 11:00:00 axial spondyloarthritis (axSpA): A prospective, national, multicenter study. 10:36:00 Gut dysbiosis linked to worse disease status in axial spondyloarthritis 10:48:00 Root Joint Involvement in Spondyloarthritis: A Post-Hoc Analysis from the International ASAS-PerSpA Study
11:24:00 Performance of standardized scores for disease assessment and pain in patients with spondyloarthritis and fibromyalgia What does remission in axial spondyloarthritis mean for clinicians? An exploratory study of 200 French rheumatologists based on a vignette 11:12:00 exercise including 36 cases and priority ratings
10:42:00 Sick leave and its predictors in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort.
Comparison of work productivity outcomes between chronic back pain patients with and without a diagnosis of axial spondyloarthritis after 2- 10:30:00 year protocolised follow-up: Data from the Spondyloarthritis Caught Early cohort Geographical prevalence of a family history in patients with axial spondyloarthritis and its association with HLA-B27: data from the worldwide 10:54:00 ASAS-perSpA study Patient Journey with Axial Spondyloarthritis: Critical Issues from the Patient Perspective. Results from the European Map of Axial 11:18:00 Spondyloarthritis (EMAS) 11:06:00 Role of HLA-B27 Carriership in Peripheral Spondyloarthritis: Data from ASAS perSpA Study Clinical vasculitis
(blank) 11:00:00 ARE CLINICAL FEATURES AND OUTCOMES OF ANCA (+) EGPA PATIENTS DIFFERENT FROM ANCA NEGATIVE ONES? 10:36:00 Interstitial ANCA-associated vasculitis associates with severe kidney injury independent of glomerulonephritis The effect of nasal Staphylococcus aureus colonization on disease activity and the effect of antibiotic treatment in patients with ANCA 10:48:00 associated vasculitis; a retrospective cohort study IMPACT OF PLASMA EXCHANGE (PLEX) IN SEVERE ANCA-ASSOCIATED VASCULITIS (AAV): A REAL-LIFE DATA FROM A 11:24:00 PROSPECTIVE COHORT
11:12:00 Rituximab-biosimilar for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single Italian center
10:42:00 Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start
Saturday, 5 June 2021 10:30:00 12:10:00 Poster Tours (blank) 10:30:00 The worldwide incidence and prevalence of ANCA vasculitis: a systematic review and meta-analysis of epidemiological studies.
10:54:00 Significant Damage Occurs Early in the Course of Eosinophilic Granulomatosis with Polyangiitis and is Mainly Due to Disease-related Sequelae
11:18:00 Efficacy of Apremilast in the Treatment of Oral Ulcers of Behçet’s Syndrome: Results From the European Subgroup of RELIEF 11:06:00 Impact of ANCA-Associated Vasculitis On Clinical Outcomes And Resource Utilization in Elective PCI HPR - Understanding and measuring: expanding the toolbox
(blank) 11:00:00 Patient perspective on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes
10:36:00 Identifying Meaningful and Detectable Change from the Patient Perspective across Common Fatigue Measures in Rheumatoid Arthritis
10:48:00 Content validity of a multiple languages questionnaire for measuring flare in knee and hip OA: development of the Flare-OA Concordance between the physician’s and the nurse’s assessment of disease activity in rheumatoid arthritis using DAS-28, CDAI and SDAI in 11:24:00 seven Middle Eastern Arab countries
11:12:00 Pharmacist’s impact on self-management for patients with chronic inflammatory arthritis treated with biological DMARDS 10:42:00 PATIENT-REPORTED ACTIVITY LIMITATIONS IN HIP AND KNEE OSTEOARTHRITIS IN PRIMARY CARE
10:30:00 Patient-perceived aspects of RA flare evolve over time, as reflected by the FLARE-RA questionnaire: post-hoc analysis of TapERA
10:54:00 Flare-OA Questionnaire to measure flares in osteoarthritis of the knee and hip: assessment of its psychometric properties Barriers to physical activity collected by the IFAB questionnaire correlate with levels of physical activity in patients with rheumatoid arthritis or 11:18:00 spondyloarthritis: a cross-sectional study of 150 patients 11:06:00 POOR RESPONSE TO TKA: THE PERSPECTIVE OF PATIENTS AND KNEE SPECIALISTS New drugs and therapies
(blank) 11:00:00 Rubus idaeus leaf extract improves symptoms in knee osteoarthritis patients: results from a double blind randomized clinical study Anabolic effect of LNA043, a novel disease-modifying osteoarthritis drug candidate: results from an imaging-based proof-of-concept trial in 10:36:00 patients with focal articular cartilage lesions
Wearable transcutaneous electrical nerve stimulation demonstrated better efficacy and safety than weak opioids in the treatment of moderate to 10:48:00 severe, chronic nociceptive pain in knee osteoarthritis. A randomized, controlled, non-inferiority trial 11:24:00 Are racial disparities in revision TKA outcomes associated with hospital or surgeon volume? Treatment patterns and clinical characteristics of patients with osteoarthritis of the hip and/or knee treated with traditional NSAIDs vs COX-2s: a 11:12:00 real-world study of commercially-insured patients A Multicenter, Observational, Extension Study Evaluating the Safety, Tolerability, and Efficacy of a Single Lorecivivint Injection in Knee OA 10:42:00 Subjects EFFICACY OF KRILL OIL IN THE TREATMENT OF KNEE OSTEOARTHRITIS: A 24-WEEK MULTICENTRE RANDOMISED DOUBLE- 10:30:00 BLIND CONTROLLED TRIAL Association of complementary and alternative medicine use with knee symptoms and knee structural changes over 2.6 years: a population- 10:54:00 based cohort study of Tasmanian older adults
11:18:00 Clinical and MRI comparison of eccentric versus concentric rehabilitation in symptomatic knee osteoarthritis: a prospective randomized study
11:06:00 Evaluation of a new hyaluronate formulation one year after single injection to patients with symptomatic knee osteoarthritis (SOYA study) Oncorheumatology The impact of drug induced and other rheumatic musculoskeletal disorders (MD) on the quality of life (QoL) of cancer patients received (blank) 11:00:00 anticancer drug treatment Use of biologic disease modifying anti-rheumatic drugs in relation to the risk of lymphoma: A cohort study of US veterans with rheumatoid 10:36:00 arthritis
10:48:00 CANCER RISK IN IMMUNOSUPPRESSED SCLERODERMA PATIENTS: A PROPENSITY SCORE MATCHING ANALYSIS
11:24:00 No causal effects of genetically determined serum urate levels on the risk of all-cause and site-specific cancer: A mendelian randomization study TRheuMa registry provides first evidence of different course of rheumatic immune-related adverse events and tumour response rates depending 11:12:00 on the tumour entity 10:42:00 A key TIF1γ epitope may facilitate the identification of patients at highest risk of cancer associated myositis.
10:30:00 Incidence of malignancies in Japanese patients with rheumatoid arthritis: data from a large Japanese national registry 10:54:00 Predicting risk factors of MALT lymphoma in Sjögren’s Syndrome 11:18:00 Profile of Spinal Tumors in Rheumatology departments 11:06:00 Osteoporosis in breast cancer patients on aromatase inhibitors therapy: About 200 cases Rheumatoid Arthritis - comorbidity and clinical aspects - Part 2 Exposure to major psychological trauma or stress in the preceding one year significantly contributes to poor disease control in patients with (blank) 11:00:00 Rheumatoid Arthritis: Single centre results from the PRIME registry cohort
10:36:00 Impact of multimorbidity on disease modifying anti-rheumatic drug therapy in early rheumatoid arthritis: data from the Espoir cohort 10:48:00 Trajectories of fatigue in early RA over 10 years: Results from the ESPOIR cohort
11:24:00 Prospective evaluation of a dedicated, serial occupational therapy exercise program on hand function in rheumatoid arthritis (RA)
11:12:00 How Does the Presence of Depression Impact on Disease Activity Scores in patients with Rheumatoid Arthritis? Fatigue in rheumatoid arthritis patients is associated to subjective but not objective assessments of disease activity during treatment with 10:42:00 tocilizumab EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Physician and Patient Attitudes towards Treat-to-Target, its Implementation and Stated Treatment Goals in Patients with Rheumatoid Arthritis in Saturday, 5 June 2021 10:30:00 12:10:00 Poster Tours (blank) 10:30:00 a Real-World Setting across Europe
10:54:00 Seropositivity Increases Risk of Incident Dementia in Individuals with Rheumatoid Arthritis: A Population-based Cohort Study Incidence and prevalence of polyautoimmunity in seropositive compared with seronegative patients with rheumatoid arthritis: a nationwide cohort 11:18:00 study
11:06:00 Neuroimaging biomarkers in individuals with and without rheumatoid arthritis: results from the Mayo Clinic Study of Aging
12:00:00 Poster Tours no session group Public Health, Health Services and Health Economics No major differences between patients with chronic inflammatory rheumatic disease who underwent mono- or multiswitching of biosimilars in (blank) 11:00:00 routine care (Perception Study)
10:36:00 Hospital Admissions for Patients with Rheumatoid Arthritis in Western Australia Hospitals Have Declined over Time Socioeconomic background is associated with discordance between health literacy of people with RMDs and assessment of health literacy by 10:48:00 their treating health professional Prevention of chronic diseases due to inflammation in Inflammatory Arthritis: results of a Delphi process to select care recommendations for an 11:12:00 electronic medical record (EMR) intervention.
10:42:00 Underserved populations identify barriers and propose solutions for self-managing arthritis and chronic conditions. 10:30:00 Dosing of bDMARDs in axSpA and PsA in a real world setting
10:54:00 Does cognitive behavioral therapy improve psychosocial outcome in rheumatoid arthritis: a systematic literature review EPIDEMIOLOGY AND ECONOMIC BURDEN ASSOCIATED WITH MENTAL HEALTH COMORBIDITIES IN SYSTEMIC LUPUS 11:18:00 ERYTHEMATOSUS AND LUPUS NEPHRITIS PATIENTS 11:06:00 Burnout in Rheumatologists in Latin America Vasculitis - Large vessel vasculitis (blank) 11:00:00 sVCAM-1 Expression in Takayasu Arteritis Treated with Tocilizumab: A Prospective Pilot Study Southend pre-test probability score and Halo Score as markers for diagnosis and monitoring of GCA: early results from the prospective HAS- 10:36:00 GCA study 10:48:00 Predictors of Death in Patients Diagnosed with Giant Cell Arteritis in Western Norway 1972-2012 11:12:00 Rituximab is superior to placebo in polymyalgia rheumatica
10:42:00 Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments 10:30:00 Patterns of large-vessel lesions and poor treatment outcomes in patients with large-vessel giant cell arteritis
10:54:00 Vascular Imaging in Patients With Refractory Takayasu Arteritis Treated With Tocilizumab: Analysis From A Randomized Controlled Trial 11:06:00 Discriminant Value of Ultrasound of the Wall of Large Vessels in the Diagnosis of Giant Cell Arteritis
12:20:00 Poster Tours no session group Scleroderma, myositis and related syndromes
(blank) 11:00:00 Poor prognosis prediction in anti-MDA5 positive dermatomyositis associated with interstitial lung disease: the CROSS-CAR decision tree model 11:30:00 Radiomic Biomarker of Pulmonary Vascular Related Structures Predicts Mortality in Systemic Sclerosis Modelling short-term FVC changes from SENSCIS to long-term FVC course in SSc-ILD demonstrates clinically meaningful reduction of FVC 10:36:00 decline and survival benefits
10:48:00 Clinical phenotype in scleroderma patients with anti-topoisomerase I positivity and limited cutaneous form: data from the EUSTAR database Smoking history and Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) as independent predictors of mortality in Systemic 11:24:00 Sclerosis in a single-centre Italian cohort. 11:12:00 Correlation between Quantitative Computed Tomography and disease activity in Systemic Sclerosis
The performance of diffusing capacity for monoxide carbon (DLCO) and forced vital capacity (FVC) in predicting the onset of systemic sclerosis 10:42:00 (SSc)-interstitial Lung Disease (ILD) in the European Scleroderma Trials and Research (EUSTAR) database. Long-term Safety and Efficacy of Lenabasum during 3 Years in an Open-Label Extension (OLE) of a Phase 2 Study of Lenabasum 10:30:00 in Refractory Skin Disease in Dermatomyositis (DM)
10:54:00 Performance of patient reported outcomes (PROs) in Scleroderma patients with reduced lung function in an observational cohort. 11:18:00 Anti PM-Scl associated auto immune diseases: multicentric cohort of 128 patients
11:06:00 Use of hydroxychloroquine and systemic sclerosis: results from a prospective observational study on the EUSTAR cohort
12:00:00 13:30:00 Room 10 EULAR Projects EULAR Projects in Investigative Rheumatology To provide an overview of the multiomics approaches in 2020 and how to tackle them in Investigative Rheumatology 12:00:00 Introduction 12:05:00 Linking single cell RNA seq to RA outcome 12:23:00 Q&A 13:05:00 Q&A 12:44:00 Q&A 13:08:00 Integrating multiomics data into macrophage biology 12:26:00 Data Mining and Modelling for Biomedicine: lessons learned 13:26:00 Q&A 12:47:00 MicroRNA in synovial tissue in arthritis: innocent bystanders? Room 11 PARE Members and Volunteers – Unknown beings? How to explore their interests, establish contacts and support To show how to explore the wishes and interests of members and volunteers. To present forms of communicating with volunteers and members. To outline how to interact with and qualify volunteers. 12:00:00 Introduction 12:05:00 Volunteers - how to find them, capture them and keep them EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Saturday, 5 June 2021 12:00:00 13:30:00 Room 11 present forms of communicating with volunteers and members. To outline how to 12:20:00 How a survey to our members changed our work as organisation 12:35:00 Qualifying volunteers for their tasks and personal development 12:50:00 Debate
“Celebrating the 50th anniversary of our organisation in times of pandemic: How we used digital tools to overcome challenges and difficulties 13:10:00 and came into contact with more participants and viewers than ever envisaged!” 13:17:00 Q&A 13:20:00 Patient information in times of crisis: Lessons learned from COVID-19 communication in rheumatology 13:27:00 Q&A Room 4 Clinical Science Deconditioning in rheumatic disease, time to recognise and tackle it To understand the pathophysiology of deconditioning To learn about the prevalence of deconditioning in an exemplar rheumatic disease To learn the therapeutic options to reverse deconditioning. 12:00:00 Introduction 13:05:00 Q&A
13:10:00 Osteosarcopenia increases the risk of falls in patients with rheumatoid arthritis: Results of a four-year longitudinal study 13:17:00 Q&A
13:20:00 Treatment Tapering and Withdrawal in Rheumatoid Arthritis with Stable Remission - Final Analysis of the RETRO Study 12:04:00 Deconditioning: lessons from space 12:48:00 Deconditioning in juvenile dermatomyositis, a case in point 12:26:00 Musculoskeletal Deconditioning in Space - Etiology and Non-Pharmaceutical Countermeasure Concepts 12:21:00 Q&A 13:27:00 Q&A 12:43:00 Q&A Room 5 Challenges in Clinical Practice RACase Treatment. 1 This case Educated discusses choice a 31-year-old or educated woman guess? with a 2-year history of seropositive rheumatoid arthritis, high levels of RF (263 IU/mL) and ACPA (>340 U/mL), currently treated with subcutaneous methotrexate (25 mg weekly). At the time of diagnosis, she was breastfeeding and therefore received salazopyrine (500 mg, 6 times daily) with an initial good treatment response. After being in CDAI remission for about 1 year, the patient presented herself in a routine check-up with disease flare (CDAI of 25, 5 swollen joints, 7 tender joints, severe pain VAS>9 cm and about 2 hours of morning stiffness) during ongoing salazopyrine treatment. After short-term glucocorticoid treatment the treatment was subsequently switched of the csDMARD therapy to oral methotrexate (25mg/week). MTX which was switched to subcutaneous MTX after 1 months due to nausea. However, at the next visit, 3 months later, the patient still is in moderate disease activity (CDAI 13,6), high levels of pain (VAS 68mm) and a morning stiffness of 60 minutes. You are now asked to choose between available treatment options. Our session will discuss the possibilities based on available superiority trials and current management recommendations. Case 2 A 47 year-old male patient from Egypt married to a Swiss wife and moved to Switzerland 10 years ago. ACPA+ rheumatoid arthritis was diagnosed two years later , but MTX therapy was delayed because of family planning. Two healthy sons were born subsequently. MTX therapy was initiated during the second pregnancy but stopped after 6 months because of nausea. Low dose prednisone was continued at 5mg daily. As the patient required intermittent increases in prednisone up to 20mg/day, initiation of a bDMARD was discussed. On routine chest x-ray, ILD was suspected. As an IGRA was positive and latent tuberculosis suspected, INH was started. The patient now presents with 3 swollen joints, 4 tender joints, and a patient global of 5/10. In this session, the diagnostic workup regarding the pulmonary situation and the potential RA 12:00:00 Introduction 12:05:00 Case 1: Should superiority trials be used to change the guidelines? 12:15:00 Discussion: Should superiority trials be used to change the guidelines? 12:35:00 Q&A 13:17:00 Q&A 12:47:00 Case 2: Are new trial design favouring the new drugs? 12:57:00 Discussion: Are new trial design favouring the new drugs? Room 6 Innovation Fake News To learn tools and tips for identifying misinformation, trustable sources, and to know examples of misleading statements in rheumatology. 12:00:00 Introduction 12:05:00 Why do we believe in fake news? 12:30:00 How do we get deceived? 12:55:00 Is there misinformation in rheumatology? 13:20:00 Discussion Room 7 Basic and Translational Science EFIS session: Emerging concepts how B cells drive systemic autoimmunity: from bench to clinic Long lived plasma cell biology among the B cell space; Understanding how long lived plasma cells may drive autoimmunity; To discuss the role of regulatory B cells and in immune homeostasis; Provide an overview of emerging new strategies to target pathogenic autoantibodies. 12:00:00 Introduction 13:10:00 Delineating the immunogenic domains of MDA5 using patient derived autoantibodies. 13:17:00 Q&A 13:20:00 Characteristics of peripheral blood B-cell subsets in patients with Sjogren syndrome. 12:04:00 Pathogenic memory plasma cells and autoimmunity 12:48:00 Targeting FcRn to Generate Antibody-Based Therapeutics 12:44:00 Q&A EULAR 2021 SCIENTIFIC PROGRAMME
Presentation Session date Session Start Session End Room Name Session Group / Title / Learning objectives Title Start Saturday, 5 June 2021 12:00:00 13:30:00 Room 7 plasma cells may drive autoimmunity; To discuss the role of regulatory B cells and in 12:26:00 Regulatory B cells: gateway to rheumatic disease 13:27:00 Q&A 13:06:00 Q&A 12:22:00 Q&A Room 8 The Young Rheumatologist Pearls and Pitfalls of manuscript submission and revision Understand the common errors that may undermine manuscript submission, and discuss Introduction with Editors of the main rheumatology journals the various aspects related to the revision process. 12:00:00 12:05:00 Are there ‘secrets’ for a successful submission? 12:15:00 Rheumatology in clinical medicine journals 12:25:00 Real life of manuscripts after submission! 12:35:00 How to avoid rejection for statistical inaccuracy 12:45:00 Roundtable discussion Room 9 Joint, Health Professionals in Rheumatology (HPR) [Joint session HPR/ PARE/ ARP] Mastering Self-management: State of art in a New Era Delegates will be able to describe what constitutes self-management in people with inflammatory arthritis discuss the evidence to support self-management interventions in people with rheumatic inflammatory diseases identify key communication skills and tools for health professionals to support self-management describe the skills used by patients to effectively self-manage their health discuss the role of peer support networks to enhance self-management. 12:00:00 Introduction 12:05:00 Self-management: it does matter making the effort 12:20:00 Q&A 12:23:00 What do healthcare professionals need to support self-management? 12:38:00 Q&A 12:41:00 The Power of peers and role of Patient Organizations 12:56:00 Q&A
12:59:00 EULAR Recommendations for the implementation of self-management strategies in patients with Inflammatory Arthritis 13:14:00 Q&A 13:17:00 Empowerment and associations to disease activity and pain in patients with Rheumatoid arthritis 13:24:00 Q&A
12:45:00 Room 3 What is New (WIN) Imaging of bone to measure strength from DXA onwards? Describe the current strengths and limitations of DXA to estimate risk of fragility fracture; Describe the upcoming imaging and analytical approaches to improve fracture risk prediction. 12:00:00 Introduction 12:05:00 Imaging of bone to measure strength from DXA onwards? 12:35:00 Q&A
12:45:00 13:30:00 Room 3 How to Treat (HOT) Anti-phospholipid syndromes Discuss recommendations and treatment of anti-phospholipid syndrome 12:45:00 Introduction 12:50:00 Primary and secondary thromboprophylaxis in APS 13:20:00 Q&A
13:45:00 14:45:00 Room 11 PARE PARE Highlight Session To provide an overview of learning and outcomes from the 2021 congress from health professionals and the scientific perspectives, and the first feedback from the PARE delegates. 13:45:00 Highlights from the Scientific Programme 14:15:00 Highlights from the HPR Programme Room 3 Basic and Translational Science, Clinical Science Clinical Basic Translational Highlights Session A dedicated debriefing session to highlight key contributions of basic/translational science and clinical science sections. 13:45:00 Introduction 13:50:00 Basic and Translational Highlights 14:15:00 Clinical Highlights 14:40:00 Q&A Room 9 Health Professionals in Rheumatology (HPR) HPR Highlights session Delegates will be able to identify important innovation reported in the conference from different perspectives take home key messages to apply in practice reinforce new knowledge obtained from the conference for their own professional development. 13:45:00 PARE highlights 14:05:00 Highlights from the medical programme 14:25:00 HPR highlights